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Abstract
Alterations in the macronutrient content of the diet and the effects on body composition,
cardiovascular disease risk and the control of energy metabolism in obese patients with
type 2 diabetes mellitus
Anna Gryka for the degree of Doctor of Philosophy
Background/Objective: Several studies have shown that a low carbohydrate diet (LCHOD) can
improve glycaemic control in type 2 diabetes (T2DM). The objective of the current study was to
compare two ways of administration of a LCHOD: self-prepared meals versus ready-made meals, and
their effects on weight loss, glycaemic control, body composition, cardiovascular risk and resting
metabolic rate over 12 months.
Research design and methods: Forty-one volunteers with the mean body mass index of 38.8 kg/m2
and poorly controlled T2DM (glycosylated haemoglobin, HbA1c > 7.5%) were randomized to either
protein sparing modified fast (< 40g of carbohydrate daily, self-cooked; PSMF) or Go Lower (ready-
made meals; GL) diet. Both groups received multivitamin supplementation and attended monthly
visits. The main outcome was weight loss and its composition.
Results: Fourteen (34 %) participants completed 12 months of the intervention. There were no
differences in the weight or any other changes between the diet groups at 12 months. Overall, body
mass and fat mass decreased (-5.5 ± 7.3 kg, P < 0.001 and -5.1 ± 6.7 kg, P < 0.001 respectively) but fat
free mass did not change. There was an overall reduction in HbA1c (-0.4 ± 1.1 %, P < 0.001), increase
in HDL-cholesterol (+0.07 ± 0.18 mmol/L, P < 0.001) and decrease in triacylglycerol (-0.6 ± 2.4
mmol/L, P = 0.014). Resting metabolic rate significantly decreased (-137 ± 265 kcal/d, P < 0.001).
Conclusion: LCHOD, independently of the approach taken, led to weight loss and improvements in
glycaemic control in obese volunteers with poorly controlled T2DM. The results confirm that lifestyle
modification using LCHOD is effective for improving T2DM and suggest that the type of approach to
the diet can be matched to an individual’s preferences.
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11 Introduction
“Today the biggest killers in the world are not infectious diseases; rather it is chronic
afflictions such as cardiovascular disease, obesity and type 2 diabetes that affect populations
across the globe”.
(Rana et al. 2007)
1.1 Background
1.1.1 Epidemiology and definitions of obesity and diabetes mellitus
The prevalence of obesity and type 2 diabetes mellitus (T2DM) is rising globally. The risks of
developing T2DM, cardiovascular disease (CVD), musculoskeletal and respiratory diseases grow
progressively with an increasing body mass index (BMI, defined as body mass1 [kg] /stature [m2]).
Obesity is the second preventable cause of cancer after smoking (World Health Organization, 2003).
As obesity is implicated in the development of chronic diseases, it has become a major public health
problem. It is estimated that in 2008 more than 500 million people were obese globally (Finucane et al.
2011), and by 2015 this number is projected to increase up to 700 million (Amasyali et al. 2008, World
Health Organization 2011b). The problem is serious in Great Britain, with one in 4 adults being obese
in 2009 (Bromley et al. 2010, Craig et al. 2010).
Obesity is usually diagnosed when the BMI (also named Quetelet’s index) is higher than 30 kg/m2.
Obesity has been divided into classes based on the BMI values: class I (30-34.99), class II (35-39.99)
and class III (over 40) (World Health Organization 2000). A BMI cut-off value for obesity was
reported to be a poor tool to estimate body fat because of low sensitivity as it failed to identify about a
half of people with excess body fat (Jumean et al. 2008). However, BMI has high specificity which
1 The mass of a body is a measure of how much matter it contains. Weight is a degree of attraction between two
bodies (gravity) that depends on the mass of those bodies and distance between them (altitude). ‘Weight’ is
wrongly but very widely used in the general health context and it is used in this work in place of the correct ‘body
mass’.
2means that individuals with a BMI over 30 kg/m2 usually have a high percentage of body fat (Jumean
et al. 2008). Moreover, the above quoted BMI cut off values are not applicable to all populations
because for some ethnic groups metabolic complications may develop already when BMI is over 22
kg/m2 (World Health Organization, 2000).
Due to the fact that there has been no systematic evaluation in large populations, there are no norms for
body fat percentage for the general population and precise values for body composition cannot be
recommended. The present classification of average body fat was based on healthy US population: men
12-15% and women 25-28% (McArdle et al. 2007). Also, the American Council on Exercise produced
their classification in which there are values of essential fat, athletes, fitness, average and obesity;
obesity being identified in men with over 25% and women with over 32% of body fat (Bryant et al.
2011).
Diabetes mellitus (DM) is a disorder where blood glucose levels are almost constantly elevated
(hyperglycaemia) and the metabolism of carbohydrate, fat and protein is disturbed. These
abnormalities are caused by either insulin deficiency or resistance to insulin, or both (World Health
Organization 2000). Of all the metabolic pathologies associated with obesity, in T2DM the link is best
established.
In the long term, elevated blood glucose concentrations can cause microvascular and macrovascular
complications and affect wound healing. Macrovascular complications involve coronary disease,
cerebrovascular disease or peripheral vascular disease, whereas microvascular complications include
retinopathies, nephropathies and neuropathies. Hypertension in addition to being a disease in its own
right is considered to be a complication of diabetes (Frayn 2003). There is also evidence that T2DM is
independently associated with an increased cancer risk (LeRoith et al. 2008). DM is usually suspected
when sugar in the urine is found and diagnosed when fasting plasma glucose concentration is over 7.0
mmol/l (Sims et al. 1973) or when plasma glucose concentration is over 11.1 mmol/l after 2 hours of
oral administration of 75g of glucose (World Health Organization, International Diabetes Federation
2006).
T2DM accounts for 90% of all diabetic cases worldwide (World Health Organization 2011a). It is
often a result of sedentary lifestyle and overweight and obesity. Increasing body mass, even in young
men with no family history of diabetes or obesity, causes insulin resistance, rise in fasting
concentrations of insulin, glucose, triacylglycerol and total cholesterol (Sims et al. 1973). Obesity is
3considered to be the primary risk factor for T2DM (Colditz et al. 1995, World Health Organization
2006). Less frequent type 1 diabetes mellitus (T1DM) is a disease indicated by the presence of the
pancreatic islet beta-cell antibodies, or by the idiopathic destruction of beta-cells (WHO, 1999).
The International Diabetes Federation (IDF) (2011) estimates the number of diabetes cases for 2010 to
be 285 million globally. The WHO estimates the current number to be smaller, about 220 million
(World Health Organization 2011a). This situation is foreseen to worsen: by the year 2030, the IDF
estimated the global number of people with diabetes to be 439 million (International Diabetes
Federation 2011b). Other sources predict less dramatic but still very serious increase to 366 million
(Wild et al. 2004). The WHO (World Health Organization 2011a) approximated that in 2004 high
blood sugar was the cause of 3.4 million deaths globally, while the IDF suggested a rough estimate of 4
million diabetes related deaths in 2010 (International Diabetes Federation 2011a). It is important to
note that many of these deaths are a result of cardiovascular disease.
Metabolic disorders such as obesity, inflammation, diabetes and dyslipidaemia often overlap and they
all have detrimental influence on the cardiovascular system. Cardiovascular disease affects a growing
number of people worldwide and is one of the main causes of morbidity and mortality (Rana et al,
2007). It is characteristic that people with the cluster of these risk factors, called jointly metabolic
syndrome (MS), have threefold increased risk for coronary heart disease and stroke (Isomaa et al,
2001). The WHO, in 1998, proposed a definition of metabolic syndrome, which identified individuals
with increased cardiovascular morbidity and mortality (Isomaa et al, 2001). There are several
definitions of MS. The most often used are definitions by the WHO (1999), National Cholesterol
Education Program Adult Treatment Panel III (NCEP ATP III) (2001), IDF (2005), and American
Heart Association / National Heart, Lung, and Blood Institute (AHA/NHLBI) (2005). NCEP ATP III
(2001) and AHA/NHLBI (2005) definitions are very similar and name 5 criteria of which 3 must be
fulfilled to diagnose MS. First four: waist circumference (≥102cm in men and ≥88cm in women),
elevated triacylglycerols (TG) (≥1.7 mmol/l or drug treatment for elevated TG), reduced HDL-
cholesterol (<1.03 mmol/l in men and <1.29 mmol/l in women or drug treatment for reduced HDL-C),
and elevated blood pressure (≥130 mmHg systolic or ≥85 mmHg diastolic or drug treatment for
hypertension) are the same for the two definitions. There is a difference in the fasting glucose
concentration threshold: NCEP ATP III suggests slightly higher value than AHA/NHLBI (> 6.1
mmol/l vs. ≥ 5.5 mmol/l). A variation in the criteria used in different definitions of MS has lead to
difficulty in comparing epidemiological studies (Baunduceau et al, 2008) and in diagnosing patients
who according to some definitions would have MS and according to others would not. Balkau and
4colleagues (2008), in their review of MS, suggested that “a score to evaluate the severity of the
syndrome, using a combination of continuous variables would be more logical than a syndrome
defined with arbitrary thresholds”. However, a definition that would score severity of MS has not been
yet developed.
1.1.2 Aetiology of obesity and T2DM
The estimations of a number of obese people worldwide over the next few years include an alarming
figure of 700 million (World Health Organization 2011b). The challenge for science is to identify the
causes and find solutions to this global epidemic. The large decrease in physical activity and the major
changes in the food supply over the last few decades have been identified as drivers of this process.
The term “obesogenic, toxic environment” was created to describe a combination of energy dense,
nutrient insufficient food supplies and poor conditions for physical activity (James 2008). Apart from
the environment, another reason for the global increase in obesity prevalence seems to be human
physiology. Through evolution mechanisms to deal with starvation were favoured over mechanisms
suppressing food intake. With the physiology set for survival for times of starvation, now in a time of a
plentiful food supply, we are facing a dramatic increase in the risk of becoming obese (Appel 2003).
T2DM is caused by both environmental and genetic factors. Genetic components, resulting in
metabolic disorders, play a bigger part in the development of T2DM than T1DM (World Health
Organization 1999). However, due to the obesity epidemic, the percentages of diabetes attributable to
weight gain in 2000 were about 90% in North America and over 80% in Western Europe (Rigby,
James 2003).
1.1.2.1 Aetiology of obesity
Weight gain occurs when energy intake is higher than energy expenditure over a period of time.
Common obesity is considered to be a result of an interaction between environmental and genetic
influences. However, the reality is very complex and different between populations. The theories of the
origin come from different fields (i.e. genetics, economics, sociology, psychology) and the lack of a
unifying theory has been highlighted (Ulijaszek 2008). The Foresight report (Tackling Obesities –
Future Choices, Butland et al. 2007) includes the famous “spaghetti plate” – an illustration of the
interplay between the obesity causing factors (Figure 1).
5Figure 1. The obesity system map. (Source: Foresight, Tackling Obesities – Future Choices Project
Report, Butland et al. 2007).
1.1.2.1.1 Hypotheses of the origin of obesity
As mentioned earlier, the prevalence of obesity has been dramatically rising over the last few decades.
It is known that certain genotypes, when exposed to today’s environment, predispose an individual to
weight gain. There are several hypotheses why humans have this genetic predisposition.
Neel (1962) suggested the “thrifty genotype” hypothesis which stated that in the course of the human
evolution there were periods of famine which were long enough to cause natural selection towards
efficient fat storage in the times of plenty. This was the start of the search for the ‘thrifty’ genes.
However, Neel in the same paper presented another possible hypothesis claiming that obesity and
diabetes are a new phenomenon associated with the changes not in genes but in the environment (i.e.
diet, physical activity, stress) (Neel 1962).
6Later, Hales and Barker (1991) proposed the “thrifty phenotype” hypothesis in which the factor
predisposing to obesity was not genetic but environmental. They claimed that thrifty factors, being
obesity and T2DM, resulted from insufficient nutrition during prenatal development which
programmed conservation of energy later in life. This hypothesis was supported by data demonstrating
the greater prevalence of diabetes among individuals with low birth weight (Hales et al. 1991).
Speakman (2006) suggested that it might be the time to call off the search for the thrifty genes. He
pointed out the flaws of the thrifty genotype hypothesis, saying that famines were relatively rare in
human evolution, caused the death of less than 10% of populations and deaths were usually due to
disease, not body weight. Speakman suggested that obesity could not have been the preferred
phenotype because of the risk of being too attractive for predators (Speakman 2006). After humans
invented tools and started using fire, the predation risk was eliminated and Speakman proposed that
random genetic mutations and drift were the only factors that predisposed to body fatness (Speakman
2007). The hypothesis that obesity may be due to an absence of selection (lack of predation and
insufficient influence of famines), and also due to genetic drift, was called the ‘drifty gene’ hypothesis.
Prentice and colleagues did not agree with Speakman’s drifty genotype hypothesis and modified the
thrifty genotype hypothesis, stating that the natural selection in favour of fat storage occurred and was
mediated through fertility (Prentice, Hennig et al. 2008). However, the counter-argument was proposed
by Speakman who argued that reduced fertility during famines was usually followed by enhanced
fertility, which compensated for the times of food deprivation (Speakman 2008a).
The knowledge of which genes predispose to weight gain and how they can interact with the
environment will provide the key to understanding and tackling the obesity epidemic.
1.1.2.1.2 Genes
The main methods used to investigate genetic loci for obesity and T2DM during the last 15 years were
candidate gene studies and genome-wide linkage studies. The progress of candidate gene studies has
been slow until recently, when meta-analyses and large studies identified a few gene variants
associated with obesity (Vimaleswaran et al. 2010). Genome-wide linkage studies were not successful
at finding loci for obesity. Saunders and colleagues (Saunders et al. 2007) published a meta-analysis of
genetic linkage data of BMI and BMI defined obesity from 37 studies. The data included 31,000
individuals from 10,000 families. However, despite sufficient statistical power the study did not
7identify loci for obesity. The last published update (12th) of the Human Obesity Gene Map (2005) has
identified 127 candidate genes associated with obesity-related phenotypes (Rankinen et al. 2006).
Methods used in the studies that contributed to building the map used mostly candidate gene and
genome-wide linkage approaches.
The genome-wide association approach started to be used in 2005 and has now replaced genome
linkage studies. It was proven to have better resolution, be more cost effective and easier as it does not
require recruiting related individuals (Vimaleswaran et al. 2010). This method can identify genetic loci
associated with the disease investigated. Usually, genome-wide association studies have a discovery
stage followed by one or more replication stages that validate the initial finding (Vimaleswaran et al
2010). Up to February 2010, there have been 19 loci identified that are associated with obesity
(Vimaleswaran et al. 2010). Among these loci, the first one found and also the one that has the largest
effect on obesity susceptibility, was the fat mass and obesity associated (FTO) gene region (Fawcett et
al. 2010). A number of studies investigated functions of FTO and it was summed up that the gene, in
human, has a role in controlling energy intake but not energy expenditure (Fawcett et al. 2010,
Speakman et al. 2008b).
Heritability of obesity has been found to explain 30-40% up to 80% of the variation in BMI (Martinez-
Hernandez et al. 2007, McPherson 2007, Allison et al. 1996). The percentage is dependent on the
ethnic group but has not yet been fully scientifically explained (Blakemore 2008).
Genes that increase the susceptibility to obesity have been divided into four major groups: (1) genes
regulating food intake, (2) genes that affect adipocyte differentiation and fat storage, (3) genes
involved in the regulation of spontaneous physical activity and finally (4) genes regulating basal and
postprandial thermogenesis (McPherson 2007). Blakemore and Froguel (Blakemore 2008) in their
review of genetics of obesity pointed out that the current evidence mainly supports the importance of
genes regulating appetite (i.e. leptin, melanocortin). Degeneration of these genes such as disturbances
of gene transcription or altered protein function may predispose to obesity. On the basis of the number
of genes involved, obesity was divided into monogenic, syndromic or polygenic (Martinez-Hernandez
et al. 2007).
Monogenic obesity, caused by a defect in a single gene is rarely seen in humans. Up to October 2005,
the human obesity gene map reported the discovery of 11 genes in which mutations resulted in obesity
(Rankinen et al. 2006). Examples of candidate genes for causing monogenic obesity are: Trp64Arg
8variant in the beta-3 adrenergic receptor gene, Val103Ile variant in melanocortin-4 receptor (MC4R),
single nucleotide polymorphisms (SNPs) in pro-opiomelanocortin (POMC) and also leptin (LEP),
leptin receptor (LEPR), and neurotrophic tyrosine kinase receptor 2 (NTRK2) (Farooqi et al. 2007).
The prevalence of single mutations in these genes in the general population is very low, which leads to
the conclusion that the obesity epidemic is not caused by the single-gene mutations. The discovery of
these rare mutations provides a basis for understanding pathways involved in the regulation of body
weight, for example pathways regulating food intake and energy expenditure (Loos et al. 2003).
Syndromic obesity is one of the phenotypic features of rare genetic or chromosomal defects. Other
features of these defects may include organ dysfunctions, mental retardation or dysmorphic features.
There are about 30 syndromes that result in obesity (Martinez-Hernandez et al. 2007). However, they
constitute a very small number of all obesity cases. The well known genetic endocrinopathies causing
obesity are: the Prader-Willi syndrome (occurring 1 in 25000 cases); even less common are the Bardet-
Biedl syndrome, Albright’s hereditary osteodystrophy and Cohen’s syndrome (Martinez-Hernandez et
al. 2007).
Polygenic obesity is the most commonly observed case. It is characterized by several genes interacting
and contributing to the obese phenotype; those effects can be additive or non-additive (Hinney et al.
2010). It is also not known whether obesity is caused mostly by common polymorphisms or by the
varied combinations of different polymorphisms (Farooqi et al 2007)
Loos and Bouchard (2003) proposed four levels of genetic determination of obesity in relation to the
environment. The levels were as follows: genetic obesity – when obesity occurs despite the
environment; strong genetic predisposition – when an individual is overweight in a normal
environment and obese in an obesogenic environment; slight genetic predisposition – when an
individual is normal-weight in a normal environment and overweight in an obesogenic environment;
and genetic resistance – when an individual is normal-weight even in an obesogenic environment.
The relationship between environment and genes can mean that the environmental factor modifies the
activity of the protein coded by the investigated gene. Also, some genes can influence the effect of
physical activity or food intake on the phenotype. If there is some degree of an additive effect of
environmental and genetic factors, then this interaction can influence a trait like body weight or BMI
(Martinez-Hernandez et al. 2007). At the population level, both the exposure to an obesogenic
environment and a high genetic susceptibility increases the risk of obesity. It is important to remember
9that environmental influences, as opposed to the genetic ones, can be modified (e.g. diet, physical
exercise). Moreover, there is also the possibility of gene-gene interactions with genes attenuating or
weakening each other’s influences.
The complexity of the genetics of human obesity cannot be underestimated. The complete knowledge
of human obesity genes would allow for the treatment of genetic obesity syndromes, the discovery of
drugs that target molecular pathways that control human energy balance, and the classification of obese
individuals into subgroups that respond to specific treatments like diets, drugs, exercise or surgery
(Farooqi et al. 2007).
1.1.2.1.3 Environment
Although genes may predispose to becoming obese, it is highly unlikely that they have significantly
changed since the 1980s when the obesity epidemic started. The most likely factors that influenced the
huge rise in obesity prevalence were changes in the environment and society. The World Health
Organization (2000) report on obesity points at modernisation, economic restructuring and transition to
market economies, increasing urbanisation, changes in the role of women and social structures, and
globalisation of world markets as the main environmental influences.
Swinburn and colleagues (1999) defined the obesogenic environment as the ‘sum of influences that the
surroundings, opportunities, or conditions of life have on promoting obesity in individuals or
populations’. These influences were grouped into 4 types: (1) food availability, (2) cost, (3) policies
concerning food and (4) attitudes and beliefs relating to food. Each type of influence was proposed to
have 2 sides: “micro-environmental” if it describes an effect on individual behaviour choices; and
“macro-environmental” if it concerns food supply and lifestyle. The same authors in 2004 proposed a
model of interactions between factors that promote obesity (movement inertia, mechanical dysfunction,
psychological dysfunction, dieting, low socioeconomic status) and prevent obesity (social
discrimination, personal physical discomfort, knowledge about weight gain causes, physiology). The
model acknowledged that factors promoting obesity are stronger than those preventing it and apart
from causing obesity they also prevent its management (Figure 2).
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Figure 2. Model of interactions between factors that promote and prevent obesity (Source: Swinburn
and Egger 2004).
The division of the obesogenic environment into “food environment” and “physical activity
environment” suggested by Hill (2006) can be analogously generalised to an “energy intake
environment” and “energy expenditure environment”. The changes that have been recently occurring in
these environments can be summarised as a tendency to overeat and to be sedentary. Changes in both
energy intake and energy expenditure environments were happening simultaneously.
The changes in the food environment during the last few decades are a reflection of urbanisation and
globalisation of world markets, which made the food more available and easily affordable (Ulijaszek
2008). The development of technology influenced the food industry which resulted in the creation of
many new foods that were attractive and palatable and did not necessarily have appropriate nutritional
value. The availability and palatability conspire to create an environment where passive overeating is
likely. Therefore, there has been a shift towards the consumption of energy dense foods which are
cheaper and more strongly advertised than the healthier options. Also, the world-wide trend for women
to work full-time has added to the global change in the food environment. As women do not have time
to cook, there has been an increasing demand for ready made meals, home deliveries and takeaways,
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which usually are high in fat and/or sugar. Passive overeating over a longer period is likely to occur
when such foods are consumed.
The physical activity environment (Hill 2006) has been changing along with the food environment.
Advancing technology has allowed jobs, that in the past required hard physical work, to be done by
machines. Nowadays, many jobs are being done sitting (e.g. using computers). The options of spending
leisure time being physically inactive are also very broad (TV, internet, video games, etc.).
Additionally, transportation modalities have changed and people walk less than they ever did.
Moreover, the urbanisation and community design often promote the use of cars rather than bicycles or
walking. All these factors result in decreased energy expenditure. Bell and co-workers (2004) showed
that individuals with higher energy expenditure and intake are better at regulating energy balance than
individuals with lower energy expenditure and intake. In other words, they showed that high energy
flux helps to regulate energy balance more accurately. Therefore, physical inactivity does not only
make it easier to gain weight because of proportionally too high energy consumption but also weakens
the body’s ability to regulate energy balance.
1.1.2.1.4 Behaviour and lifestyle
Humans, just like other mammals, have a tendency to overeat when food is plentiful, palatable and
high in fat. However, as mentioned above, the availability of food for humans is different than for other
non-domesticated mammals. There are social and cultural eating norms and, on an individual level,
there are also personal feeding constraints (Ulijaszek 2008). All these influences make the behavioural
model of human feeding very complex. The diagram from the Foresight report (on Figure 1) illustrates
those relationships. There are various psychological theories for the causes of obesity. Generally, they
associate obesity with behavioural, cognitive or emotional processes (British Nutrition Foundation
2000). The origin of those processes can be genetic, environmental, or the interaction of both.
Social differences also influence the risk of obesity. It has been established that higher socio-economic
groups and those (with higher income) eat healthier foods and their physical activity is higher than
subjects from lower groups (Ulijaszek 2008). In contrast with tradition of regular meals at set times, it
has become culturally acceptable to have and consume food almost everywhere and at all times.
1.1.2.1.5 Physiology
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Appetite and satiety are centrally regulated by the hypothalamus. The hypothalamic function is
regulated by certain hormones: insulin, glucagon, gut-peptides, leptin, melatonin and cytokines. Within
the hypothalamus there are specific peptides operating on numerous pathways that either stimulate or
suppress appetite and satiety. These pathways often have very similar functions; therefore if one fails,
others can compensate (British Nutrition Foundation 2000). The systems that regulate human feeding
behaviour work in both the short term and long term (Frayn 2003). The full neuroendocrine map of
human feeding control is very complex and there are still areas that need to be investigated. Figure 3
presents a simple model of negative-feedback regulation of food intake proposed by Morton et al.
(2006) in their review on central nervous system control of food intake and body weight.
Figure 3. Regulation of food intake in response to adiposity signals (Source: Morton et al. 2006).
ARC, arcuate nucleus; DMN, dorsomedial nucleus; FX, fornix; ME, median eminence; PFA,
perifornical area; VMN, ventromedial nucleus.
The homeostasis of body weight maintenance, namely the mechanisms that prevent the body gaining
or losing weight vary between individuals. Weight gain occurs when energy intake is greater than the
body’s ability to compensate with energy expenditure. The physiological control of the reduction of
food intake is weak (Ulijaszek 2008) but the body does have the mechanisms to address this. Swinburn
and Egger (2004), in their model of the obesity epidemic drivers (Figure 2) placed physiology as one of
the factors that counterbalanced obesity. Among the physiological mechanisms that prevent weight
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gain, they listed a decrease in appetite; increase in fat oxidation; increase in energy expenditure;
occurrence of insulin resistance; increase in the activity of sympathetic nervous system and increase in
leptin concentration.
1.1.2.2 Development of T2DM
There are two theories on the causes of hyperglycaemia; “glucocentric” and the more modern
“lipocentric”. The classic glucocentric view on the causes of hyperglycaemia assumes that there is an
impaired glucose metabolism. According to this view, the cause of hyperglycaemia is insulin resistance
resulting from obesity and the loss of pancreatic beta-cells. Seen as a disease of glucose metabolism,
T2DM should therefore be treated with glucose lowering drugs and insulin. The lipocentric view
recognizes calorie surplus as the reason for hyperglycaemia in T2DM (Figure 4). The majority of type
2 diabetic patients are overweight and obese (World Health Organization 1999). Therefore, T2DM
ought to be treated by eliminating excess calories and excess body weight. According to this view,
insulin therapy should be a last resort in the treatment of T2DM.
There is a paradox of insulin resistance during T2DM. The body is resistant to insulin action on the
glucose metabolism and at the same time sensitive to insulin action on lipogenesis. The paradox exists
because these two actions have different molecular pathways. Resistance to insulin action on the
glucose metabolism occurs because insulin down-regulates insulin receptor substrate 2 (IRS-2), which
is the main effector of insulin signalling in the liver (Boissan et al. 2005). This results in liver
resistance to suppress glucose production. On the other hand, sensitivity to insulin action on
lipogenesis is observed because insulin stimulates production of sterol response binding element
protein 1c (SREBP-1c), which stimulates lipolysis. Increased liver synthesis of fatty acids may in the
long run lead to increased adiposity.
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Caloric surplus
Hyperinsulinemia
Increased expression of the lipogenic transcription factor SREBP-1c
Increased lipogenesis
Increased adiposity
Ectopic lipid deposition
Insulin resistance
Beta-cell lipotoxicity
Hyperglycaemia
Figure 4. Pathway to hyperglycaemia according to the lipocentric view on T2DM (Unger et al. 2008).
Stefanović and co-workers (2008) reported that an increased oxidative stress and elevated levels of
leptin which occur during obesity are likely to play a role in the development of T2DM (Figure 5).
Oxidative stress causes insulin resistance and beta-cell dysfunction. Elevated levels of leptin are
considered to be the main mediator of insulin resistance induced by oxidative stress. Although leptin
concentrations depend on the adipose tissue excess and not on the presence of diabetes, these
concentrations were higher in obese patients with T2DM than in obese non-diabetics (Stefanović et al.
2007).
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Figure 5. Interrelationship between levels of leptin, oxidative stress, obesity and T2DM (based on
Stefanović et al. 2007). Obesity causes insulin resistance (1), higher levels of leptin (2) and increases
oxidative stress (3). Both hyperleptinemia (4) and an increased oxidative stress (5) can cause insulin
resistance which in the long run may cause T2DM (6). Elevated concentrations of leptin are said to
induce oxidative stress (7). T2DM can cause oxidative stress (8) through an increased concentration of
glucose and free fatty acids. Finally, oxidative stress can contribute to the development of T2DM (9)
by causing pancreatic beta-cell dysfunction.
It was shown that circulating serum levels of leptin were more closely associated with subcutaneous
than visceral adipose tissue (Wauters et al. 1998, Park et al. 2004). Montague et al (Montague et al.
1997) and Lefebvre et al (Lefebvre et al. 1998) also showed that leptin mRNA expression levels were
higher in subcutaneous than in visceral adipocytes. Additionally, women tend to have higher leptin
levels than men, due to more body fat and less visceral fat until menopause. Bennett et al (1997)
observed that this was also the case after the correction for fat mass. They suggested that this
difference can be explained by different partitioning between subcutaneous and visceral fat.
Genome-wide association studies identified up to date about 30 loci associated with risk of T2DM. It is
possible to predict diabetes in a general population using risk scores developed from the identified loci.
A study by Hivert et al (2011) on over 2800 participants from the United States, has shown that in high
risk individuals, genetic risk score was associated with the higher risk of getting diabetes.
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The difficulty in fighting the obesity epidemic lies in its complex and multifactorial etiology. It is
equally hard to tackle T2DM with it being much related to obesity (90% in North America and 80% in
Western Europe; Rigby and James, 2003). Therapies stemming from the glucocentric view of the
disease development that aim to lower blood glucose levels, may ease the complications but cannot
address its causes. Some of the newer drugs (i.e. incretin mimetics) along with lowering blood glucose
can also induce a certain amount of weight loss. Finally, weight loss has been shown to be a very
successful strategy for T2DM treatment, proving the validity of the lipocentric view of the obesity
origin. Therefore, the recent Scottish Intercollegiate Guidelines Network (2010) guidelines on the
management of diabetes state that obese patients with T2DM should be offered individualized obesity
treatments to achieve metabolic control (SIGN, 2010). The interplay of genetic and environmental
factors involved in T2DM etiology is complicated and the sets of genes involved and the
environmental circumstances are different for each individual.
1.1.3 Tackling obesity and T2DM
There are numerous programmes, guidelines and recommendations that aim to tackle obesity and
T2DM at the individual level. The majority of these suggest lifestyle changes, namely improvements in
the quality of diet and increases in physical activity. This approach is not new. Hippocrates recognized
that the diseases are caused naturally by environmental factors and lifestyle and therefore advised
treatments that very often addressed diet and physical activity (Mantzoros 2006). In 1934, William
Howard Hay wrote in ‘Health via Food’: “All we can do about disease after all is to stop creating it
daily, as we do by our customary habits of living”. Anand and Yosuf (2011) when commenting on the
very recent world BMI trends report (Finucane et al. 2011) concluded that the global population should
be a part of the solution to the global obesity problem, in other words, a problem that affects everyone
should be corrected with everyone’s effort.
Currently, the WHO suggests preventive measures of limiting energy from total fats, and consuming
more unsaturated fats; increasing consumption of fruit, vegetables, legumes, whole grains and nuts,
limiting sugar intake and increasing physical activity to 30 minutes of moderate intensity activity on
most days (World Health Organization 2011b). The WHO leaves the implementation of the above
recommendations to governments, public and individuals. The National Institute for Health and
Clinical Excellence (NICE 2008) placed lifestyle and diet modifications as the first step in the
treatment of obesity and T2DM. If these are not sufficient, then appropriate oral medications and
perhaps insulin with the latter should be introduced (NICE 2008).
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On the national level, there are many projects and actions undertaken to tackle both obesity and T2DM.
The UK government Foresight Programme produced the ‘Foresight Tackling Obesities: Future
Choices’ report that presents challenging visions of the future, to stimulate appropriate actions now.
The report predicts that if no action is taken, in 2050 obesity will affect 60% of men and 50% of
women (Butland et al. 2007). Recently, the Scottish government published a document ‘Preventing
Overweight and Obesity in Scotland: A Route Map Towards Healthy Weight’. The report was aimed at
decision makers in local and central government. It outlined policies that are already in place and
stressed that the scale of preventive activities has to increase. Finally, the report listed further
government actions that have to be taken in order to address the obesity problem (The Scottish
Government 2010). Among those actions were controlling exposure to energy consumption by
intervening at the food supply level, increasing opportunities for energy expenditure by promoting and
facilitating physical activity, delivering early life interventions to develop positive health behaviours,
increasing responsibility of organizations for health of their employees, raising awareness among
decision makers or changing public attitudes. The English government has produced the ‘White Paper
Healthy Lives, Healthy People: Our Strategy for Public Health in England’, which described
government’s plans to improve various areas of public health (HM Government, Department of Health
2010). The key documents linked to this paper will follow; the obesity document is planned to be
published in spring 2011.
At the world wide level, the WHO produced the WHO Global Strategy on Diet, Physical Activity and
Health which outlines what has to be done to promote healthy diets and physical activity. The
Department of Nutrition for Health and Development of the WHO additionally promotes healthy
nutrition to address the nutrition-related health problems. This work is done by supporting countries in
building and implementing nutrition policies. The work also aims to contribute to the achievement of
the Millenium Development Goals (United Nations 2010). Finally, there are organizations and charities
that address the issues of obesity and diabetes, promote research, encourage education and help to
support affected individuals. Examples include the International Association for the Study of Obesity,
Diabetes UK and the American Diabetes Association.
During the recent years, scientists have become interested in the use of high-protein, low-carbohydrate
diets as supplementary treatment for T2DM, obesity and also CVD. Westman and colleagues
(Westman et al. 2007) argued that before agriculture allowed access to starchy foods, people lived on
low-carbohydrate, high-protein diets, and therefore such a nutritional approach should be well accepted
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by humans. There is a counter argument that carbohydrate intake was high due to fruit and berry
scavenging in some parts of the world. However, carbohydrate amounts and the nutritional value of
berries and fruit (hand-picked) cannot be compared to those of processed foods available in unlimited
quantities nowadays.
It was proposed that, as recent increases in the prevalence of obesity and diabetes occurred
concomitantly with an increase of carbohydrate consumption, restriction of carbohydrate intake may
prove a successful therapy for these diseases (Westman et al. 2007). The Hindu physician Sushruta,
who lived in the 6th century BC, described a disease of sweet urine (Tattersall 2009). The physician
observed that this disease was occurring in families, and people who had it, were often overweight.
Sushruta recommended physical activity and diet consisting of vegetables as the treatment for obese
people with this disease (Tattersall 2009). Before insulin therapy became available for diabetic patients
in the 1920s, the main treatment for diabetes was a low-carbohydrate diet, normal or high in protein
and very high in fat (Yancy et al. 2005, Westman et al. 2006). Such a diet resulted in the control of the
glucose levels in the urine (Westman et al. 2007).
1.2 Cardiovascular risk in obesity and T2DM
1.2.1 Cardiovascular risk in obesity
Obesity increases the risk of coronary heart disease (Zalesin et al. 2008) and stroke (Chan et al. 1994).
Coronary heart disease (CHD) is the main reason for mortality among the obese (British Nutrition
Foundation 2000). Excess adipose tissue increases the risk of developing cardiovascular disease (CVD)
by association with increased inflammation processes, hypertension, increase in triacylglycerol (TG)
levels, and changes in high density lipoprotein cholesterol (HDL-cholesterol) and low density
lipoprotein cholesterol (LDL-cholesterol) to smaller and denser particle sizes (Frayn 2003).
It has been established that tissues may become resistant to insulin action when obesity develops.
Metabolic changes observed in obesity come mostly from insulin resistance (Frayn 2003). Typically,
the level of HDL cholesterol decrease and the levels of both LDL-cholesterol and TG increase. If the
LDL-cholesterol particles are smaller and denser than in the healthy conditions, this profile is described
as an atherogenic lipoprotein phenotype (Frayn 2003).
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Elevated total cholesterol levels are associated with atherosclerosis (Willeit et al. 2000).
Atherosclerosis is a process in which fatty acid deposits build up in the arterial walls (Frayn 2003).
These deposits start from the damage to the arterial wall (Ross 1999). The damage may be caused by
oxidative stress, hypertension, hyperlipidaemia (especially high LDL cholesterol), chronic infections,
smoking, frequent alcohol consumption (Willeit et al. 2000) and also by the elevated concentrations of
glucose in blood (Massi-Benedetti et al. 1999). The damage causes endothelial dysfunction and results
in inflammatory processes. The process of formation of atherosclerotic lesion that results from the
damage to the endothelium is explained on Figure 6. Atheromateous plaque has a complex structure
that comprises of lipids rich in cholesterol and inflamed, proliferating cells of smooth muscle and
connective tissue. Atheromateous plaque narrows arteries, which may result in the insufficient supply
of blood to the organs. Atherosclerosis of coronary arteries (coronary heart disease) is especially
dangerous, as it can result in chest pains (angina) due to ischemia and even in death. The Framingham
study has shown that both adiposity and coronary risk factors relate to the volume of coronary plaque
(Takeshita et al. 2008).
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Figure 6. Damage to the vascular endothelium and formation of an atherosclerotic lesion (adapted
from Arici and Walls, 2011). SMC – smooth muscle cells.
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Obesity also has a lipotoxic effect on the heart itself. Increased concentrations of TG in non-adipose
tissues (steatosis) are likely to increase intracellular acyl-CoA. Acyl-CoA is a substrate for ceramide
synthesis which leads to cell dysfunction and apoptosis (Rana et al. 2007). Moreover, elevated non-
estrified fatty acids (NEFA) concentrations can cause an irregular heartbeat and in severe cases,
ventricular fibrillation which is an irregular fluttering of ventricles that can lead to death (Frayn 2003).
1.2.1.1 Lipid profile
The atherogenic lipoprotein phenotype characteristic for obesity, metabolic syndrome and T2DM
(Packard 2003) increases the risk of coronary heart disease by predisposing to atherosclerosis. The
mechanism for this process is associated with insulin resistance and illustrated in Figure 7.
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KEY:
1. In obesity, NEFA are released from
adipocytes into the blood and they
compete with glucose for uptake into
skeletal muscles which can be part
of the reason for insulin resistance
(Parker, Noakes et al. 2002,
Miyashita, Koide et al. 2004).
2. During insulin resistance, the rates of
lipolysis in adipocytes increase
causing even more elevated NEFA
levels (Volek, Sharman et al. 2004).
3. Increased concentrations of NEFA
promote the secretion of VLDL1.
4. An increase in VLDL1 concentrations
facilitatesTG transfer from VLDL1 to
LDL and HDL and cholesteryl esters
from HDL and LDL to VLDL1 via
CETP (Frayn 2003).
5. This results in VLDL1 becoming
richer in cholesterol and HDL and
LDL richer in TG.
6. Additionally, LPL hydrolyses large
VLDL1 to LDLβ that has longer life in
circulation than LDL hydrolysed from
normal sized VLDL.
7. Longer life of LDLβ gives the particle
more opportunities to be remodelled
by CETP and to become rich in TG.
8. Particles of both LDL and HDL rich in
TG are more prone to the action of
HL which removes TG and makes
them smaller and denser.
Figure 7. Stages in the linkage of insulin resistance and atherosclerosis (adapted from Packard, 2003).
NEFA – non-estrified fatty acids; VLDL1 – large VLDL particles; CE – cholesteryl esters; CETP -
cholesteryl ester transport protein; LDLβ – LDL with prolonged life; LPL – lipoprotein lipase; HL –
hepatic lipase; TG, triacylglycerol.
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HDL, when rich in TG, becomes susceptible to the lipolytic action of hepatic lipase (HL) (Volek et al.
2004). Hepatic lipase turns HDL into smaller, denser particles. Small HDL is less able to accept
cholesterol from tissues for transfer to the liver and consequently levels of cholesterol in blood rise.
Cholesteryl ester transfer protein (CETP) transfers TG from VLDL cholesterol into LDL cholesterol.
Lipolytic hydrolysis of TG-rich LDL particles by hepatic lipase (HL) results in the formation of small
LDL particles (Packard 2003). Small, dense LDL cholesterol has a lower affinity to LDL receptors,
therefore its life in circulation is longer and consequently chances of infiltration of arterial walls are
higher. Additionally, smaller, denser LDL particles are more prone to oxidation (Packard 2003), which
further increases the risk of developing atheromateous plaque.
1.2.1.2 Endocrine activity of adipose tissue
In adults, the majority of the fat tissue is composed of white adipose tissue (WAT). Brown adipose
tissue is characteristic of neonates; the darker colour is a result of a high number of mitochondria in
brown adipocytes. WAT includes not only adipocytes and pre-adipocytes, but also other types of cells
like macrophages, endothelial cells, leukocytes and fibroblasts (Wozniak et al. 2008).
WAT has a significant role in energy homeostasis, immunity and inflammation (Antuna-Puente, Feve
et al. 2008) because it produces specific molecules, named adipose derived hormones or adipokines.
Adipokines are involved in autocrine and paracrine signalling and include leptin, adiponectin, resistin,
and also adipsin, visfatin, apelin, vaspin, hepcidine, chemerin and omentin (Trayhurn 2005, Wozniak
et al. 2008). WAT also has the capability of producing various inflammatory cytokines.
One of the features of obesity is a mild inflammatory state (Trayhurn 2005). An increase in the amount
of fat tissue is related to the increase of inflammation-related adipokines. Therefore, levels of
inflammatory markers are higher in obese subjects (Trayhurn 2005). Increased inflammation in obese
individuals may result in the occurrence of T2DM or metabolic syndrome. For example, increased
concentrations of leptin, resistin and TNF-α impair insulin sensitivity and trigger atherogenesis (Rana
et al. 2007).
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1.2.1.3 Inflammation
Typically, obesity and T2DM are characterized by a state of chronic low-grade inflammation that
occurs in the liver, muscles and adipose tissue (Rana et al. 2007). It has been observed that in obese
individuals there is an increased macrophage infiltration of WAT (Heilbronn 2008). Macrophages as
well as WAT secrete various pro-inflammatory molecules.
Cytokines are molecules that facilitate cellular communication (proteins, peptides, glycoproteins).
They are critical for the function of the immune system. Cytokines are secreted by immunity cells in
response to pathogens. There are cytokines with pro- and anti-inflammatory properties. Cytokines
secreted by adipose tissue are called adipocytokines and include interleukin (IL)-1beta, IL-6, IL-8, IL-
10; tumour necrosis factor (TNF)-α; plasminogen activator inhibitor (PAI)-1; and retinol binding
protein 4 (RBP4); monocyte chemoattractant protein-1 (MCP-1), macrophage migration inhibitory
factor, nerve growth factor, vascular endothelial growth factor, and haptoglobin (Trayhurn 2005,
Wozniak et al. 2008, Antuna-Puente et al. 2008).
Pro-inflammatory adipocytokines play a role in the pathogenesis of atheroscleroctic cardiovascular
disease (Amasyali et al. 2008). Interleukin-6 (IL-6) is a cytokine with both pro- and anti-inflammatory
properties and is secreted by macrophages and T-cells. In obesity, and also in T2DM, IL-6
concentration is increased and the compound is thought to interfere with insulin action by suppressing
insulin signalling transduction (Rana et al. 2007). IL-6 has the ability to inhibit TNF-α which is another
pro-inflammatory cytokine, and one of the regulators of vascular homeostasis (Zhang et al. 2009).
TNF-α can inhibit viral replication; induce apoptotic cell death and inflammation. If over expressed,
TNF-α induces the production of reactive oxygen species (ROS) which results in endothelial
dysfunction (Zhang et al. 2009). Another cytokine, PAI-1, is produced by endothelial cells and also by
adipose tissue. It inhibits activators of fibrynolysis, and therefore inhibits the degradation of blood
clots. IL-18 is a proinflammatory cytokine produced by macrophages. IL-18 induces severe
inflammatory reactions.
Cytokines 1, 6, 8, and TNF-α all stimulate the liver to produce proteins of the acute-phase group. As
their levels increase the response to inflammation, they are often used as markers to assess the state of
inflammation. Acute-phase proteins have various functions during inflammation, for example
opsonization2 of antigens (C-reactive protein), inhibition of micronutrient uptake by microbes (ferritin,
2 opsonization is the process by which an antigen is marked for destruction by a phagocyte.
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haptoglobin), inhibition of coagulation or fibrynolysis (alpha-2-macroglobulin) or facilitation of
immune cell migration to the sites of inflammation (serum amyloid A) (Gruys et al. 2005).
C-reactive protein (CRP) is a marker of inflammation that is produced in the liver. The protein is
produced in response to high levels of IL-6 and it binds to microbes and enhances phagocytosis by
macrophages. Elevated CRP levels are associated with an increased risk of cardiovascular disease. The
risk is considered low when the concentration of CRP is lower than 1mg/L and is accepted as high
when the concentration is higher than 3 mg/L (Shine et al. 1981, Seshadri et al. 2004). Levels higher
than 10 mg/l are considered to be alarming in a biochemical setting (Shine et al. 1981). CRP levels
were found to be decreased with weight loss only in insulin resistant obese subjects (McLaughlin et al.
2002). These effects were proportional to the amount of weight lost but independent of dietary
macronutrient composition.
Apart from producing molecules that promote atherogenesis, WAT also produces a hormone which has
anti-atherogenic actions: adiponectin. Unfortunately, in obesity, diabetes, atherosclerosis and
hypertension, concentrations of this hormone are decreased (Han et al. 2007). Anti-atherogenic effects
of adiponectin include the increase of secretion of nitric oxide (NO) and the inhibition of production of
adhesion factors (Maia-Fernandes et al. 2008).
1.2.1.4 Blood pressure
Hypertension can cause vascular endothelial injury predisposing to atheroma formation (Turner et al.
2002). Systems involved in the aetiology of hypertension in obese patients are complex
(Kurukulasuriya et al. 2008) and are still being investigated. The main mechanisms considered are the
activation of the sympathetic nervous system and the dysregulation of the renin-angiotensin-
aldosterone system (RAAS) and the cardiac natriuretic peptide (CNP) system.
In obesity, the sympathetic nervous system is constantly activated (Morse et al. 2005). The sympathetic
nervous system is a part of the autonomic nervous system and mobilizes the body during activity. The
sympathetic over-activity affects kidneys by increasing the reabsorption of sodium in the renal tubules
(Rahmouni et al. 2005) and also causes peripheral vasoconstriction (Morse et al. 2005). Therefore,
sympathetic activation leads to hypertension. Rahmouni and co-workers (2005) suggested that this
activation is caused by hyperinsulinemia, hyperleptinemia, increased NEFA concentrations, and
increased aldosterone concentrations.
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The RAAS is dysregulated in obese patients (Sarzani et al. 2008). RAAS is an endogenous system that
answers to a decrease in renal perfusion and promotes hypertension by increasing tubular active
reabsorption of chloride and sodium, the secretion of potassium, and also water retention. In obesity,
this system is activated and therefore blood pressure increases. RAAS influences the metabolism of
adipocytes, because angiotensin II stimulates adipogenesis and adipocytes metabolism (Karlsson et al.
1998). Angiotensin II is produced by the cleavage of angiotensinogen by angiotensin converting
enzyme and renin (Karlsson et al 1998). Angiotensionogen mRNA levels were found to be higher in
the visceral fat than in the subcutaneous fat (Duserre et al. 2000). This relationship was more
pronounced in obese individuals.
Another mechanism that is likely to cause hypertension in the obese is the dysregulated CNP system.
Obese patients were found to have lower levels (Sarzani et al. 2008) and lower biological activity of
CNP (Morse et al. 2005). CNP is involved in the sodium balance and metabolism, by inducing
natriuresis and diuresis and also by inducing lipolysis and mobilization of fat stores (Sarzani et al.
2008).
1.2.2 Cardiovascular risk in T2DM
Diabetes is a major independent risk factor for CHD and other forms of cardiovascular disease (NHLBI
2002). The AHA (2007) considers T2DM along with overweight, obesity, high blood pressure and
high blood total cholesterol as a risk factor for stroke (AHA 2007).
The widely used markers of cardiovascular risk factor are the blood lipid profile (TC, HDL, LDL and
TG), blood pressure, waist circumference or waist to hip ratio (WHR) as well as the percentage of body
fat and serum concentration of C-reactive protein. Hyperglycaemia is the main risk for adverse
cardiovascular outcomes of T2DM and it is independent of other cardiovascular risks that are likely to
occur during diabetes such as overweight, obesity and dyslipidaemia (National Heart, Lung and Blood
Institute 2002). Hyperglycaemia causes the release of inflammatory cytokines, endothelial dysfunction
and hypercoagulability (Golden et al. 2007).
Tight glycaemic control reduces the risk of microvascular complications in diabetes but only a trend
towards reducing macrovascular complications has been reported (National Heart, Lung and Blood
Institute 2002). Endothelial dysfunction and disturbances in vascular structure were proposed to be a
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result of a series of processes activated by hyperglycaemia, like oxidative stress. Oxidative stress
inhibits nitric oxide (NO) production. Instead of NO, peroxynitrite and nitrotyrosine are produced.
Nitrotyrosine may cause cardiomyocyte apoptosis and vascular DNA damage (Rana et al. 2007).
Monitoring of lipid profile in patients with diabetes is of a high importance. Diabetics compared to
non-diabetics have elevated TG and fibrinogen and decreased HDL-cholesterol concentrations (Kannel
et al. 1990). Additionally, patients with T2DM also have elevated concentrations of non-estrified fatty
acids (NEFA) (Frayn 2003). Patients with both metabolic syndrome and T2DM, have increased levels
of small, dense LDL particles which are more atherogenic (Rana et al. 2007). The especially harmful
lipid profile, also called the “lipid triad” is characterized by the elevated TG, decreased HDL-
cholesterol and increased levels of small, dense LDL-cholesterol (Rana et al. 2007). Therefore one of
the main aims of treatment for patients with T2DM should be improvement of their lipid profile.
It was shown that weight loss in obese type 2 diabetic patients improves risk factors for CHD and
lowers glycaemia (Heilbronn et al. 1999). Moreover, the ATPIII report (National Heart, Lung and
Blood Institute 2002) stated that weight reduction will achieve more overall risk reduction than will
LDL lowering without an emphasis on weight control.
1.3 Treatments for obesity and T2DM
Treatment of obesity in subjects with T2DM is recommended to be a priority in the management of
these patients (Gagliardi et al. 2007). A weight loss of 5-10% improves glycaemic control, often
allowing the reduction or withdrawal of medication (Turner et al. 2002). Lifestyle change is the first
line of the treatment with subsequent introduction of medications if the former is not successful. This
section will focus on the treatments of obesity and T2DM.
1.3.1 Current guidelines for dietary treatment of obesity and T2DM
Dietary guidelines for type 2 diabetics are based on the knowledge of digestion and absorption
processes and postprandial metabolism (Frayn 2003). Scottish Intercollegiate Guidelines Network new
guideline on the management of diabetes stated that appropriate diet in T2DM should prevent
macrovascular complications (SIGN 2010). Particular attention should be paid to the carbohydrates in
the diet because they directly influence glycaemia. The content of simple sugars should be low,
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because they rapidly increase blood glucose levels, and fibre content should be higher because it slows
down glucose absorption (Frayn 2003). Additionally, overall calorie intake should also be monitored,
as weight loss in overweight or obese individuals improves insulin sensitivity (American Diabetes
Association et al. 2008) and is an integral part of diabetes care (SIGN 2010).
The Nutrition Subcommittee of the Diabetes Care Advisory Committee of Diabetes UK (Connor et al.
2003) based on the American Diabetes Association (ADA) and European Association for the Study of
Diabetes (EASD) guidelines recommended the following nutritional composition of the diet for people
with diabetes. Protein intake should be less than 1g per kg of body mass per day. Total energy from fat
should not be higher than 35%. Saturated fatty acids (SFA) and trans unsaturated fatty acids should not
constitute more than 10% of total energy intake. The n-6 polyunsaturated fatty acids (PUFA) should
not constitute more than 10% of energy intake. The amount of PUFA n-3 was not specified but
consumption of fish (especially oily) twice a week was suggested. Monounsaturated fatty acids
(MUFA) should be from 10 to 20% of energy intake and together with carbohydrate should make up
60 to 70% of energy intake. Carbohydrate should constitute 45-60% of energy intake; the carbohydrate
sources with low glycaemic index3 were promoted.
Diabetes UK recently published a position statement about the use of LCHODs for people with T2DM
(Diabetes UK 2011) based on the review of the available evidence from 1998 to 2009. The main
recommendation stated that the type of the weight loss diet should be agreed on between the person
with diabetes and their dietitian with the main objective of energy expenditure being higher than
energy intake. Secondly, people who chose LCHOD should be aware of its possible side effects (i.e.
headaches, constipation, lack of concentration, and risk of hypoglycaemia). Thirdly, blood glucose
levels should be closely monitored and possible changes in medications considered. Fourthly, the diet
should have appropriate amounts of vitamins, minerals and fibre. Finally, the amount of carbohydrate
in the diet should be agreed on between the person with diabetes and their dietitian.
The ADA has published a position statement on nutrition recommendations for people with diabetes
(2008). In the statement there are four goals of nutritional therapy distinguished: to achieve and
maintain normal range of blood glucose levels, lipid and lipoprotein and blood pressure; to prevent or
slow progression of diabetes complications; to address individual nutritional needs and to maintain the
pleasure of eating. Moreover, the ADA (2008) did not give advice on the optimal macronutrient
3 Glycaemic index is calculated as the area under the 2 h blood glucose response curve, plotted after the ingestion
of a given amount of carbohydrate.
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composition of the diet for diabetics, and stated that such composition probably does not exist because
of individual circumstances of diabetic patients. On the contrary to such a flexible approach, the Joslin
Diabetes Center currently advocates a diet composition of CHO, 40%; P, 30% and F, 30% of total
energy for overweight and obese adults with T2DM or pre-diabetes or those at risk of developing
T2DM (Acheson 2010).
Weight loss in overweight and obese diabetics is of particular importance. However, people with
T2DM have more difficulty with losing weight than people without diabetes (Pi-Sunyer 2005). Low-
carbohydrate or low-fat, low calorie diets are effective for weight loss for up to 1 year (Nordmann et al.
2006). It was advised for patients on low-carbohydrate diets to monitor their lipid profiles, kidney
function and, in the presence of nephropathy, also protein intake (ADA 2008).
SIGN guidelines on diabetes management (2010) recognised that options of diet induced weight loss
for patients with T2DM should be varied and allow individual preferences. The diet should also be able
to improve glycaemic control. Choices included calorie restricted diets, low fat diets, low glycaemic
index diets and low carbohydrate diets (with not less than 50 g of CHO per day for not longer than 6
months). Additionally, supplementation of vitamin E (500 mg/d) and PUFA n-3 was not generally
recommended for T2DM. Finally, the guidelines recognized that alcohol is likely to contribute to the
energy intake, and recommended that it should be taken in moderation as part of a healthy lifestyle.
The target consumption levels recommended for people without diabetes should not be exceeded.
Alcohol, as well as hypoglycaemia, negatively affects cognitive function. Moreover, effects of alcohol
and hypoglycaemia on cognitive function are additive.
1.3.2 Low-carbohydrate, high-protein diet
The recommended carbohydrate intake for an adult is 130g/day (Food and Nutrition Board 2005).
Long term safety of diets containing less carbohydrate for diabetic patients remains to be answered.
According to the ADA (2008) there is insufficient evidence to modify recommended daily intake of
protein (15-20% of total daily energy) and therefore high-protein diets are not currently recommended
by the ADA.
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1.3.2.1 Definition
The Reference Nutrient Intake (RNI) of protein for both men and women is 0.75 g of good quality
protein/kg body weight/day (Department of Health 1991). To meet the body’s nutritional needs and
minimize the risk for chronic disease, protein should constitute between 10 and 35 % of total diet
energy (Food and Nutrition Board 2005); Department of Health (1991) suggests avoiding intakes
higher than twice the RNI (over 1.5 g/kg/d). The Australian National Survey (McLennan 1998)
reported that the usual percentage of energy from protein was 18 % (90 g in 2000 kcal diet). According
to the Food Agricultural Organization’s FAOSTAT Foodbalance sheets, world’s protein consumption
in 2007 was 77.1 g per capita per day, out of which 47.3 g was from vegetal products and 29.8 g was
from animal products (FAO, 2011). In the United Kingdom in 2007, protein consumption was higher
than the world’s mean and equated 104.5 g per capita per day. Specifically, vegetal protein
consumption was very similar to the world’s mean (44.9 g) but consumption of protein from animal
products was twice as high (59.6 g) (FAO, 2011).
A standard protein diet contains about 15 % of energy content as protein, which is about 75 g of
protein per day for 2000 kcal diet (St. Jeor et al. 2001). In high-protein and very high-protein diets,
according to the AHA (St. Jeor et al. 2001), protein constitutes over 20 % and 30 % of total energy
(100g/d and 150 g/d respectively for 2000 kcal diet). However, this classification has not been widely
recognized. For example, the “high-protein” term was applied by Brinkworth and co-workers
(Brinkworth et al. 2004b) to a diet in which protein accounted for 30 % of energy, whereas Muzio et al
(2007) used it to describe a diet in which protein constituted only 19 % of total energy.
Although low-carbohydrate diets are also defined in many ways, there is a clear division on low-
carbohydrate diets which do not induce ketogenesis and those that do. The latter are called low-
carbohydrate ketogenic diets (LCKD) and contain 20 to 50 g of carbohydrate per day. During such low
intake of carbohydrate (less than 60 g/d), availability of glucose is restricted and the body starts using
substantially more fatty acids as a fuel source. This metabolic state is called ketosis and is detectable
by blood or urine test for ketone bodies. Low-carbohydrate but non-ketogenic diets (LCHOD), on the
other hand, contain more than 50 g but less than 200 g of carbohydrate per day. Westman and
colleagues (2007) suggested that LCHODs are those containing 50 - 150 g of carbohydrate per day
because they usually do not induce ketogenesis. Due to the lack of a standardized definition of a low-
carbohydrate diet, Bravata and associates (2003), in their systematic review of low-carbohydrate diets,
referred to diets containing 20g/d or less as lowest-carbohydrate, those containing 60g/d as lower-
carbohydrate and those containing more than 60g/day of carbohydrate as higher-carbohydrate diets.
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The restriction of carbohydrate during LCHOD and LCKD results in greater proportions of both fat
and protein. Therefore, very often, diets in which the amount of carbohydrate is reduced are high in fat
and/or high in protein.
The protein sparing modified fast (PSMF) is an example of a very high-protein LCKD. PSMF was
defined as an ad libitum low calorie diet (1200 kcal/d) containing approximately 50 % of energy
derived from protein, 40 % from fat and only 10 % from carbohydrate which should be no more than
40 g/day (Robertson et al. 2002). Although PSMF is a low calorie diet, it aims at preservation of lean
body mass by providing an abundance of protein. This nutritional approach was used to treat a group of
obese type 2 diabetic patients who were resistant to drug and standard diet therapy. At 12 months, this
intervention was shown to reduce weight and improve glycaemic control in these subjects (Robertson
et al. 2002).
Comparability of diet treatments could be improved if the macronutrient content of the diets
investigated was expressed not only as a percentage of energy but also as grams per day. The
expression of macronutrient content in absolute terms would help to avoid different interpretations of
high, normal and low contents of a given macronutrient in the diet (Westerterp-Plantenga 2007). Such
caution is especially advisable, when modifications of dietary proteins are reported.
Guidelines for evaluating high-protein diets are provided in the AHA’s statement on Dietary Protein
and Weight Reduction (St. Jeor et al. 2001). There are three main features evaluated: protein content of
the diet (15 % of energy or 50-100 g/d is recommended), carbohydrate content of the diet (minimum of
100 g/d) and amount of fat, saturated fat and cholesterol in high-protein foods. When evaluated by
these criteria, low-carbohydrate, very high-protein (protein accounting for over 30 % total energy) diets
are not recommended. However, results of numerous studies published after 2001, with obese subjects
with or without metabolic syndrome and T2DM, reported that low-carbohydrate, high-protein diets
decreased body weight (Brehm et al. 2003), improved lipid profiles (Yancy et al. 2004) and lowered
insulin (Seshadri et al. 2004, Foster et al. 2003) and glucose concentrations (Samaha et al. 2003) more
than conventional low-fat diets for up to 6 months. It has to be noted that the above studies did not
provide evidence that low-carbohydrate diets gave more favourable outcomes than low-fat diets for
over 12 months. Bravata and co-workers (2003), in their systematic review, stated that low-
carbohydrate diets are safe only for short-term use (up to 90 days) in non-diabetic patients. More recent
reviews of low-carbohydrate diets suggested that on the condition of the weight loss occurrence, low-
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carbohydrate diets are safe and effective when used for up to 6 months (Nordmann et al. 2006, Astrup
et al. 2004, Hession et al. 2009). Nordmann and colleagues (2006) added that low-carbohydrate diets
were at least as efficient as low-fat diets in inducing weight loss for up to 1 year. The agreement exists
that there is a need for long term studies investigating overall safety and efficacy of high protein diets
in healthy and at risk subjects.
It has been recognized that there is no nutritional strategy suitable for all patients. Different
macronutrient compositions of the diets may prove to be beneficial in different groups of patients.
Bloch (2005) proposed that the recognition of an individual’s health condition and needs is crucial for
the determination of the best nutritional strategy resulting in improved health and weight loss. Pros and
cons of the diet should be considered before it is given to an individual. For example, it is known that
diets low in carbohydrate can adversely affect exercise capability; therefore LCHOD or LCKD would
not be the first choice for very active people. However, explained later on in this chapter, the majority
of people with T2DM are not active (Morrato et al. 2007). Baba and co-workers (1999) reported
favorable responses to high-protein, low-energy diets for individuals presenting with insulin resistance.
Similarly, Robertson and colleagues (2002) reported that the PSMF resulted in weight loss and
improved glycaemic control in patients with T2DM. Following these studies, Volek and Feinman in
their review (2005a) concluded that LCHODs offer clinical benefits for insulin resistant patients.
Finally, the study by Cornier and colleagues (Cornier et al. 2005) showed very clearly suitability of
low carbohydrate diet for obese insulin resistant women. In this 16 week intervention non-diabetic
insulin sensitive or insulin resistant women were randomised into low fat (CHO, 60%; P, 20%; F,
20%) or low carbohydrate diet (CHO, 40%; P, 20%; F, 40%). A low carbohydrate diet was more
beneficial for insulin resistant women who lost about 13% of the initial body mass compared to 8% for
insulin sensitive women. Low fat diet on the other hand, was better for insulin sensitive women who
lost about 13% of the initial body weight on it compared to only 7% lost by insulin resistant women.
All of the above results could lead to a global recommendation of a low-carbohydrate, high-protein,
low calorie diet as a safe and efficient option for weight loss in obese subjects with T2DM.
1.3.2.2 Physiological response to low-carbohydrate diets
Starvation is a condition in which, as a result of lack of energy intake, muscle protein, glycogen, and
fat stores are all used as energy supplies (Westman et al. 2007). This condition leads to both fat mass
loss and lean body mass (LBM) loss. However, appropriate intake of protein can help to preserve LBM
during negative energy balance (Krieger et al. 2006).
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A decrease in dietary carbohydrate results in a decrease in blood glucose and insulin concentrations
and increase in glucagon concentration. Additional observed hormonal changes include an increase in
blood concentrations of epinephrine, norepinephrine, glucagon and growth hormone. All these trigger
lipolysis in adipose tissue and induce the release of free fatty acids and glycerol into circulation (Food
and Nutrition Board 2005).
When carbohydrate intake falls below a certain threshold, and the glycogen stores in the liver decrease
slightly, the oxidation of fatty acids in the liver increases. The products of the oxidation, ketone bodies:
aceto-acetate and 3-hydroxybutyrate, are released into the circulation. Most of the tissues and organs
can use fatty acids and ketone bodies as a source of energy; the organs that need glucose are red blood
cells, healing tissue and the brain; however the latter can use ketone bodies as a major part of its fuel
(Food and Nutrition Board 2005). The rate of fatty acid oxidation is the main determinant of ketone
body production. Ketogenesis takes place in the mitochondrion and is regulated at several steps. β-
oxidation of fatty acids produces acetyl-CoA that can enter either the tricarboxylic acid cycle or the
ketogenesis pathway. The ketogenesis pathway is presented in Figure 8.
2 Acetyl-CoA
Acetyl-CoA acetyltransferase
Acetoacetyl-CoA
HMG-CoA synthase
Acetyl-CoA HMG-CoA
HMG-CoA lyase
Acetoacetate 3-HydroxybutyrateAcetone
CO2
NADH NAD+
Figure 8. Ketogenesis pathway (adapted from Frayn 2003).
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In humans, the threshold for ketosis has been reported to be between 50g and 100g of carbohydrate per
day (Food and Nutrition Board 2005), which in terms of energy would constitute 10% of a 2000 kcal
diet. The restriction of energy intake occurs naturally when carbohydrates account for 5–10% of the
total energy of the diet (Westman et al. 2007). Yancy and co-workers (2004) suggested it to be a likely
result of restricted food choices, the appetite suppressing properties of the diet, increased thermic effect
of the diet or loss of energy through ketonuria. However, these still need to be proven and the extent of
the effect is still being debated.
During ketosis, in contrast to starvation, glucose levels are sustained because the body produces it from
the glycerol part of dietary fat and from protein through gluconeogenesis and glycogenolysis (Figure
9). The liver and kidney can deliver about 200g of glucose per day during dietary carbohydrate
insufficiency (Westman et al. 2007). It is important to note that gluconeogenesis increases during
severe carbohydrate restriction in an eucaloric diet (Bisschop et al. 2000) and it was proposed that it
also increases during a hypocaloric LCKD (Krieger et al. 2006). Substrates for gluconeogenesis may
be lactate, alanine or other amino acids and glycerol (Coffee 1998). As hepatic stores of glycogen
depend on the amount of carbohydrate in the diet (Gannon et al 2004), in people on a low-carbohydrate
diet, stores of hepatic glycogen are reduced (Figure 9). Much of the initial weight loss on LCHODs is
glycogen and its bound compliment of water which is about 2kg in a typical adult.
Carbohydrate intake < 40g/day
GLYCOGENOLYSIS
Blood glucose levels
sustained
GLUCONEOGENESIS
GLYCOGEN
Fatty acids
Ketones
Fat tissue
MAIN
FUELS
Figure 9. Fuels of the body during carbohydrate depletion. Arrows in bold signify enhanced effect;
dashed arrows signify weakened effect (adapted from Frayn 2003).
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1.3.2.3 Animal studies
Krieger and associates (2006) in their meta-analysis of studies investigating diets varying in
carbohydrate and protein content, stated that low-carbohydrate, high-protein diets favourably affect
body mass and composition independent of energy intake. They compared diets containing 41.4% of
energy derived from carbohydrate with those containing a greater amount of carbohydrate.
Additionally, they observed that protein intake over the recommended value of 0.75 g/kg/d
(Department of Health 1991), namely over 1.05g/kg/d, resulted in the preservation of LBM. Moreover,
recent animal studies showed that macronutrient composition influenced hypothalamic gene expression
in ways that could affect overall food intake (Kinzig et al. 2005, Kinzig et al. 2007). Specifically,
Kinzig and colleagues (2005, 2007) were measuring expression levels of POMC mRNA. POMC is a
peptide precursor of the adrenocorticotrophic hormone (ACTH), lipotropin (LPH), melanocyte-
stimulating hormones (MSH) and endorphins and is synthesised in the pituitary gland, hypothalamus
and brainstem. Expression of POMC mRNA is elevated in obesity and during high-fat feeding and
induces decreased food intake and body weight (Kinzig et al. 2007). In rats, low-carbohydrate, high-fat
diets (CHO, 5 %; P, 15 %; F, 80 %) decreased the expression of POMC mRNA in the hypothalamus as
compared to a standard chow diet (66:18:16 carbohydrate-protein-fat ratio) (Kinzig et al. 2005).
However, more recently, Kinzig and co-workers (2007) showed that a diet with 5:65:30 carbohydrate-
protein-fat ratio, significantly increased the expression of POMC mRNA in the arcuate hypothalamus
as compared to the same chow diet (Kinzig et al. 2007). In summary, these data show that in rats,
dietary macronutrient composition, independently of energy intake, influences feeding behaviours and
body weight regulation.
1.3.2.4 Human studies
In contrast to animal studies, human studies show that observed positive effects of high-protein, low-
carbohydrate diets were due to the lower energy intake and not due to the diet macronutrient
composition (Heilbronn et al. 1999). Scientists in the AHA statement on Dietary Protein and Weight
Reduction (St. Jeor et al. 2001), and many researchers after them (Farnsworth et al. 2003, Luscombe, et
al. 2003, Sargrad et al. 2005, Foster et al. 2010) stated that weight loss is determined by total energy
intake rather than macronutrient composition of the diet. They claimed that that there was no sufficient
evidence that improved health, occurring as a result of high-protein diets, would take place without
reduction in energy of the diet. Therefore, it was advised that while investigating LCKDs, particular
attention should be put on the effects which are independent of weight loss. In 2007, Dashti and
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colleagues published results of a one year long study that demonstrated that a LCKD is safe for use in
longer term in obese individuals with T2DM (Dashti et al. 2007).
1.3.2.4.1 Glycaemia
Low-carbohydrate, high-protein diets, either ketogenic or not, are effective at lowering blood glucose
levels. When a diabetic person is fasting, the rate of glycogenolysis is decreased due to depleted stores
of glycogen, which results in a decrease in fasting blood glucose (Gannon et al 2004). The blood
glucose lowering effect during the low-carbohydrate diet occurs mainly because postprandial glucose
levels are determined by the amount of ingested carbohydrate (Boden et al. 2005) but also because
dietary proteins stimulate insulin secretion (St. Jeor et al. 2001, Nuttall et al 2004, Nuttall et al. 2007).
The responses of patients with T2DM to different dietary macronutrient composition have been
investigated. In 2003, Gannon and colleagues compared postprandial blood glucose responses of type 2
diabetics after 5 weeks on diets containing 30% fat and either 40% carbohydrate and 30% protein, or
55% carbohydrate and 15% protein. The higher protein diet significantly decreased posprandial
glucose levels and improved overall glucose control (based on HbA1c values). There was no difference
in weight loss, therefore it was suggested that the observed differences in blood glucose responses were
due to the variation in the protein: carbohydrate ratio. A year later, Nuttall and Gannon (2004) reported
similar results in patients with T2DM, when they observed that replacing some of the dietary
carbohydrates with protein reduced 24h integrated plasma glucose concentration. They also observed
decreases in postprandial glucose concentration (Gannon et al 2004). In 2006, Nuttal and Gannon did a
similar 5-week-long study on patients with untreated T2DM, this time examining the metabolic
responses to LCHOD (CHO, 20 %; P, 30 %, F, 50%). As well as the improved glucose control, they
reported improved nitrogen balance in these patients.
Miyashita and colleagues (2004) conducted a 4-week-long study in obese patients with T2DM. They
reported that a low calorie LCHOD had more favourable outcomes on insulin sensitivity, visceral fat
loss and HDL-cholesterol levels than an isocaloric low-fat diet. Amounts of protein in the two diets
were the same. Similarly, Daly and associates (2006), on the basis of the results from their 3-month-
long randomized controlled trial, reported similar results. In this trial, however, protein intake was
significantly higher in the low-carbohydrate group than in the low-fat group (26.4% vs. 20.9%
respectively). Results from the trials lasting a year and longer indicate either equal lowering blood
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glucose effect of low-fat and low-carbohydrate diets (Davis et al. 2009, Larsen et al. 2011) or
superiority of low-carbohydrate diets (Westman et al. 2008).
1.3.2.4.2 Energy expenditure
High-protein, low-carbohydrate diets have often appeared to be more efficient in enhancing weight loss
than conventional diets in the short term. Advocates for these diets claim that this success is partly due
to increased energy expenditure.
Normally, reduction in resting energy expenditure (REE) is expected to occur with the loss of fat mass
and fat free mass (FFM) (Brehm et al. 2005). As REE depends on the amount of FFM, then
preservation of FFM which can take place on energy restricted high-protein diets can reduce the fall in
REE. This was observed by Baba and co-workers (Baba et al. 1999) who reported that patients on a
high-protein diet (45% P, 25% CHO) had 12% higher REE than those on a high-carbohydrate diet
(12% P, 58% CHO). They suggested that it may have been due to the formation of potentially
thermogenic serotonin and dopamine in peripheral tissues. Luscombe and co-workers (2002) on the
other hand, did not report REE to be increased by a high-protein diet (28% P, 42% CHO), but observed
a blunting in the normal fall in energy expenditure seen during weight loss in T2DM patients. This
disparity may be partly explained by the amounts of protein in the high-protein diets. For example, in
the study by Baba et al (1999) it was 45 % of energy and in the study by Luscombe et al (2002) 28% of
energy. Unfortunately, it is difficult to compare amount of protein in grams between these two studies
because in study by Baba et al. (1999) subjects were receiving diet with an energy content equal 80%
their resting energy expenditure and there was no mean values for the energy reported.
The majority of the studies agree that a decrease in REE occurs with weight loss and is independent of
diet macronutrient composition. For example, Brehm and co-workers (2005) observed a reduction in
REE with weight loss after 2 and 4 months but there was no influence of macronutrient (low-fat diet
15% P, 55% CHO, 30% F or LKCD ad libitum diet with up to 20g of CHO for the first 2 weeks and
40-60g CHO afterwards). However, weight loss was significantly greater in the LCKD group in this
study when compared to the low fat group (9.79 ± 0.71 kg vs. 6.14 ± 0.91 kg). Neither the thermic
effect of food (TEF) nor the physical activity levels explained the differences in body weight loss. The
difference in weight loss was suggested to be a result of underreporting of food consumption by
subjects on the low-fat diet. Similarly, Luscombe and colleagues (2002 and 2003) reported that the
amount of weight loss and the decrease in REE was dependent on energy restriction but not on the diet
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composition. They observed that there was no difference in weight loss (7.9 ± 0.6kg) and REE in both
the high-protein (27% P, 45% CHO) and the low-protein (16% P, 57% CHO) diet groups after 16
weeks of intervention (Luscombe et al. 2003).
In the study by Sargrad et al (2005) REE did not change and there was no difference in weight loss
after 8 weeks between patients on either a high-protein (30% P, 40% CHO) or a high-carbohydrate diet
(15% P, 55% CHO). Boden et al (2005) reported that total energy expenditure (TEE) of patients on a
LCKD (ad libitum with up to 21g of CHO per day) did not change after 2 weeks apart from ~1000 kcal
decrease in energy intake. In this study, patients lost 1.65 kg during 2 weeks and in the study by
Sargrad et al (2005) weight loss was just above 2 kg after 8 weeks. The lack of decrease in REE in the
study by Sargrad et al (2005) might have been due to a relatively small decrease in body weight (-2.2
kg in high-carbohydrate and -2.5 kg in high-protein group) as compared to the weight loss achieved in
the study by Luscombe et al (2003) (-7.9 kg overall weight loss in both groups) in which REE fell
(overall decrease 172 ± 25 kcal/d).
The rate of energy expenditure increases after a meal due to the costs of the digestion, absorption and
the energy needed to store fuel (Frayn 2003). It was shown that a high-protein meal compared with a
standard-protein meal, has a greater increase in the thermic effect of food (TEF) and can reduce the
decrease in the TEF after weight loss (Luscombe et al. 2002, Luscombe et al. 2003, Luscombe-Marsh
et al. 2005). In the short term, TEF in patients on a high-protein diet compared with a standard-protein
diet did not improve weight loss. Although it can be theoretically calculated that in the long term TEF
has the potential of enhancing weight loss, it was not observed (Luscombe-Marsh et al. 2005).
1.3.2.5 Appetite and satiety
Several studies have reported that low-carbohydrate, high-protein diets have better appetite suppressing
effects compared to low-fat diets. In a single-meal study, Luscombe-Marsh and colleagues (2005)
reported that the amount of food desired by obese hyperinsulinaemic subjects over a 3-h period
following a test-meal was smaller after the high-protein low-fat meal than after an isocaloric standard-
protein, high-fat meal. Similarly, Boden and colleagues (2005) showed that despite a 1000 kcal lower
energy intake during 14 days on LCKD (ad libitum with up to 21g of CHO per day) hunger levels were
similar to those of a low-fat diet in obese patients with T2DM.
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It was proposed that potential factors influencing appetite during LCKD diets are ketosis, increased
amount of protein, and lower serum insulin concentrations. Ketosis which occurs during LCKD has a
potential anorectic effect (St. Jeor et al. 2001). Although ketone bodies in the blood may be appetite
suppressing (Astrup et al. 2004), in a study by Foster et al (2003) there was no association between
urinary ketones and weight loss. Likewise, Brehm et al (2003) reported that despite the fact that plasma
levels of beta-hydroxybutyrate had returned to control values, subjects on a low-carbohydrate diet were
losing weight for up to 6 months. Apart from ketosis, appetite could also be affected by the monotony
of the diet and restricted food choices (Astrup et al. 2007).
Satiating effects of dietary protein could be related to the suppression of postprandial ghrelin secretion
and satiety maintenance. Ghrelin concentrations were reported as total immunoreactive ghrelin
(acylated and de-acylated forms) in some studies and as acylated ghrelin, which is the bioactive form
of this hormone, in other studies. El Khoury et al (2006) observed in healthy men that a high-protein
meal maintained lower acylated ghrelin concentrations 3 hours after ingestion than a high-carbohydrate
or a high-fat meal. However, another study reported that satiating effects of protein was not related to
the secretion of ghrelin after a meal (Moran et al. 2005).
1.3.2.6 Adverse events
Most of the adverse effects of LCKDs are usually reported during the first two weeks. These may be
due to the loss of total body water and it may be attenuated by drinking more (Yancy et al. 2004).
Other adverse effects that have been reported were constipation, headache, halitosis, muscle cramps,
diarrhea, general weakness and rash (Yancy et al. 2004). Moreover, due to muscle glycogen depletion,
fatigue was observed during exercise (St. Jeor et al. 2001). However, not all the studies report adverse
effects. For example, Skov et al (1999) found no differences on high-protein or high-carbohydrate
diets. Nevertheless, patients with diabetes or hypertension who go on low-carbohydrate high-protein
diets are advised to be under the care of a clinician, because sudden changes in the proportions of
macronutrients in the diet may influence their response to diabetic drugs (Westman et al. 2007).
Disturbances of renal function and bone metabolism are often reasons for rejecting high-protein diets
as a weight loss therapy. According to the AHA a very high-protein diet is especially risky for patients
with diabetes, because it can speed the progression, even for short lengths of time, of diabetic renal
disease (St. Jeor et al. 2001). However, most of the studies examining high-protein diets did not report
adverse effects on either kidney function or bone metabolism. In a study by Noakes et al (2005)
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markers of renal function (urine urea: creatinine, serum urea and creatinine clearance) did not differ
from baseline for neither high-carbohydrate, normo-protein (58 g/d) nor high-protein (104 g/d) diets.
The study also did not report adverse effects on bone metabolism (Noakes et al. 2005).
One of the concerns about LCHODs is the limitation of fruits, vegetables, cereals, grains and low-fat
milk. According to the AHA, these limitations are likely to cause deficiencies in vitamins and minerals
and inadequate fibre intake (St. Jeor et al. 2001). The recommended intake of these nutrients was
shown to lower blood pressure (St. Jeor et al. 2001); and reduced fiber intake could have long term
adverse effects (Boden et al. 2005). However, there is no evidence that diabetic patients would benefit
from increased amounts of fibre higher than the RDI (American Diabetes Association 2008).
Additionally, according to our knowledge, none of the studies investigating LCHODs reported nutrient
deficiencies. To address the problem of potential deficiencies in patients on LCHODs, vitamin and
mineral supplements are recommended (Westman et al. 2007).
Trials that investigate the use of LCHODs have common limitations. Firstly, it may be difficult to
distinguish the effects of a LCHOD and dietary supplements provided. Secondly, the state of health of
participants - extrapolation of the results from healthy to diseased populations may be inadequate.
Thirdly, in the case of studies with small numbers of participants / high dropout rates, results must be
considered as preliminary (Sargrad et al. 2005). Fourthly, compliance to LCKD is often poor (Stern et
al. 2004) and usually decreases after 6 months (St. Jeor et al. 2001, Robertson et al. 2002, Foster et al.
2003). Finally, the use of drugs confounds the contribution of the diet to the change of measures,
biological markers, blood lipids, cardiovascular risk etc.
1.3.3 Very low calorie diets
Very low calorie diets (VLCD) containing up to 800 kcal/d have been used to achieve rapid weight
loss since the 1970s (Tsai et al. 2006). The National Institute of Diabetes and Digestive and Kidney
Diseases underlined that VLCDs should be delivered only under medical supervision (NIDDK 2008).
VLCDs are intended for moderately to extremely obese patients and should be a part of a programme
that includes behavioural therapy, nutrition counselling, physical activity and / or drug treatment.
Weight loss expected on VLCD is in the range of 1.5 to 2.5 kg per week resulting in about 20 kg in 3
months. This degree of weight loss is comparable to complete starvation (Howard 1981). Such a rapid
weight loss has the potential to improve diabetic control, blood pressure and lipid profile (NIDDK
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2008). VLCDs have been associated with substantial improvements in glycaemic control (Wing et al.
1991) and cardiovascular health in a 12 months period (Dhinsa et al. 2003). It has to be pointed out that
the length of very low calorie intervention in the two above cited studies was 7 and 8 weeks
respectively; the reported positive effects were observed at 1 year’s time. Moreover, it is not
uncommon that patients on VLCDs report fatigue, nausea, diarrhoea and constipation (NIDDK 2008).
These adverse events are usually reported during the first two weeks due to the occurrence of ketosis
(Rolland et al. 2009). The serious side effect that may occur is gallstones formation (NIDDK 2008).
The maintenance of weight loss achieved by means of VLCD may be difficult and weight regain is
common. It has been suggested that weight maintenance and long-term glycaemic control in T2DM,
are more likely to be achieved by combining VLCDs with increased physical activity, behavioural
therapy and active follow up treatment (Hensrud 2001, NIDDK 2008).
Tsai and Wadden (2006) in a meta-analysis of VLCDs concluded that VLCDs did not produce greater
long term weight losses than low calorie diets. It was suggested that this was the case due to poorer
adherence on VLCDs than on less restrictive diets (NIDDK 2008). However, VLCDs may be
beneficial for obese people with T2DM, as caloric restriction has substantial effects on glycaemic
control even in the absence of weight loss (Wing 1995). Additionally, VLCDs induce greater
improvements in glycaemic control than low calorie diets that achieved the same weight loss (Wing
1995). Monnier and associates in their review of VLCDs in the management of T2DM (2000)
concluded that short term VLCDs may be useful for initiating weight loss and for introducing patient to
the potential benefits of adhering to a dietary regimen. It was pointed out however, that overall
improvements in glycaemic control in people with T2DM in the longer term were small (Monnier et al.
2000, Hensrud 2001).
1.3.4 Exercise
Physical activity was defined by the American College of Sports Medicine (ACSM) and American
Diabetes Association (ADA) as “bodily movement produced by the contraction of skeletal muscle that
substantially increases energy expenditure” (Colberg et al. 2010). While exercise was described as a
“subset of physical activity done with the intention of developing physical fitness” (Colberg et al.
2010).
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It has been recognized that the obesity epidemic and associated increase in T2DM are related to
decreased physical activity levels (ADA 2002). Additionally, the majority of people with T2DM are
not active (Morrato et al. 2007). Therefore, physical activity was suggested to be a crucial way of
preventing as well as managing T2DM. The American Diabetic Association (2002) stated that in
patients with T2DM regular exercise may improve insulin sensitivity and help to bring glucose levels
to a normal range. This effect seems to be greater at the early stages of T2DM and insulin resistance.
Both strength and aerobic exercise were beneficial for people with T2DM and a regular and varied
exercise is recommended; other forms of exercise (i.e. yoga, tai-chi) have shown mixed results
(Colberg et al. 2010).
The American College of Sports Medicine stated that, there is strong evidence that while glucose
uptake by skeletal muscle during rest is impaired in T2DM, during exercise glucose is transported into
cells by a different mechanism not impaired by T2DM or insulin resistance (Colberg et al. 2010).
Acute improvements in insulin action facilitated by physical activities can last from 2 to 72 hours.
Chronic effects of physical activity on T2DM include improvements in insulin action, blood glucose
control, fat oxidation, lipid profile, blood pressure, cardiovascular events and mortality (Colberg et al.
2010). Regular exercise can also reduce depression and improve health related quality of life in T2DM.
About an hour per day of exercise may be needed to achieve weight loss, if relying on exercise alone.
Additionally, it may be necessary to adjust the dose of hypoglycaemic medication according to the type
and duration of exercise, and the type and progress of diabetes (ADA, 2002).
It has been recommended for people with T2DM to do aerobic exercise for at least 2.5 hours a week;
the exercise should be moderate to vigorous and spread out over at least 3 days of the week. This
should be supplemented with resistance training 2 to 3 times per week (Colberg et al. 2010). The
presence of diabetes complications may make exercise more difficult; however, the specific physical
activity recommendations were suggested for people with different complications (Colberg et al.
2010).
1.3.5 Medications
Medications which facilitate weight loss are targeted for obese individuals (BMI > 30kg/m2). There is
currently only one drug available, orlistat. Orlistat (Xenical, Roche) is a lipase inhibitor and therefore it
reduces the digestion and absorption of dietary fat. Medications that reduce fat absorption are
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considered to be safer than those influencing appetite, because they do not act on the nervous system
and heart rate. The recommended dose is 120mg at meal times three times a day. Treatment with
orlistat results in mean weight losses of around 3kg (Padwal and Majumdar, 2007). Orlistat was shown
to improve total and LDL-cholesterol, blood pressure and glycaemic control in patients with diabetes
(Rucker et al, 2008). Due to the fact that dietary fat is excreted, low-fat diets are advised during the
treatment to avoid gastro-intestinal discomforts. The lower dose of Orlistsat (60mg) is now available
over the counter under the name Alli (GlaxoSmithKline). It has been observed that in patient on orlistat
HbA1c and lipid profiles improve more than what would be expected with the weight loss that occurs
(Davidson et al. 1999).
In the past, there were two other drugs available. Sibutramine (Reductil, Meridia) was a drug that
suppressed appetite by the inhibition of the re-uptake of noradrenaline and serotonin in the brain. Apart
from the inhibition of appetite it also displayed antidepressant qualities and could lower TG (Rucker et
al. 2008). It was also reported that on average, sibutramine reduced weight by 4-5 kg (Padwal et al.
2007). Adverse effects of this drug included increased blood pressure and pulse rate. Sibutramine was
suspended by the Medicines and Healthcare Products Regulatory Agency (MHRA) in January 2010
due to the risk of non-fatal heart attacks and strokes. Another anorectic drug, which was made
available in the UK in 2006 but withdrawn due to serious adverse events shortly after, was rimonabant
(Acomplia, Zimulti, Rimoslim, Slimona). It selectively blocked cannabinoid type 1 receptor (CB1).
Cannabinoids stimulate hunger by binding to CB1 receptors. Rimonabant bound to CB1, blocked the
access of cannabinoids to the receptor and prevented hunger stimulation which in the longer term
resulted in weight loss. On average, rimonabant reduced weight by 4-5 kg (Padwal et al. 2007). Apart
from the suppression of appetite, rimonabant was reported to improve waist circumference,
concentrations of HDL-cholesterol and TG (Padwal et al. 2007), blood pressure and glycaemic control
in diabetic patients (Rucker et al. 2008).
Oral antidiabetic drugs are used in the treatment of T2DM when diet and lifestyle modification for at
least 3 months does not maintain glucose concentrations with desirable ranges. They should be used to
support, and not replace the effect of diets and exercise (BNF 2006). Actions of these drugs vary from
the stimulating of pancreatic beta-cells to synthesise insulin; sensitizing tissues for insulin actions;
decreasing the rate of hepatic gluconeogenesis, to slowing down the absorption of carbohydrates from
the intestine. Currently available drugs and their actions are presented in Table 1.
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Table 1. Oral agents used in the treatment of diabetes and their actions (adapted from Diabetes UK,
2008; BNF 2006; Frayn 2003).
Group of drugs Name of drugs Action
Sulphonlyureas glibenclamide, gliclazide,
glipizide, glimepiride,
tolbutamide, chloropropamide
Act on beta-cells to synthesize and secrete
insulin; improve insulin sensitivity in the longer
term.
Biguanide metformin Improves peripheral insulin sensitivity by
increasing peripheral utilization of glucose and
decreases the rate of gluconeogenesis.
Prandial glucose
regulators
rapaglinide, neteglinide Stimulate pancreas to synthesize insulin;
should be taken only during the meals; action
time is shorter than sulphonylureas.
Thiazolidinediones rosiglitazone, pioglitazone Improve peripheral insulin sensitivity.
Alpha glucosidase
inhibitor
acarbose Slows the absorption of starch and sucrose
from the intestine, consequently slows the
postprandial rise of glucose concentration.
Dipeptidyl peptidase-4
(DPP-4) inhibitors
sitagliptin Increases levels of incretins, which stimulates
insulin synthesis and decreases the rate of
gluconeogenesis.
Insulin injections are used as a treatment in T2DM when oral therapy is not enough to keep glucose
levels in the normal ranges. There are three groups of insulin available for subcutaneous injections:
animal insulin, synthetic insulin which mimics human insulin and insulin analogues which are similar
to human insulin but slightly vary in amino acid sequence (Diabetes UK, 2008). There is a wide
selection of available insulin treatments ranging from those which act immediately or after some hours
to those acting up to 30 hours (Diabetes UK, 2008).
Incretin mimetics is a new therapy which, similarly to insulin, is delivered in subcutaneous injections
(Diabetes UK, 2008). The drugs available, Exenatide and Liraglutide, are glucagon-like peptide 1
(GLP-1) receptor agonists. GLP-receptor agonists act on different levels. Firstly, they stimulate insulin
synthesis and slow down hepatic gluconeogenesis. They also delay stomach emptying and digestion at
the same time slowing down the postprandial rise in glucose concentration. Finally, they reduce
appetite and both Exenatide and Liraglutide treatments have been associated with weight loss (Diabetes
UK, 2008).
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Specific glucose-lowering strategies are being investigated at the moment and they include the use of
insulin or one or more oral agents with or without revascularization (Golden et al, 2007). However, if a
diet and lifestyle modification for obese patients with T2DM could achieve similar results or at least
support the action of oral agents in lowering cardiovascular disease risk, that would be cheaper for
health systems and would be of benefit to patients as they would reduce their risk of adverse effects
induced by drugs.
1.3.6 Bariatric surgery
The NICE guideline on Obesity (2006) recommended bariatric surgery as a treatment option for adults
whose BMI is over 40 kg/m2 or between 35 and 40 kg/m2 and accompanied by T2DM, hypertension or
obstructive sleep apnoea. Bariatric surgery should only be performed when all other ways of
addressing their obesity problem failed. Nevertheless, for patients with BMI over 50 kgm2, bariatric
surgery is recommended to be the first line treatment.
1.3.7 Cognitive behavioural therapy
Cognitive behavioural therapy (CBT) addresses difficulties with emotions and behaviours. It was
developed in 1960s by Aaron Beck, to treat depression (Beck 1995). CBT is characterized by a
systematic approach to achieve clearly defined goals. CBT deals with dysfunctional beliefs which
results in improvements in mood and behaviour. The treatment is now used for a wide range of
problems including anxiety, substance abuse, psychotic disorders, personality issues and eating
disorders. CBT can be used to work with individuals and with groups in which individuals have similar
goals.
CBT has proved successful in supporting obesity treatment (Cooper et al. 2001) and the approach has
been employed by some of the commercially available weight loss programmes (i.e. Lighter Life).
CBT has been used both, during weight loss as a supporting therapy and for the purpose of weight
maintenance. In the context of obesity, CBT aims to change the habits that caused weight gain and
promote behaviours that will help to lose weight and maintain it. There is a lack of evidence that
psychological treatments of obesity, including CBT, work in the longer term without any other therapy
(Cooper et al. 2010).
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1.4 Resting metabolic rate prediction
Understanding of patophysiology of obesity was improved through measurements of energy
expenditure and substate oxidation (Weyer et al. 1999). Energy expenditure has been first measured by
Lavoisier who used calorimeter to measure heat production (Gibney at al. 2002). Direct measurement
of heat production is technically demanding and currently is not frequently used. Indirect calorimetry
provides an alternative way of resting metabolic rate (RMR) measurement. The method is based on the
analysis of respiratory gases. Namely, the volumes of oxygen that individual consumes and carbon
dioxide that individual produces during oxidation of carbohydrate, fat, protein and alcohol are
measured over a period of time. Twenty four hour energy expenditure can be measured in the human
whole body respiratory chambers. It can be also measured under a ventilated hood or with a face mask
over a shorter period of time and then the results are extrapolated to 24 h. The measurement typically
lasts about half an hour and is conducted when an individual is fasted and lies quietly at rest in the
morning time (Gibney et al. 2002).
As the above measurements require considerable amounts of time, subject preparation, specialised
equipment, and trained technicians, they are not always practical. Many equations that predict various
aspects of energy expenditure were proposed: there are equations predicting the whole 24-h energy
expenditure, sleeping metabolic rate, basal metabolic rate and finally resting metabolic rate.
Development of an equation to predict RMR is based on the measurement of RMR which is assumed
to be the true value.
It was shown before, that patients with T2DM had higher measured RMR than non-diabetic people
(Huang et al. 2004, Bitz et al. 2004, Visockiene et al. 2006). Pi-Sunyer (2005) suggested this to be a
result of deregulated energy metabolism and resulting from its inefficiency. The author also explained
that this inefficiency was improved with weight loss and therefore resting metabolic rate decreases
more in people with T2DM than expected with weight loss alone. Bitz et al (2004) suggested that a
new predictive equation for people with T2DM should be developed. In the current work, twenty nine
equations that predict RMR were tested for accuracy and bias when used for obese individuals with
T2DM. These equations included variables such as age, gender, body mass, height, body composition
and size.
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1.5 Summary and conclusions
Obesity is a serious global problem and its linkage with T2DM is well established. Governments and
nongovernmental organisations keep producing recommendations, guidelines and programs for actions
to manage and prevent it. Low-carbohydrate, high-protein diets are an alternative option for obese
individuals with T2DM who struggle with losing weight on standard Diabetes UK recommendations.
The evidence supporting efficacy and safety of low-carbohydrate diets is growing and this alternative
to the low fat diet has been recently acknowledged by the national and international guidelines for
management of diabetes. The low-carbohydrate diet has been shown to be safe for up to two year
period for obese subjects with T2DM.
Obesity and T2DM are related diseases and their aetiology is often common. Despite increasing
knowledge about these conditions, their prevalence worldwide is increasing. Additionally, nutritional
recommendations for those conditions do not always follow quickly expanding knowledge. A low-
carbohydrate, high-protein diet is one of the alternative ways for obese individuals with T2DM to lose
weight, improve diabetic control and reduce the risk of cardiovascular disease.
There have been numerous studies of the effects of low-carbohydrate diet on health of the people with
T2DM. None of those studies compared different approaches to administering low-carbohydrate diet.
Present study compares the effects of low-carbohydrate ketogenic diet administered either as
commercially available ready-made meals or as self-prepared meals.
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2 Aims
The current study aimed to investigate the efficiency of high-protein LCKD in the management of
obesity and T2DM and to determine the effects on cardiovascular risk, body composition and energy
metabolism.
There is no information in the current literature about the effect that the approach to a LCKD (i.e.
ready made meals or self prepared meals) has on weight loss in obese individuals with T2DM. It is a
novel idea to compare the two approaches to a diet.
The primary aim was to assess weight loss and its composition achieved after 12 months on two
alternative hypoenergetic, high-protein LCKDs (the protein-sparing modified fast compared to
commercial ready-made meals provided by Go Lower). The hypothesis was that the convenience of
ready made meals would result in better adherence and consequently greater weight loss at 12 months.
It was also assumed that the high protein component of the diet would result in losing fat mass and not
fat free mass.
The secondary aims of the study included assessment of changes in cardiovascular risk associated with
the diets; assessment of improvements in glycaemic control; assessment of changes in resting
metabolic rate; assessment of improvements in quality of life, wellbeing, motivation to lose weight,
physical activity, depression, fatigue, sleepiness and satisfaction with diabetes treatment using
standardised and validated questionnaires; and testing of existing equations to predict resting metabolic
rate in the studied population.
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3 Methods
3.1 Study design
The study was a randomized clinical trial of weight management and diabetic control. It was conducted
in a single centre located at the Aberdeen Royal Infirmary in Scotland. The trial was assigned ISRCTN
number ISRCTN20400186.
The study was conducted as a dietary intervention for twelve months (Figure 10). Potential participants
were invited to take part in the trial by a letter. If interested, they could contact the study centre by
telephone, e-mail or post by returning their contact details in pre-stamped return envelope. If, after the
screening visit, they fulfilled the inclusion criteria, were willing to participate and signed informed
consent, they were randomizsed into one of the arms of the study. Randomisation method is described
in the Statistics part of this chapter.
During the time of the programme patients visited the study centre on 14 occasions: at baseline, at 2
and 4 weeks and then monthly. The descriptions, timing and duration of all participants’ visits are
collated in the Patient Visits Table (Table 2). Participants were randomly assigned to either the protein-
sparing modified fast (PSMF) diet or the Go Lower (GL) diet.
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Figure 10. The timeline of the study.
The primary outcome measure was weight loss after 12 months of a dietary intervention. Secondary
outcomes included improvements in glycaemic control as determined by HbA1c and homeostasis model
assessment – insulin resistance index (HOMA-IR) calculated from the following equation: fasting
insulin × fasting glucose/22.5, (Matthews et al. 1985)); improvements in cardiovascular disease risk as
determined by serum lipid profile, blood pressure and changes in visceral adiposity and also by the
Framingham risk score; and improvements in quality of life using standardized and evaluated
questionnaires. Fasting blood draws were performed in the morning on 5 occasions, at baseline and
after 3, 6, 9 and 12 months into the dietary intervention. On these days, participants received breakfast
(adjusted accordingly to their diet) at the study centre. Participants were seen by the research student
who took all measurements and gave lifestyle advice. All measurements are summarised in Table 2;
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the lifestyle advice consisted of a discussion of the practical side of dieting, weight related issues, and
any problems arising during the programme that could potentially affect it (such as eating out or
holiday).
Table 2. Visits and their descriptions.
Date Visit No Duration Visit description + measurements
1
Baseline 2 hrs
Diet & Lifestyle instructions
Standard medical check, height, weight, waist & hips circumferences, blood
pressure, blood tests, body composition, resting metabolic rate, diet
composition, questionnaires, urine and blood ketones, 24h urine sample
2
2nd week
30 min Diet & Lifestyle advice
Weight, urine and blood ketones
3
4th week
30 min Diet & Lifestyle advice
Weight, urine and blood ketones
4
2nd month
30 min Diet & Lifestyle advice
Weight, urine and blood ketones
5
3rd month
1.5 hrs
Diet & Lifestyle advice
Weight, waist & hips circumferences, blood pressure, blood tests, body
composition, diet composition, questionnaires, urine and blood ketones,
24h urine sample
6
4th month
30min Diet & Lifestyle advice
Weight, urine and blood ketones
7
5th month
30 min Diet & Lifestyle advice
Weight, urine and blood ketones
8
6th month
2 hrs
Diet & Lifestyle advice
Weight, waist & hips circumferences, blood pressure, blood tests, body
composition, resting metabolic rate, diet composition, questionnaires, urine
and blood ketones, 24h urine sample
9
7th month
30 min Diet & Lifestyle advice
Weight, urine and blood ketones
10
8th month
30 min Diet & Lifestyle advice
Weight, urine and blood ketones
11
9th month
1.5 hrs
Diet & Lifestyle advice
Weight, waist & hips circumferences, blood pressure, blood tests, body
composition, diet composition, questionnaires, urine and blood ketones,
24h urine sample
12
10th month
30 min Diet & Lifestyle advice
Weight, urine and blood ketones
13
11th month
30 min Diet & Lifestyle advice
Weight, urine and blood ketones
14
Final visit
12th month
2 hrs
Weight, waist & hips circumferences, blood pressure, blood tests, body
composition, resting metabolic rate, diet composition, questionnaires, urine
and blood ketones, 24h urine sample
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3.2 Participants
The participants were included if they were between 18 and 75 years old, obese (BMI > 30 kg/m2), and
with poorly controlled T2DM (HbA1c ≥ 7.5%). All of the recruited patients had previously standard
lifestyle approaches as part of their diabetes care (Diabetes UK guidelines). Participants with renal or
hepatic disease, cancer, diet related illnesses, on antidepressant or obesity-related pharmacotherapy,
pregnancy or lactation, and inability to monitor glucose levels were excluded. Patients with known
coronary heart disease were included provided no major coronary event had taken place in the previous
6 months.
Participants were recruited from an outpatient Diabetes Centre in Aberdeen. They were under the care
of a hospital based diabetes consultant. All participants provided written informed consent. All
experimental procedures were approved by the North of Scotland Research Ethics Committee and the
Robert Gordon University Ethics Committee.
3.3 Attrition
Of the 41 randomized participants, 25 were randomized to PSMF and 16 to GL (Figure 11). Twenty
seven dropped out (66%) during various stages of the programme. There was no significant difference
in the dropout rates between the two diet groups (p = 0.747). Dropout incidence was significant already
at 3 months (10 participants from PSMF and 3 participants from GL) (p<0.001). The times and reasons
for dropout are described in Table 3.
Figure 11. Participant flow chart. Abbreviations: PSMF, protein sparing modified
LCKD, low-carbohydrate
17 withdrawals
8 lifestyle issues
3 medical concern
3 did not give reason
1 side effects of LCKD
1 moved away
1 died
15 excluded, did not fulfil
inclusion criteria
247 not responded /
not interested / excluded
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ketogenic diet.
303 contacted
56 screened
41 randomized
baseline:
25 PSMF
12 months:
8 PSMF
baseline:
16 GL
12 months:
6 GL
10 withdrawals
3 did not enjoy food
2 lifestyle issues
2 did not give reason
1 side effects of LCKD
1 medical concern
1 did not like the new
body shape
fast; GL, Go Lower;
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Table 3. Times and reasons for dropout (total dropouts n = 27).
PSMF
Dropout
time
GL
Reasons for dropout
Dropout
No
n = 17
% of all
dropouts
% of all
dropouts
Dropout
No
n = 10
Reasons for dropout
side effects of LCKD
medical concern
1
1
17.6
During
the first
2 weeks
30.0
did not give reason 1 1 month
1
1
1
side effects of LCKD
did not enjoy the food
medical concern
lifestyle issues
did not give reason
medical concern
5
1
1
41.1 2 months
3 months 10.0 1 did not give reason
4 months
lifestyle issues 1 5.9 5 months 10.0 1 did not enjoy the food
6 months 20.0
1
1
did not like new body
shape
did not enjoy the food
7 months
lifestyle issues 1 5.9 8 months 20.0 2 lifestyle issues
medical concern
moved away
1
1
11.8 9 months
10
months
10.0 1 did not give reason
death
did not give reason
lifestyle issues
1
1
1
17.6
11
months
53
3.4 Dietary intervention
In this novel study, the two experimental high-protein LCKDs were the protein sparing modified fast
(PSMF) and commercial Go Lower (GL) diet. Each approach investigated differed; Table 4 compares
the two approaches.
For the PSMF, patients were provided with an information booklet (Appendix 1). Carbohydrate intake
was restricted to a maximum of 40 g per day to induce ketosis. Patients were encouraged to include
fruit and vegetables in their carbohydrate allowance. Foods encouraged during PSMF were lean meat,
fish, eggs, green leafy vegetables, and at least 2 litres of fluids per day.
GL is a low-calorie (~1500 kcal/d) ketogenic diet. Participants who were randomized into GL diet
were given their first food pack at the study centre. After that, according to their preferences, the
foodpacks were available for collection at the study centre or delivered directly to their homes. Each
food pack contained food for 2 weeks which included nut and seed granola for breakfast, choice of
soups for lunch, main meals for dinner, and low carbohydrate snacks and treats such as nuts or seed
and nut bars. Preparation of GL food typically involves heating up and adding selected vegetables, fruit
or youghurt. The participants on GL were provided with an information booklet as well (Appendix 2).
Additionally, all participants received multivitamin supplements.
Table 4. Comparison of what dieters were required to do when following protein sparing modified fast
(PSMF) and Go Lower (GL) approaches.
Go Lower PSMF
- receive ready-made meals (3 a day plus
snacks) that can be supplemented with
vegetables and certain fruit from the
provided list; occasionally can have low-
carbohydrate meals not produced by Go
Lower
- shop themselves
- prepare meals themselves
- do not pay for the Go Lower food - pay for the food they buy
- are guided by the information booklet
listing allowed amounts of certain
vegetables and fruit (kitchen measures)
- are guided by the information booklet
explaining how to count carbohydrate,
read product labels, and informing about
carbohydrate content in various food
groups
- do not need to know carbohydrate
content of the foods but have to adhere to
the recommended portion sizes of non-Go
- need to learn how to weigh and calculate
carbohydrate content of foods and drinks
they consume
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Lower products (if eaten)
- should eat mostly Go Lower food; the
information booklet contains the eating
out guide
- can eat most of the foods provided they
know their carbohydrate content and do
not exceed 40g per day
Participants received initial instruction on how to follow their randomly assigned diet. They were then
given assistance by phone or email at any time between the visits. Subjects were asked to complete 3-
day food diaries at baseline and at every three months afterward. The food diaries were analyzed for
energy and macronutrient content (WinDiets Research version) to confirm dietary compliance.
Compliance to the experimental diets was mainly assessed by the occurrence of weight loss but also by
testing urine and capillary blood for the presence of ketone bodies at each visit, and by recording levels
of plasma urea and albumin every 3 months. All methods to measure compliance are described in detail
later on in this chapter.
3.5 Measurements
3.5.1 Anthropometry
Body mass was measured at each visit, with participants wearing light clothing and no shoes. This
measurement was done on the Tanita Body Composition Analyzer (type BC 410 MA III, Tanita
Corporation of America, Inc., Arlington Heights, IL, USA) (Figure 12) and was mostly for the
participant’s information about their progress. Body mass reported in the results was recorded at
baseline and then every 3 months based on the Bod Pod® Body Composition Tracking System
measurements (Bod Pod, Life Measurement, Inc., Concord, CA, USA) as the weight measurement is a
step in measuring body density. Conditions for this measurement are described below.
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Figure 12. Tanita Body Composition Analyzer (BC 410 MA III, Tanita Corporation of America, Inc.,
Arlington Heights, IL, USA) used in the study.
Stature was measured at baseline only, with the use of SECA Leicester Height Measure (421S).
Participants were measured with no shoes and their back to the vertical scale of the measure. When in
the position and ready, the participant was asked to inhale; the measurer then gently applied upward
pressure at the base of the jaw while instructing the participant to exhale. The reading was recorded to
the nearest 0.5 cm.
Hip and waist circumferences were done using an anthropometric tape that was non-extensible but
flexible. To keep participants as comfortable as possible, the measurer approached them from the
front-side. Waist circumference was measured at the narrowest point between the lower costal (10th
rib) border and the top of the iliac crest, perpendicular to the long axis of the trunk. If there was no
obvious narrowing, the measurement was taken at the mid-point between the lower costal rib and the
iliac crest (ISAK, 2006). Hip circumference was taken at the level of greatest posterior protuberance
of the buttocks, perpendicular to the long axis of the trunk, with feet together (ISAK, 2006).
Body composition was measured five times, at baseline and every 3 months afterwards, by using a
densitometric method of air-displacement plethysmography (Bod Pod, Life Measurement Inc., USA;
presented on Figure 13). The method is based on the determination of body density by measuring body
mass and volume. The Bod Pod equipment was placed in a quiet room of its own, away from any
direct source of heat, in a temperature between 21 and 32 ºC. Prior to testing, participants were asked
to use the toilet. They were also asked not to exercise or eat for 12 h before the test but they could
drink water up to 2 h before the test. Participants wore minimal, form-fitting clothing and removed any
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additional elements of clothing (i.e. jewellery, socks, or glasses). During the volume measurement
participants wore a Lycra swim cap.
Figure 13. Body composition measuring equipment, BodPod (by Life Measurements Inc, USA) in a
clinic room in Westburn House.
To ensure accuracy, body composition was also determined by whole body impedance analysis (Body
Composition analyzer BC-418 MA, Tanita Corporation of America, Inc., Arlington Heights, IL, USA).
This measurement was done at the same times as the Bod Pod test, therefore participants were fasted.
For this measurement, participants were asked to wear light clothing, take off any metal parts of
clothing or jewellery and take out any heavy objects from their pockets. They were asked to stand bare-
foot on the metal electrodes of the Tanita analyzer and hold the metal handles for a few seconds until
the reading was obtained. The measurement, apart from weight and percentage of fat mass included, fat
mass (kg), fat free mass (both kg and %), BMI (kg/m2) and total body water (kg and %).
3.5.2 Blood pressure and metabolic rate
Blood pressure was measured with a digital manometer (Omron 705 IT, Omron Healthcare Co Ltd,
Kyoto, Japan.). Participants were asked not to smoke, drink any coffee, tea or cola or participate in any
strenuous activity 12 h before the test. Blood pressure readings were taken after at least 5 minutes of
rest, on the non-dominant arm.
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Resting metabolic rate (RMR) was measured using indirect calorimetry (Quark RMR, COSMED, Italy,
presented on Figure 14) at baseline, 6 months and 12 months. The equipment was placed in the quiet
room. Participants were asked not to exercise, eat, drink tea/coffee, alcohol or smoke for 12h or more
before the measurement. RMR was measured after at least 20 minutes of rest in the study centre.
During the measurement participants were resting in a supine position in thermoneutral conditions. For
the first 5 to 10 minutes of the test participants were given time to relax. Once the RMR stabilized, an
actual measurement was started and lasted 20 minutes.
Figure 14. Resting metabolic rate measuring equipment, Quark RMR (by Cosmed, Italy) in a clinic
room in Westburn House.
Twenty nine previously developed by others equations estimating RMR were compared using indirect
calorimetry data from the present study, as described by Weijs (2008). The accuracy of the equations
was assessed by the calculating the percentage of subjects whose estimated RMR fell within ± 10% of
the measured RMR (mRMR). The equations were also assessed by bias (between the predicted and
measured RMR) expressed as the mean percentage difference.
3.5.3 Cardiovascular risk
The cardiovascular risk (CVD) was determined from the information about the lipid profile, glycaemic
control and blood pressure. The CVD risk points for men and women were calculated as proposed by
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the group involved in the Framingham Heart Study (D'Agostino et al. 2008). The points were given for
gender, age, total cholesterol, HDL-cholesterol, systolic blood pressure, treatment for hypertension,
smoking and the presence of diabetes. The sum of the points could then be converted to a percentage of
CVD risk and to heart age/vascular age. Above the limit of 21 points for women and 18 for men, CVD
risk was over 30 %. This meant that if women had less than 18 points and men had less than 21 points,
they were allocated a percent of the CVD risk (from 0 to 29.4 %). This also meant that women with 18
points and more and men with 21 points or more were all assumed to have CVD risk over 30 %. Apart
from CVD risk, the points could also estimate heart age. Above the limit of 15 points for women and
17 points for men, heart age (or vascular age) was described to be 80 years.
3.5.4 Biochemistry
Fasting blood samples were drawn at baseline and every 3 months thereafter. Samples were delivered
to the Aberdeen Royal Infirmary Clinical Biochemistry Department for analysis. The tests included
lipid profile (total cholesterol, LDL-cholesterol, HDL-cholesterol, triacylglycerol), glycaemic control
(HbA1c, fasting glucose), thyroid function (thyroid stimulating hormone (TSH)), liver function (total
bilirubin, alanine amino tansferase (ALT), alkaline phosphatase (ALKP), and gamma-glutamyl
transferase (GGT), and kidney function (electrolytes, urea, creatinine and albumin). Most of the above
(apart from glucose and HbA1c) were determined from the samples collected into the vacutainer tubes
with silicone coated interior for clot activation and polymer gel for serum separation (SST™II, serum
separation tube, by Becton Dickinson). Samples for fasting plasma glucose and glycosylated
haemoglobin were collected into the vacutainer tubes containing preservative fluoride (stops blood
enzymes from working, so that glucose in the sample is not used) and oxalate (anticoagulant).
Additionally, blood was collected into the purple top tube (with ethylenediaminetetraacetic acid,
EDTA, which binds calcium in the blood and keeps the blood from clotting) and immediately spun at
4ºC to aliquot the plasma sample. Blood was also collected into the plain red top tube (containing clot
activator, silica), kept at room temperature for 60 minutes, and then spun to aliquot serum. Both plasma
and serum samples were stored in -80ºC until analysis. Fasting serum samples were used to measure
insulin concentration. The analysis was done with the use of Human Insulin ELISA kit EZHI-14K by
Millipore (Millipore, Billerica, MA, USA) in Robert Gordon University laboratories.
Blood samples that were collected into the gold top SST™II tubes and grey top tubes were sent to
Clinical Biochemistry Department in the Aberdeen Royal Infirmary, Aberdeen. The laboratory was
using ADVIA Chemistry systems (Bayer Healthcare LLC, Leverkunsen, Germany) for analysis.
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3.5.4.1 Lipid profile
All the components of the lipid profile were determined from the serum samples in the Clinical
Biochemistry Department in the Aberdeen Royal Infirmary, Aberdeen. This section summarizes
methodology used to determine lipid profile.
3.5.4.1.1 Total cholesterol
Total cholesterol was determined by an enzymatic method with colorimetric (Trinder) endpoint. Firstly
cholesterol esters were hydrolysed to free cholesterol and free fatty acids using cholesterol esterase
(Varley 1969). Then the reactions were as follows:
[1] Cholesterol + O2 → cholest-4en-3one + H2O2 (cholesterol oxidase)
[2] H2O2 + phenol + 4-aminoantipyrine → quinoneimine dye + 2 H2O (peroxidase)
The action of cholesterol oxidase in reaction [1], resulted in the production of hydrogen peroxide
which was then measured colorimetrically in the Trinder reaction [2]. Phenol and 4-aminoantipyrine,
called jointly Trinder reagent, react with hydrogen peroxide under influence of peroxidase and a red-
violet quinone complex was formed which was read at 500nm (Varley 1969).
3.5.4.1.2 LDL-cholesterol
LDL cholesterol was calculated from the following Friedewald formula (1972):
LDL cholesterol = total cholesterol – HDL cholesterol – (0.46 * TG) [mmol/L]
or
LDL cholesterol = total cholesterol – HDL cholesterol – (0.2 * TG) [mg/dL].
3.5.4.1.3 HDL-cholesterol
To leave only HDL-cholesterol in a sample, LDL, VLDL and chylomicrons were eliminated by
cholesterol esterase and cholesterol oxidase. Peroxide produced in this step was removed by catalase.
In the second step, reagent containing sodium azide was added. Sodium azide inhibited the catalase and
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Trinder reagent. Therefore, HDL was determined by an enzymatic method similar to that for total
cholesterol.
3.5.4.1.4 Triacylglycerol
The method combined a three step enzymatic reaction with a Trinder reaction. Firstly, lipase from
C.viscosum was used to hydrolyze the triacylglycerol [1] (Fossati et al, 1982). The released glycerol
was measured with use of an enzymatic method. It was converted to glycerol-3-phosphate under the
influence of glycerol kinase [2]. Glycerol-3-phosphate was then oxidized to dihydroxyacetone and
hydrogen peroxide [3]. The latter was measured with the use of Trinder reaction [4].
[1] triacylglycerol → glycerol + free fatty acids   (lipase)
[2] glycerol + phosphate → glycerol-3-phosphate (glycerol kinase)
[3] Glycerol-3-phosphate + O2 → dihydroxyacetone + H2O2 (glycerol-3-phosphate oxidase)
[4] H2O2 + phenol + 4-aminoantipyrene → quinoneimine + 4 H2O (peroxidase)
3.5.4.2 Glycaemic control
3.5.4.2.1 HbA1c
The method required a whole blood sample; therefore the blood was collected into a fluoride and
oxalate tube. The concentration of HbA1c and the concentration of total haemoglobin were measured
separately. The ratio was reported as % HbA1c.
For the measurement of total haemoglobin, there were two reagents needed: Haemoglobin Denaturant
Reagent and Total Haemoglobin Reagent. Firstly, the whole blood sample was mixed with the first
reagent and incubated in the room temperature for 5 min. The red blood cells were lysed and the
haemoglobin chain was hydrolysed by the protease from the reagent. Then the second reagent was
used. The method was based on the conversion of all haemoglobin derivatives into alkaline hematin in
an alkaline solution of a nonionic detergent.
HbA1c was measured by a latex agglutination inhibition method. It required the use of HbA1c
Agglutinator Reagent (R1), and HbA1c Antibody Reagent (R2). The HbA1c from the sample competed
with the agglutinator for the anti-HbA1c antibody, therefore reducing the rate of agglutination. A
61
concentration curve was obtained by monitoring the change in scattered light as a change of
absorbance. The actual change in absorbance was inversely proportional to the concentration of HbA1c
in the sample.
3.5.4.2.2 Fasting plasma glucose
Glucose was measured with an enzymatic method. Glucose in a sample was oxidized to gluconic acid
and hydrogen peroxide due to the catalytic action of glucose oxidase [1] (Varley 1969). The formed
hydrogen peroxide was measured with the use of the Trinder reaction [2].
[1] β-D-glucose + O2 → gluconic acid + H2O2 (glucose oxidase)
[2] 2 H2O2 + phenol + 4-aminoantipyrene → quinoneimine + 4 H2O (peroxidase)
3.5.4.2.3 Fasting plasma insulin
Blood for the measurement of fasting plasma insulin was collected into the purple top tubes (with
EDTA). Once drawn, a tube was kept on the ice on the way from the clinic room to the laboratory
(which took no more that 1-2 minutes) and immediately spun at 4ºC to aliquot the plasma sample.
Plasma samples were stored in -80ºC until analysis.
The analysis was done with the use of Human Insulin enzyme linked immunosorbent assay (ELISA)
kit EZHI-14K by Millipore (Millipore, Billerica, MA, USA) in Robert Gordon University laboratories.
After thawing, the plasma was pipetted into the wells of a microtiter plate and insulin from the samples
bound to the monoclonal mouse anti-human insulin antibodies that coated the inside of the wells. Then,
a second biotinylated monoclonal mouse anti-human antibody bound to the captured insulin and
unbound materials were washed away from the sample. Following this, horseradish peroxidase
conjugated to the immobilized biotinylated antibodies and free enzyme conjugates were washed away.
The immobilized antibody-enzyme conjugates were quantified by monitoring horseradish peroxidase
activities in the presence of the 3,3’,5,5’-tetramethylbenzidine. The enzyme activity was measured
spectrophotometrically by the increased absorbency at 450 nm after acidification of the formed
products. The amount of captured insulin in an unknown sample is proportional to the increase in
absorbency. Therefore the insulin concentration was derived by interpolation from a reference curve
generated from the same assay with reference standards of known concentrations of human insulin.
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3.5.4.3 Kidney function
3.5.4.3.1 Sodium, Potassium and Chloride
For the measurement of sodium, potassium and chloride concentrations in samples, an ion-selective
electrode (ISE) method was used. Serum samples were mixed with ISE buffer that has a constant pH
and a constant ionic strength solution. ISE is a sensor that converts the activity a (concentration) of an
ion in the sampled electrolyte to electrical potential. The potential of the electrode was compared
against a standard electrode potential and measured by voltmeter. The voltage, according to the Nernst
equation [1], depends on the log of ionic activity.
[1] E = E0 + ((2.303 * RT) / nF) * log ax
where E, electrolyte potential recorded; E0, constant for the electrode system; R the universal or molar
gas constant, 8.31 J/K; T, temperature (k); F, the Faraday, 96487 coulombs; n, the number of charges
on the ion, including sign; a, activity of the ion x to which the electrode responds (Varley 1969).
3.5.4.3.2 Creatinine
The method to determine the concentration of serum creatinine was based on the Jaffe reaction (Jaffe
1886). In this reaction, creatinine reacted with picric acid in an alkaline solution. A red coloured
creatinine-picrate complex was formed. The sample was read at 505/571 nm.
3.5.4.3.3 Urea
The urease/glutamate dehydrogenase method was used to measure serum urea concentration. Firstly,
urea was hydrolysed to carbamic acid and ammonia in the presence of urease. Carbamic acid then
decomposed to a molecule of ammonia and carbon dioxide [1]. The produced ammonia then reacted
with 2-oxoglutarate in the presence of glutamate dehydrogenase and NADH [2]. The oxidation of
NADH to NAD+ was measured at 340 nm (Varley 1969).
[1] urea + H2O → NH3 + carbamic acid → 2NH3 + CO2 (urease)
[2] ammonia + 2-oxoglutarate + NADH →  glutamate + NAD+ (glutamate dehydrogenase)
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3.5.4.3.4 Albumin
Serum albumin was quantified by the method that uses bromocresol green solution (BSG) as a binding
dye (Doumas et al. 1971). An albumin-BCG complex was formed and then measured as an endpoint
reaction at 596/694 nm.
3.5.4.3.5 Creatinine clearance
Creatinine clearance is an approximation of glomerular filtration rate (GFR) and is expressed in
milliliters per minute. Renal clearance is a volume of plasma cleared of a given substance (here
creatinine) in 1 minute (Pocock et al. 2006). Creatinine clearance was calculated by multiplying the
creatinine concentration in the urine by the amount of urine excreted in one minute (24h sample urine
volume / 1440) and dividing it by serum creatinine concentration (Pocock et al. 2006). 24-hour urine
samples were collected from the subset of participants only (n = 21) because some of participants
found collecting urine for 24 hours and keeping it chilled in the fridge unpleasant and refused
collection. Consequently, changes in creatinine clearance were only assessed in 21 participants (last
observation carried forward (LOCF) analysis).
Urine creatinine concentration was measured with creatinine assay KGE005 by R&D Systems (R&D
Systems, Inc., Minneapolis, MN, USA) in Robert Gordon University laboratories. The urine creatinine
assay was, just like serum creatinine assay, based on Jaffe reaction. In this reaction creatinine reacted
with alkaline picrate solution to create a bright orange-red complex. Samples were diluted and pipetted
into the wells on a microplate. Then, alkaline picrate reagent was added and incubated for 30 minutes
in a room temperature. Intensity of the orange-red colour at 490 nm corresponded to the concentration
of creatinine in the sample. The investigated samples were compared to the standard curve.
GFR can also be estimated from prediction equations. In the present study the CKD-EPI equation was
used because it was shown to be more accurate than the Modification of Diet in Renal Disease Study
equation (MDRD) (Levey et al. 2009). The equation required information about serum creatinine (Scr)
concentration, age, gender and ethnicity. For the white race the CKD-EPI equations were as follows:
Female Scr (μmol/l) ≤ 62 GFR = 144 × (Scr/0.7)-0.329 × (0.993)Age
Scr (μmol/l) > 62 GFR = 144 × (Scr/0.7)-1.209 × (0.993)Age
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Male Scr (μmol/l) ≤ 80 GFR = 141 × (Scr/0.9)-0.411 × (0.993)Age
Scr (μmol/l) > 80 GFR = 141 × (Scr/0.9)-1.209 × (0.993)Age
3.5.4.4 Liver function
3.5.4.4.1 ALKP
Alkaline phosphatase was determined from serum samples. The enzyme hydrolyzed pNPP substrate in
2amino-2methyl-1propanol (AMP) buffer to form p-nitrophenol [1]. The zinc and magnesium ions
were added to the AMP to activate and stabilize the enzyme. The reaction was followed by the
colorimetric measurement of the rate of formation of p-nitrophenol at 410/478 nm, which was
proportional to the ALKP activity.
[1] pNPP + AMP → P-Nitrophenol + P-AMP (ALP, Mg2+, Zn2+)
3.5.4.4.2 ALT
The reaction was initiated by the addition of α-ketoglutarate [1]. The concentration of NADH [2] was
measured by its absorbance at 340/410 nm and the rate of absorbance decrease was proportional to the
ALT activity.
[1] L-Alanine + α-Ketoglutarate → Pyruvate + L-Glutamate (ALT)
[2] Pyruvate + NADH → Lactate + NAD   (lactate dehydrogenase)
3.5.4.4.3 GGT
In the reaction with synthetic substrate (L-γ-glutamyl-3-carboxy-4-nitroanilide), glycilglycine acted as
an acceptor for the γ-glutamyl residue and 5-amino-2-nitro-benzoate (ANB) was liberated. The product
had an absorption maximum near 400 nm. The rate of formation was measured photometrically at
410/478 nm as a zero-order kinetic assay.
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[1] L-γ-glutamyl-3-carboxy-4-nitroanilide + glycylglycine → 5-amino-2-nitrobenzoate + L-γ-
glutamyl-glycylglycine (GGT)
3.5.4.4.4 Total bilirubin
The method used to measure total bilirubin was an endpoint reaction based on chemical oxidation by
vanadate (Tokuda and Tanimoto 1993). Vanadate oxidizes bilirubin at pH 2.9 to produce biliverdin.
Oxidation, in the presence of detergent, decreased bilirubin’s (both conjugated and unconjugated)
yellow colour. The decrease in optical density at 451/545 nm is proportional to the total bilirubin
concentration.
3.5.4.5 Thyroid function
3.5.4.5.1 Thyroid stimulating hormone (TSH)
The assay is a two-site sandwich assay using chemiluminescence technology and two antibodies
(immunochemiluminometric assay, ICMA) (Weeks et al. 1984). The capture antibody is a polyclonal
sheep anti-TSH bound to a paramagnetic particle. The signal antibody is a monoclonal mouse anti-
TSH labelled with chemiluminescent acridinium ester. The total reaction time is 2 h and bound labelled
antibody is quantified luminometrically (RLU, relative light units). Siemens Advia Centaur XP system
was used for this assay.
3.5.4.6 Ketone bodies monitoring
To ensure that carbohydrates were restricted throughout the diets, ketone bodies were measured both in
urine and in capillary blood at each visit. Urine was tested using reagent strips (Ketostix® Reagent
Strips, Bayer HealthCare LLC, Mishawaka, IN, USA). The procedure was delivered according to the
instructions provided with the strips. Participants were given a disposable container and asked to
provide a urine sample. Then, researcher took the sample to the laboratory, dipped the reagent strip in
the sample and immediately removed it. At this point, timing begun; and at exactly 15 seconds the
reagent area of the strip was matched to the ketone colour chart (on the bottle of strips). The results
were read and recorded. Each color block on the colour chart represented a range of values. The
reagents in the strip were 7.1% w/w sodium nitroprusside and 92.9% w/w buffer. The reaction
involved acetoacetic acid in the urine but not acetone or beta-hydroxybutyric acid. The test was based
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on the development of colours ranging from buff pink to maroon when acetoacetic acid reacted with
nitroprusside. The threshold of acetoacetic acid detection by Ketostix reagent trips was at 0.3 to 0.6
mmol/l.
Concentration of ketone bodies in capillary blood was determined using an electrochemical method
(Optium Xceed Sensor and Optium β-Ketone Test Strips, Abbott Diabetes Care Ltd., Witney, UK).
The procedure was delivered according to the instructions provided (Abbot, 2006). The sensor was
calibrated for every new batch of test strips. Before obtaining a drop of blood finger tip was cleaned
with an alcohol swab and dried. A finger prick was done by a single use sterile lancet; the lancet was
disposed of after use. A drop of blood was applied to the test strip immediately. The sample needed
was 1.5µl of capillary blood. The sensor displayed blood β-ketone concentration in 10 seconds. The
test measures beta-hydroxybutyrate concentration in the range between 0.0 and 8.0 mmol/l. If present
in capillary blood, β-hydroxybutyrate reacts with the chemicals on the strip producing a small electrical
current. The current is measured and the result is displayed on a sensor. The size of the current depends
on the β-hydroxybutyrate concentration in the sample. The test strip contains β-hydroksybutyrate
dehydrogenase (≥ 0.03 U), NAD (free acid form, ≥ 1.67µg), phenanthroline quinone (≥ 0.29 µg), and
non-reactive ingredients (≥ 19.51 µg). The β-Ketone tests strips were calibrated to reflect plasma β-
hydroxybutyrate using the Randox assay kit (RB1007).
3.5.5 Questionnaires
Questionnaires were administered at baseline and every 3 months afterwards to assess quality of life
(Audit of Diabetes-Dependent Quality of Life and The Obesity-Related Wellbeing Questionnaire 97),
satisfaction with diabetes treatment (Diabetes Treatment Satisfaction Questionnaire status version),
physical activity (General Practice Physical Activity Questionnaire), motivation to lose weight based
on transtheoretical model (Decisional Balance Description), depression (Major Depression Inventory),
sleepiness (Epworth Sleepiness Scale) and fatigue (Lee Fatigue VAS Scale). Questionnaires were
given to participants by the end of the long visit (see Table 2) after all the planned measurements were
done and participants received breakfast.
3.5.5.1 Audit of Diabetes-Dependent Quality of Life
Audit of Diabetes-Dependent Quality of Life (ADDQoL) was developed for measurement of quality of
life (QoL) per se (single item) and for measurement of impact of diabetes on quality of life (Bradley
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2005) (Appendix 3). ADDQoL, among other uses, was recommended for use as an assessment tool
with groups of patients and as an outcome measure for clinical research trials evaluating new
treatments (Bradley 2005). The license to use this questionnaire in the present study was obtained from
Prof Clare Bradley, Health Psychology Research, Department of Psychology, Royal Holloway,
University of London.
ADDQoL consisted of two items asking about present QoL and impact of diabetes on present QoL,
and of18 items assessing impact of diabetes on specific areas of life. The first two items were scored
individually on a 7-point Likert scale as follows:
I. In general, my present quality of life is: excellent = 3, very good = 2, good = 1, neither
good nor bad = 0, bad = -1, very bad = -2, extremely bad = -3.
II. If I did not have diabetes my quality of life would be: very much better = -3, much better =
-2, a little better = -1, the same = 0, a little worse = 1, much worse = 2, very much worse =
3.
The 18 areas of life included working life and work-related opportunities, family life, friendships and
social life, sex life, physical appearance, things participants could do physically, holidays and leisure
activities, ease of travelling, confidence in ability to do things, motivation to achieve things, they way
the society at large reacts to participants, worries about the future, finances, need to depend on others
for things the participants would like to do themselves, living conditions, freedom to eat as they wish,
enjoyment of food and freedom to drink as they wish (Bradley et al. 1999). Each of the 18 items
consisted of two questions asking about the impact of diabetes on an aspect of life and the importance
of this aspect. The impact part (“If I did not have diabetes my … would be”) was scored on a 7-point
Likert scale as follows: very much better = -3, much better = -2, a little better = -1, the same = 0, a little
worse = 1, much worse = 2, very much worse = 3. The importance part was scored on a 4-point Likert
scale as follows: very important = 3, important = 2, somewhat important = 1, not at all important = 0.
A score for each item was obtained by multiplying impact and importance. Therefore, -9 meant
maximum negative impact of diabetes and +9 meant maximum positive impact of diabetes. Each of the
eighteen aspects can be interpreted separately; however, an average weighted impact (AWI) can also
be calculated by summing up all applicable item scores and dividing the result by the number of them.
Again, -9 meant maximum negative impact of diabetes and +9 meant maximum positive impact of
diabetes.
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3.5.5.2 Obesity Related Wellbeing Questionnaire
The Obesity-Related Well-Being questionnaire (ORWELL-97) is a validated and reliable tool (Duval,
Marceau et al. 2006) specifically built for measuring health related QoL in obese people following
treatment (Mannucci et al. 1999). It has been developed by an interdisciplinary team of psychiatrists,
endocrinologists, nurses, and dietitians and has been used for research purposes in randomised
controlled trials (Mazzoni et al. 1999). ORWELL-97 measures the intensity and the subjective
relevance of physical and psychological distress generated by overweight (Mannucci et al. 2010).
ORWELL-97 questionnaire has been published and made freely available for the research purposes
(Mannucci et al. 1999).
The questionnaire consists of 18 items related to the obesity-caused somatic symptoms and physical
functioning, impact on obesity-related worries and emotional status, and on relationships and social
network (Mannucci et al. 1999). Each item of the ORWELL-97 questionnaire contains two questions
addressing occurrence of a symptom and its relevance (Appendix 4). Both occurrence and relevance
questions are scored on a 4-point Likert scale with the following scoring: not at all = 0, just a little = 1,
not so much = 3, much = 4. The score of each item was calculated by multiplying occurrence and
relevance. The score of the whole questionnaire was calculated by adding up all items. Lower scores of
ORWELL-97 meant higher the quality of life.
3.5.5.3 Diabetes Treatment Satisfaction Questionnaire
Diabetes Treatment Satisfaction Questionnaire in its status form (DTSQs) was used to measure
patients’ satisfaction with the programme as a diabetes treatment (Bradley 1994) (Appendix 5). The
questionnaire included six items assessing treatment satisfaction and two items assessing perceived
frequency of hyperglycaemia and hypoglycaemia (Bradley 2006). DTSQs has been used in numerous
studies to measure diabetes treatment satisfaction (Jennings et al. 1991, Witthaus et al. 2001, DAFNE
Study Group 2002, Ashwell et al. 2008) and was proved sensitive to the changes in treatment (Bradley
1994).
Each of the items of the questionnaire was rated on a 7-point scale (0 to 6), where 6 meant a high level
of satisfaction and 0 meant a high level of dissatisfaction. The treatment satisfaction Scale Total was
computed by summing up the six items assessing treatment satisfaction. Then, the sum was divided by
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the number of existing scores and finally multiplied by 6 (the number of items in the subscale). The
scale had a minimum of 0 and a maximum of 36.
The DTSQ change version (DTSQc) was developed to overcome the ceiling effects4 often seen with
DTSQs (Howorka et al. 2000). DTSQc has the same items as DTSQs but requires comparison between
the current and the previous treatment. The license to use DTSQs and DTSQc questionnaires in the
present study was obtained from Prof Clare Bradley, Health Psychology Research, Department of
Psychology, Royal Holloway, University of London.
3.5.5.4 General Practice Physical Activity Questionnaire
General Practice Physical Activity Questionnaire (GPPAQ) provides a 4-level physical activity index
(inactive, moderately inactive, moderately active and active) that reflects participants’ current activity
level (Appendix 6). It is a validated tool intended for use in adults in routine general practice (National
Health Service 2006). GPPAQ was not designed for use in physical activity interventions but provides
a simple tool for assessing participant’s physical activity. It takes only 30 seconds to complete,
therefore, it was selected to be used with seven other questionnaires in the present study. GPPAQ
consists of three items. It is scored with the use of the provided algorithm (National Health Service
2006). The questionnaire is available for free.
3.5.5.5 Weight Decisional Balance Scales
The Weight Decisional Balance (WDB) questionnaire is a valid and reliable measure suitable for use in
research (O'Connell et al. 1988). The questionnaire consists of 20 items: 10 Pros and 10 Cons for the
decision to lose weight (O'Connell et al. 1988). The importance of each of the items in making a
decision about losing weight was scored by patients on a 5 point scale: not at all = 1, slightly = 2,
moderately = 3, very = 4, extremely = 5 (Appendix 7).
In order to score the questionnaire, the scores for Pros were added up and divided by 10, and the same
procedure was applied to Cons. The difference score was obtained by subtraction of Cons from the
Pros. A positive value indicated more positive attitude towards weight loss, while negative value
suggested negative attitude towards weight loss.
4 Ceiling effect may occur when a lot of scores are in the upper level of the instrument’s scale. When this
happens, variance of an independent variable is not estimated/measured above a certain level.
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3.5.5.6 Major Depression Inventory
The Major Depression Inventory (MDI) was designed to measure the severity of major depression
according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) published by the
American Psychiatric Association and also according to the International Statistical Classification of
Disease and Health Related Problems , 10th version (ICD-10) (Bech et al. 2001). MDI has been
validated and it can be used as a screening instrument for detecting depression (Olsen et al. 2003).
MDI can be scored according to DSM-IV and ICD-10 algorithms for symptoms of depression but also
it can be scored as a depression rating scale by adding up the individual items (Bech et al. 2001). In the
current study MDI was scored as a depression rating scale. The scale had a minimum of 0 and
maximum of 50. Total scores below 20 did not indicate depression. The scores of 20 to 24 indicated
mild depression, the scores of 25 to 29 indicate moderate depression and the scores of 30 or more
indicated severe depression (Olsen et al. 2003)
MDI consists of ten items (Appendix 8). Two of those items contain two questions 8a, 8b and 10a, 10b.
Only the higher ones of the two choices in items 8 or 10 are used to calculate the overall score. The
items refer to the occurrence of different symptoms of depression two weeks prior to completing the
questionnaire. There are 6 possible responses for each item which, when treated as a depression rating
scale, were scored as follows: all the time = 5, most of the time = 4, slightly more than half time = 3,
slightly less than half time = 2, some of the time = 1, at no time = 0. MDI is free for use and available
to download from the dedicated website of Psychiatric Research Unit at the Mental Health Centre in
Denmark (Bech et al. 2001).
3.5.5.7 Epworth Sleepiness Scale
The Epworth Sleepiness Scale (ESS) contains eight items that assess daytime sleepiness in adults
(Johns 1991). Each item requires patients to rate the chance of dozing in a specific situation (Appendix
9). There are four possible scores to rate the chance of dozing: 0 = no chance of dozing, 1 = slight
chance of dozing, 2 = moderate chance of dozing, and 3 = high chance of dozing. The ESS score is
calculated by summing up all eight items. Therefore, the minimum score is 0 and the maximum score
is 24.
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The ESS was originally developed to distinguish between normal patients and patients with a range of
sleep disorders (Johns 1991). It has been confirmed to be a reliable method for measuring daytime
sleepiness in adults (Johns 1992).
3.5.5.8 Visual Analogue Scales to assess fatigue
The fatigue and energy levels were assessed by the visual analogue scales (VAS-F) developed by Lee
and colleagues (1991). VAS-F is a simple validated tool that is suitable for research purposes (Lee et
al. 1991). The questionnaire consists of 18 items, of which five relate to energy levels and thirteen
relate to fatigue levels (Appendix 10). Each of the items has a 100 mm line with two extremes defined
(i.e. not at all tired on 0 mm end and extremely tired on 100 mm end). Participants were asked to place
a mark on the line to indicate how they felt at the moment of completing the questionnaire. The scores
of VAS-F were calculated for the fatigue and for the energy subscales independently. The scores from
13 fatigue items were summed and divided by 13 to get an average fatigue rating. The same procedure
was applied to five energy items.
3.6 Statistical analysis
The target sample size of 84 subjects (42 in each group) was calculated for the study to have 80%
power to demonstrate mean (± SD) weight loss of 5 ± 8 kg difference between the diets (nQuery
Advisor 4.0, Statistical Solutions Ltd.). A standard deviation of 8 kg was taken from study by Wadden
et al. (1989). Given an anticipated dropout rate of 30 % (based on Samaha et al. 2003) the enrollment
target was set at 120 subjects. Unfortunately, only 41 volunteers were recruited before the study was
stopped (25 on PSMF and 16 on GL) due to problems with funding.
Simple randomisation was used to assign individuals to the two dietary groups (Durham et al. 2008).
It was done using Microsoft Excel software. First column was created and contained sixty “1” (coding
GL group) and sixty “2” (coding PSMF group). Then, a parallel column of RAND functions were
created (using command =RAND() ). Finally, RAND functions were sorted from smallest to largest
with selection expanded to the first column with “1”s and “2”s. The order of two groups (1 for GL and
2 for PSMF) was saved. One hundred and twenty envelopes were prepared, each given a number
between 1 and 120. A person not involved in the study put into the envelopes pieces of paper with the
numbers coding dietary groups (1 or 2) in the saved order, and the sealed the envelopes. If a volunteer
fulfilled inclusion criteria after screening, an envelope with the smallest available number on the cover
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(between 1 and 120) was opened and acoording to the code inside it, the participant was being assigned
to one of the dietary groups.
All variables were assessed for normality before entry into the analysis using the Kolmogorov-Smirnov
test. The distribution was normal for most of the variables analyzed except fasting plasma glucose and
insulin, HOMA-IR, reported dietary fat and protein content (g/d), triacylglycerol, LDL cholesterol,
creatinine, ALKP and GGT. These were log transformed before the analyses. FFM, ALT and total
bilirubin were reciprocally transformed as logging did not correct non-normality. Finally, there were a
number of variables that were dichotomous, ordinal or were not corrected by any of the tried
transformations (log, reciprocal, square root): questionnaire data, medication data, HbA1c, HDL-
cholesterol, TSH, and reported dietary carbohydrate intake both as percent of energy and expressed as
grams per day. These were analysed using non-parametric tests.
All p-values were 2-sided, and we assumed a p-value of 0.05 as statistically significant. Analyses were
performed with SPSS statistical software, version 17.0 (SPSS Inc., Chicago, Illinois).
There are two analyses presented in the results. First is the last observation carried forward analysis
(LOCF) in which the last available measurement was carried forward through the missing time points
to the final assessment. LOCF approach allowed using data of all participants who started the
programme (n = 41). Second is the completers’ analysis, using only the data of participants who
completed the study (n = 14).
In the results section two dietary arms (GL and PSMF) were compared to investigate whether trends
for clinically important differences between the diets could exist. The study did not have sufficient
power to detect significant differences; however, it could indicate the direction of changes.
Additionally, to check whether the LOCF approach biases the results, outcomes for completers and
non-completers were compared. Outcomes of comparisons were reported as either significant
differences, non-significant trends or lack of difference.
The following statistical methods were used:
- To compare baseline values between the dietary groups and also changes between the
groups, an independent t-test was used (non-parametric, Mann-Whitney test).
- To compare baseline values between the dietary groups for categorical and nominal
outcomes, a Chi squared analysis was performed (non-parametric).
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- To compare differences from baseline within the groups, a paired t-test was used (non-
parametric, Wilcoxon signed ranks test).
- To assess time effect on changes in variables, a repeated measures ANOVA was used (non-
parametric, Friedman ANOVA).
- To assess time effect on the proportions of participants (i.e. changes in adverse events over
time) a Cochran Q test was used; this test is a Friedman ANOVA for dichotomous data
(Field 2009)
- To correlate variables or changes between variables, a Pearson correlation coefficient was
used (Spearman’s correlation coefficient for ordinal data)
- Stepwise linear regression models were used to identify the determinants of RMR. The
adjusted coefficients of determination (R2), derived from this analysis for each step,
represent the percentage of variance in RMR, explained by the variables entered into the
model (Field 2009). Measured RMR was entered as a dependent variable and age, body
mass, height, BMI, waist circumference, FM, FFM, fasting glucose and glycosylated
haemoglobin as independent variables. The models provided by the software, that explained
the most variability in RMR were selected and described.
3.6.1 Funding source
The Go Lower company provided food for the Go Lower group, vitamin supplement for both groups
and funded a studentship of the research student. Go Lower had no role in the design, conduct or
reporting of the study.
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4 Results
4.1 Baseline characteristics
LOCF
The physical characteristics of subjects at baseline are shown in Table 5a. Fat mass, fat free mass and
medication use are described later on in this chapter. Most of the participants were Caucasians (n =
39), two were Asians. At baseline age, stature, body mass, BMI, waist circumference and RMR were
not different between the two diet groups. Females were shorter (mean ± SD) (161.4 ± 6.1 vs. 175.7 ±
9.3 cm, p < 0.001), had smaller waists (118.6 ± 12.3 vs. 127.6 ± 10.9 cm, p = 0.021) and lower RMR
than males (1860 ± 413 vs. 2165 ± 418 kcal/d, p = 0.026). However, when controlled for FFM, RMR
(kcal/d) was significantly higher in women (p = 0.015). Age, weight and BMI were not different
between the two genders. There was a difference in the proportion of males and females between the
two diet groups; there were more males in the PSMF group (n = 14) than in the GL group (n = 3)
(56.0% vs. 18.8%, p = 0.025). Also, in the PSMF group men had lower mean BMI than women (36.1
± 4.0 vs. 42.4 ± 6.1, p = 0.005).
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Table 5a. Baseline characteristics of participants (LOCF; n = 41).
All (n = 41) GL (n = 16)m, (n = 3)
PSMF (n = 25)
m, (n = 14) P
†
Age (years)
m
f
Total
57.1 ± 9.4
55.6 ± 8.6
56.5 ± 9.0
56.7 ± 8.0
58.1 ± 7.9
57.9 ± 7.7
55.4 ± 9.0
55.9 ± 11.3
55.6 ± 9.9
0.830
0.574
0.447
Stature (cm)
m
f
Total
175.7 ± 9.3*
161.4 ± 6.1*
167.4 ± 10.3
176.0 ± 7.8
162.1 ± 5.9
164.7 ± 8.2
175.6 ± 9.9
160.6 ± 6.5
169.0 ± 11.3
0.954
0.556
0.199
Body mass (kg)
m
f
Total
115.6 ± 18.4
103.9 ± 19.8
108.8 ± 19.9
133.2 ± 6.4
98.8 ± 18.8
105.3 ± 21.9
111.8 ± 18.0
109.9 ± 20.0
111.0 ± 18.5
0.066
0.177
0.376
BMI (kg/m2)
m
f
Total
37.3 ± 4.5
39.9 ± 6.4
38.8 ± 5.8
43.0 ± 1.9
37.7 ± 6.1
38.7 ± 5.9
36.1 ± 4.0
42.4 ± 6.1
38.9 ± 5.9
0.011
0.072
0.918
Waist (cm)
m
f
Total
127.6 ± 10.9*
118.6 ± 12.3*
122.3 ± 12.4
138.3 ± 6.4
117.6 ± 14.8
121.5 ± 15.8
125.3 ± 10.4
119.9 ± 9.0
122.9 ± 10.0
0.057
0.665
0.755
RMR (kcal/d)
m
f
Total
2165 ± 418*
1860 ± 413*
1987 ± 437
2585 ± 688
1834 ± 430
1975 ± 550
2075 ± 305
1891 ± 411
1994 ± 360
0.052
0.746
0.894
Presented values are means ± standard deviation. All variables were normally distributed. Abbreviations: GL, Go Lower;
PSMF, protein sparing modified fast; BMI, body mass index; RMR, resting metabolic rate; m, male; f, female.
† Significance level of the difference between the diet groups at baseline, calculated using an independent t-test
* marks the significant difference between the genders at baseline, p < 0.05, calculated using independent t-test
Completers
Completers’ analysis gave similar results to the LOCF analysis. The physical characteristics of
completers (n = 14) at baseline are shown in Table 5b. All completers were Caucasians. At baseline
age, stature, body mass, waist circumference and RMR were not different between the two diet groups
and genders. Men on GL (n = 2) had higher mean BMI than men on PSMF (n = 6) (44.0 ± 1.2 vs. 33.8
± 3.4 kg/m2). There were more males in the PSMF group (n = 6) than in the GL group (n = 2) but the
trend was not significant (75.0% vs. 33.3%, p = 0.277). Finally, there were no differences between
completers and dropouts at baseline in age, stature, body mass, BMI, and waist circumference.
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Table 5b. Baseline characteristics of participants (completers, n = 14).
All (n = 14) GL (n = 6)m, (n = 2)
PSMF (n = 8)
m, (n = 6) P
†
Age (years)
m
f
Total
57.4 ± 6.8
58.7 ± 5.5
57.9 ± 6.1
60.5 ± 6.4
60.2 ± 6.4
60.3 ± 5.7
56.3 ± 7.2
55.5 ± 0.7
56.1 ± 6.1
0.498
0.379
0.215
Stature (cm)
m
f
Total
177.9 ± 11.0
163.7 ± 8.3
171.8 ± 12.0
171.5 ± 0.7
162.9 ± 8.2
165.7 ± 7.9
180.0 ± 12.2
165.5 ± 11.3
176.4 ± 13.0
0.386
0.756
0.103
Body mass (kg)
m
f
Total
115.0 ± 18.2
108.3 ± 25.8
112.2 ± 21.1
129.6 ± 2.4
97.2 ± 18.6
108.0 ± 22.1
110.1 ± 18.7
130.6 ± 28.3
115.3 ± 21.3
0.213
0.146
0.547
BMI (kg/m2)
m
f
Total
36.4 ± 5.5
40.1 ± 6.9
38.0 ± 6.1
44.0 ± 1.2
36.4 ± 4.4
39.0 ± 5.2
33.8 ± 3.4
47.3 ± 3.9
37.2 ± 7.0
0.007
0.042
0.613
Waist (cm)
m
f
Total
127.6 ± 13.4
113.3 ± 9.9
121.5 ± 13.7
142.0 ± 1.4
112.2 ± 11.0
122.2 ± 17.6
122.8 ± 11.9
115.5 ± 10.6
121.0 ± 11.4
0.075
0.748
0.882
RMR (kcal/d)
m
f
Total
2156 ± 354
1769 ± 338
1990 ± 389
2205 ± 286
1669 ± 388
1848 ± 428
2140 ± 398
1967 ± 297
2097 ± 346
0.842
0.365
0.251
Presented values are means ± standard deviation. All variables were normally distributed. Abbreviations: GL, Go Lower;
PSMF, protein sparing modified fast; BMI, body mass index; RMR, resting metabolic rate; m, male; f, female.
† Significance level of the difference between the diet groups at baseline, calculated using an independent t-test
* marks the significant difference between the genders at baseline, p < 0.05, calculated using independent t-test
4.2 Body mass and body composition
LOCF
At baseline weight was similar in both diet groups and genders (Table 6a). However, men had
significantly greater fat free mass (65.3 ± 10.4 kg vs. 50.6 ± 7.0 kg, p < 0.001) than women, and
women had significantly greater percentage of body fat (50.6 ± 6.1 vs. 43.1 ± 6.1 %, p < 0.001).
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Table 6a. Changes in weight, fat mass, and fat free mass (LOCF, n = 41).
Baseline 6 months 12 months Total Change Timeeffect †
Group
effect ‡
Weight (kg) a
GL (n=16)
PSMF (n=25)
Total (n=41)
m (n=17)
f (n=24)
105.3 ± 21.9
111.0 ± 18.5
108.8 ± 19.9
115.6 ± 18.4
103.9 ± 19.8
97.3 ± 22.2*
105.1 ± 18.7*
102.1 ± 20.2*
108.7 ± 19.2*
97.3 ± 19.9*
98.3 ± 21.8*
106.4 ± 19.4*
103.2 ± 20.5*
110.1 ± 19.1*
98.3 ± 20.3*
-6.9 ± 6.2
(-6.7 ± 6.2 %) §
-4.6 ± 7.9
(-4.2 ± 6.7 %) §
-5.5 ± 7.3
-5.5 ± 6.7
-5.6 ± 7.8
<0.001
0.001
<0.001
0.001
<0.001
0.326
0.979
FM (kg) a
GL
PSMF
Total
m
f
51.7 ± 14.9
52.3 ± 14.6
52.1 ± 14.6
50.3 ± 12.7
53.4 ± 15.9
44.6 ± 15.2*
47.4 ± 15.8*
46.3 ± 15.5*
43.7 ± 13.3*
48.1 ± 16.9*
45.8 ± 14.9*
47.6 ± 14.1*
46.9 ± 14.3*
45.1 ± 12.7*
48.2 ± 15.4*
-5.9 ± 5.8
-4.7 ± 7.3
-5.1 ± 6.7
-5.2 ± 6.4
-5.1 ± 7.0
<0.001
0.001
<0.001
<0.001
<0.001
0.565
0.981
FM (%) a
GL
PSMF
Total
m
f
48.7 ± 7.1
46.7 ± 7.1
47.5 ± 7.1
43.1 ± 6.1
50.6 ± 6.1
45.1 ± 7.8*
43.9 ± 9.3*
44.4 ± 8.6*
39.6 ± 7.1*
47.8 ± 8.0*
45.9 ± 7.7*
44.3 ± 7.8*
44.9 ± 7.7*
40.4 ± 6.3*
48.1 ± 7.0*
-2.8 ± 3.4
-2.4 ± 3.8
-2.6 ± 3.6
-2.7 ± 3.2
-2.4 ± 3.2
<0.001
0.001
<0.001
<0.001
0.001
0.705
0.805
FFM (kg) b
GL
PSMF
Total
m
f
53.6 ± 12.9
58.6 ± 9.7
56.6 ± 11.1
65.3 ± 10.4
50.6 ± 7.0
52.8 ± 12.6*
58.2 ± 10.3
56.1 ± 11.4*
65.1 ± 10.6
49.7 ± 6.7*
52.6 ± 12.3*
58.7 ± 10.7
56.3 ± 11.6
65.0 ± 10.3
50.1 ± 8.1
-1.0 ± 1.5
+0.1 ± 4.5
-0.3 ± 3.7
-0.2 ± 1.7
-0.4 ± 4.6
0.029
0.565
0.350
0.789
0.342
0.333
0.863
Presented values are means ± standard deviation. Abbreviations: GL, Go Lower; PSMF, protein sparing modified fast; FM,
fat mass; FFM, fat free mass; m, male; f, female. There were no differences between dietary groups at baseline.
† Time effect – significance level of changes over 12 months, calculated using repeated measures ANOVA
‡ Group effect – significance level of the difference in changes between the diet groups at 12 months, calculated using Mann-
Whitney test
§ percent of base line body weight
* significant difference from the baseline, p < 0.05, calculated using paired t-test
a normal distribution
b positive skew, reciprocal transformation
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At the end of the programme there were no differences in weight loss and body composition changes
between the two dietary groups (Figure 15a). Overall, weight was significantly reduced (-5.5 ± 7.3 kg,
p < 0.001), fat mass decreased (-5.1 ± 6.7 kg, p < 0.001 and -2.6 ± 3.6 %, p < 0.001), and fat free mass
in kg did not change (-0.3 ± 3.7 kg, p = 0.350) but fat free mass expressed as a percentage of body
mass significantly increased (from 52.5 ± 7.1 % to 55.1 ± 7.7 %, p < 0.001). Fat mass (%) measured by
the whole body impedance analysis showed very similar decrease as detected by the air displacement
plethysmography (-2.3 ± 4.1 %, p = 0.001). However, at all time points FM (%) measurements were
significantly lower (42.7 ± 7.1 vs. 47.5 ± 7.1 % at baseline; 39.9 ± 8.0 vs. 44.4 ± 8.6 % at 6 months;
40.4 ± 8.0 vs. 44.9 ± 7.7 % at 12 months) than the ones delivered by the densitometric method (p <
0.001).
Figure 15a. Body weight changes (LOCF; GL n = 16, PSMF n = 25). There was no difference
between the diets. Both diets were significantly different at each time point when compared to baseline
(p < 0.001) (time effect). Values are means +/- 1 SE.
* marks significant difference from baseline, p < 0.05
Completers
Completers’ analysis gave similar results to the LOCF analysis (Table 6b, Figure 15b). Namely, weight
was significantly reduced (-5.0 ± 7.2 kg, p = 0.001), fat mass decreased (-6.1 ± 7.8 kg, p = 0.002; and -
3.3 ± 4.2 %, p < 0.001), and fat free mass did not change (+1.1 ± 5.4 kg, p = 0.497). There was an
effect of time on the changes in weight and fat mass; fat free mass was affected by neither time, diet
group nor by the dropout status. There were no differences in weight changes between the GL and
PSMF groups at any of the time points.
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Table 6b. Changes in weight, fat mass, and fat free mass (completers, n = 14).
Baseline 6 months 12 months Total Change Timeeffect †
Group
effect ‡
Weight (kg) a
GL (n=6)
PSMF (n=8)
Total (n=14)
m (n=8)
f (n=6)
108.0 ± 22.1
115.3 ± 21.3
112.2 ± 21.1
115.0 ± 18.2
108.4 ± 25.8
97.4 ± 19.5*
108.8 ± 24.3*
103.9 ± 22.3*
106.2 ± 21.4*
100.9 ± 25.2*
99.6 ± 16.5*
112.8 ± 24.5
107.1 ± 21.7*
108.5 ± 20.4*
105.3 ± 25.3*
-8.4 ± 7.7
(-7.0 ± 6.3 %) §
-2.5 ± 5.9
(-2.6 ± 5.8 %) §
-5.0 ± 7.2
(-4.5 ± 7.2)
-6.5 ± 7.1
-3.0 ± 8.3
<0.001
0.001
0.001
<0.001
0.076
0.228
0.345
FM (kg) a
GL
PSMF
Total
m
f
55.3 ± 14.5
52.5 ± 19.9
53.7 ± 17.2
50.3 ± 14.2
58.2 ± 21.1
45.6 ± 12.5*
46.2 ± 22.0*
45.9 ± 17.9*
41.4 ± 14.8*
51.9 ± 21.3
48.0 ± 10.8
47.3 ± 18.2
47.6 ± 15.0*
43.6 ± 14.0*
52.9 ± 15.7
-7.4 ± 7.2
-5.2 ± 8.6
-6.1 ± 7.8
-6.7 ± 6.4
-5.3 ± 10.0
<0.001
0.009
<0.001
<0.001
0.173
0.491
0.755
FM (%) a
GL
PSMF
Total
m
f
50.7 ± 4.5
44.6 ± 9.5
47.2 ± 8.2
43.2 ± 6.9
52.5 ± 6.9
46.3 ± 5.4*
40.8 ± 12.1*
43.1 ± 9.9*
38.1 ± 7.7*
49.9 ± 8.8
47.9 ± 5.7
40.8 ± 8.9
43.8 ± 8.2*
39.4 ± 6.8*
49.7 ± 6.3
-2.8 ± 3.2
-3.8 ± 5.0
-3.4 ± 4.2
-3.7 ± 3.0
-2.8 ± 8.3
0.001
0.021
<0.001
<0.001
0.446
0.755
0.362
FFM (kg) b
GL
PSMF
Total
m
f
52.7 ± 10.7
62.8 ± 10.7
58.4 ± 10.8
64.7 ± 9.1
50.1 ± 6.3
51.8 ± 8.4
62.8 ± 12.1
58.1 ± 11.8
64.9 ± 10.4
49.0 ± 5.9
51.6 ± 8.4
65.5 ± 10.9
59.5 ± 11.9
64.9 ± 9.3
52.4 ± 11.9
-1.1 ± 1.8
+2.7 ± 6.7
+1.1 ± 5.4
+0.2 ± 1.8
+2.3 ± 8.3
0.160
0.592
0.135
0.413
0.154
0.108
0.662
Presented values are means ± standard deviation. Abbreviations: GL, Go Lower; PSMF, protein sparing modified fast; FM,
fat mass; FFM, fat free mass; m, male; f, female. There were no differences between dietary groups at baseline.
† Time effect – significance level of changes over 12 months, calculated using repeated measures ANOVA
‡ Group effect – significance level of the difference in changes between the diet groups at 12 months, calculated using Mann-
Whitney test
§ percent of base line body weight
* significant difference from the baseline, p < 0.05, calculated using paired t-test
a normal distribution
b positive skew, reciprocal transformation
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Figure 15b. Body weight changes (completers; GL n = 6, PSMF n = 8). There was no difference
between the diets. Both diets were significantly different at each time point when compared to baseline
(p < 0.001) (time effect). Values are means +/- 1 SE.
* marks significant difference from baseline, p < 0.05
4.3 Medication
LOCF
At baseline, there were no differences between the two diet groups in the reported medication doses
(Table 7a). Overall, among patients taking metformin (32 out of 41) the dose was 1506 ± 835 mg/d,
and among patients on insulin (13 out of 41) the dose was 130 ± 70 U/d. There were no significant
associations of medications with weight apart from metformin. Participants on metformin (n = 32)
were heavier than those not on metformin (n = 9) (112.2 ± 19.0 vs. 96.6 ± 19.0, p = 0.036). As
explained in the methods section, patients who were on sulphonylureas at baseline were taken off these
medications before starting the programme. At baseline, 14 (87.5%) of the GL group were on
hypoglycaemic medications (insulin only n = 1, oral agents only n = 8, insulin plus oral agents n = 5),
and 20 (80 %) of the PSMF group were on hypoglycaemic medications (insulin only n = 1, oral agents
only n = 13, insulin plus oral agents n = 6). The proportion of participants on hypo-glycaemic
medications was not different between two groups (p = 0.066).
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Table 7a. Baseline medication and smoking status (LOCF, n = 41).
All (n=41) GL (n=16) PSMF (n=25) P †
Diabetic medication
metformin only n (%)
insulin only n (%)
metformin + insulin n (%)
no metformin or insulin n (%)
21 (51.2)
2 (4.9)
11 (26.8)
7 (17.1)
8 (50.0)
1 (6.3)
5 (31.3)
2 (12.5)
13 (52.0)
1 (3.0)
6 (24.0)
5 (20.0)
1.000
1.000
0.723
0.685
Anti-hypertensive medication n (%) 32 (78.0) 15 (93.8) 17 (68.0) 0.066
Lipid-lowering medication n (%) 36 (87.8) 13 (81.3) 23 (92.0) 0.362
Smoking n (%) 4 (9.8) 0 (0) 4 (16.0) 0.143
Presented values are numbers, with percentages within the group in brackets. Abbreviations: GL, Go Lower; PSMF, protein
sparing modified fast. † Significance level of the between-group proportions of subjects on medications or smoking at
baseline, calculated using a chi-squared test.
Completers
At baseline, there were no differences between the two diet groups in the reported medication doses
(Table 7b). Proportions of participants on medications were similar to LOCF analysis (Tables 7a and
7b). Overall, at baseline among patients taking metformin (12 out of 14) the dose was 1750 ± 965
mg/d, and among patients on insulin (4 out of 14) the dose was 85 ± 55 U/d. There were no significant
associations of medications with weight at baseline.
Table 7b. Baseline medication and smoking status (completers, n = 14).
All (n=14) GL (n=6) PSMF (n=8) P †
Diabetic medication
metformin only n (%)
insulin only n (%)
metformin + insulin n (%)
no metformin or insulin n (%)
8 (57.1)
0 (0)
4 (28.6)
2 (14.3)
2 (33.3)
0 (0)
3 (50.0)
1 (6.7)
6 (75.0)
0 (0)
1 (12.5)
1 (12.5)
0.277
-
0.245
1.000
Anti-hypertensive medication n (%) 10 (71.4) 6 (100.0) 4 (50.0) 0.085
Lipid-lowering medication n (%) 12 (85.7) 4 (66.7) 8 (100.0) 0.165
Smoking n (%) 3 (21.4) 0 (0) 3 (37.5) 0.209
Presented values are numbers, with percentages within the group in brackets. Abbreviations: GL, Go Lower; PSMF, protein
sparing modified fast. † Significance level of the between-group proportions of subjects on medications or smoking at
baseline, calculated using a chi-squared test.
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Lipid-lowering and anti-hypertensive medication doses were not significantly changed in any of the
groups during the study. Table 8 shows changes in hypoglycaemic medication for participants who
completed the study (n = 14). Participants on insulin had the mean dose decreased from 130 ± 70 U/d
to 89 ± 65 U/d (p < 0.001); metformin dose did not change. Three of 6 GL group participants (50%)
had a reduction or removal of hypoglycaemic medication; in the PSMF group 3 participants had
glimepiride discontinued.
Table 8. Changes in hypoglycaemic medications* among completers (n=14).
Participant Baseline: total daily dose 12 months: total daily dose
Go Lower group (total n = 6)
1 metformin 1000 mg
rosiglitazone 8 mg
metformin 1000 mg
rosiglitazone 8mg
2 metformin 3000 mg metformin 3000 mg
3 insulin 68 units
metformin 3000 mg
insulin 36 units
metformin 2000 mg
4 insulin 164 units
metformin 3000 mg
insulin 53 units
metformin 1000 mg
5 insulin 26 units
metformin 3000mg
glimepiride 3.0 mg
metformin 2000 mg
6 none none
Protein sparing modified fast group (total n = 8)
1 metformin 3000 mg
rosiglitazone 8 mg
glimepiride 4 mg
metformin 3000 mg
rosiglitazone 8 mg
2 metformin 1000 mg
pioglitazone 30 mg
metformin 3000 mg
pioglitazone 30 mg
3 metformin 500 mg
4 metformin 2000 mg
glimepiride 4.0 mg
metformin 2000 mg
5 metformin 1000 mg metformin 1000 mg
6 metformin 1000 mg
glimepiride 4.5 mg
metformin 1000 mg
7 metformin 2000 mg metformin 2000 mg
8 metformin 1000 mg
pioglitazone 15 mg
metformin 1000 mg
pioglitazone 15 mg
* medications were adjusted as advised by participants’ physician
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4.4 Dietary composition
LOCF
At baseline, dietary groups did not differ with respect to calorie or macronutrient intake (Table 9a).
Total energy intake for the GL group was 1892 ± 627 kcal/d, and for the PSMF group was 1812 ± 716
kcal/d. About 41% of calories were from carbohydrate, 39 % were from fat, and 20% were from
protein. Total energy intake was similar in both groups across all stages of the programme (Figure
17a).
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Table 9a. Macronutrient composition changes of the diet in both treatment groups (LOCF, n = 41).
P-value
Baseline 6 months 12 months Total Change
Time
effect †
Group
effect
‡
Energy (kcal/d) a
GL (n=16)
PSMF (n=25)
Total (n=41)
1892 ± 627
1812 ± 716
1845 ± 673
1400 ± 556*
1450 ± 590*
1430 ± 570*
1360 ± 558*
1539 ± 687*
1467 ± 637*
-532 ± 430
-253 ± 561
-368 ± 524
<0.001
0.024
<0.001
0.103
Carbohydrate (g/d) c
GL
PSMF
Total
195 ± 71
194 ± 78
195 ± 74
105 ± 94*
128 ± 90*
119 ± 91*
113 ± 82*
135 ± 97*
126 ± 91*
-83 ± 78
-57 ± 77
-67 ± 78
<0.001
0.001
<0.001
0.318
Carbohydrate
(% of energy) c
GL
PSMF
Total
40.8 ± 10.6
41.9 ± 8.6
41.4 ± 9.4
26.3 ± 14.6*
32.1 ± 14.2*
29.8 ± 14.5*
28.7 ± 12.6*
32.4 ± 15.0*
30.9 ± 14.1*
-12.1 ± 14.5
-9.1 ± 12.9
-10.3 ± 13.5
0.001
<0.001
<0.001
0.503
Protein (g/d) b
GL
PSMF
Total
91.3 ± 35.5
83.5 ± 30.7
86.7 ± 32.6
78.1 ± 14.6
78.4 ± 27.9
78.3 ± 23.2
85.2 ± 34.9
77.0 ± 31.3
80.3 ± 32.6
-6.1 ± 34.6
-5.6 ± 23.7
-5.8 ± 28.3
0.700
0.253
0.458
0.763
Protein (% of energy) a
GL
PSMF
Total
19.6 ± 3.9
19.8 ± 6.4
19.8 ± 5.5
25.8 ± 8.8*
23.6 ± 8.8*
24.5 ± 8.8*
26.2 ± 8.7*
22.1 ± 6.7
23.8 ± 7.7*
+6.6 ± 8.6
+2.2 ± 6.4
+4.0 ± 7.6
0.005
0.015
0.001
0.081
Fat (g/day) b
GL
PSMF
Total
86.3 ± 41.6
80.5 ± 38.9
82.9 ± 39.6
75.3 ± 26.3
71.8 ± 32.0
73.2 ± 29.5
76.8 ± 32.9
76.6 ± 36.8
76.7 ± 34.8
-9.5 ± 31.5
-3.4 ± 26.6
-5.9 ± 28.5
0.756
0.377
0.303
0.656
Fat (% of energy) a
GL
PSMF
Total
38.7 ± 10.0
38.4 ± 6.5
38.5 ± 8.0
51.2 ± 13.2*
44.2 ± 10.4*
47.0 ± 11.9*
49.6 ± 12.4*
45.4 ± 11.6*
47.1 ± 12.0*
+10.8 ± 16.4
+6.7 ± 9.2
+8.4 ± 12.6
0.004
0.003
<0.001
0.328
Presented values are means ± standard deviation. Abbreviations: GL, Go Lower; PSMF, protein sparing modified fast. There
were no differences at baseline between the diet groups.
† Time effect – significance level of changes over 12 months, calculated using repeated measures ANOVA or Friedman
ANOVA
‡ Group effect – significance level of the difference in 12 months changes between the diet groups, calculated using
independent t-test
* significant difference from the baseline within the groups, p < 0.05, calculated using paired t-test
a normal distribution
b positive skew, log transformation
c non-normal distribution, untransformed, non-parametric tests used
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There were no differences in 12 months changes in energy or macronutrient content of the diet between
the diet groups (Table 9a). Participants on the GL diet reported a slightly greater decrease in caloric
consumption (GL, -532 ± 430 kcal vs. PSMF, -253 ± 561 kcal, p = 0.103), however, this difference
was not significant (Figure 17a). Overall, LOCF analysis showed that energy restriction and weight
loss were correlated at 6 months (r = 0.372, P = 0.020) (Figure 16) but not at 12 months (r = 0.079, p =
0.632). In other words, at 6 months, energy restriction could account for 13.9% of the variation in
weight loss.
Figure 16. Scatter plot of weight loss and energy restriction at 6 months (LOCF, n = 41) (r = 0.372, p
= 0.020). R2 Linear, coefficient of determination.
From baseline, overall carbohydrate intake decreased from 195 ± 74 g/d to 134 ± 99 (p < 0.001) at 3
months, to 119 ± 91 g/d (p < 0.001) at 6 months, to 126 ± 91 g/d (p < 0.001) at 12 months. The mean
reported carbohydrate intakes did not reach the target level of 40 g/d and was over 25 % of total energy
at all time points (Figure 18a).
Participants reported slightly decreased intake of protein when expressed as grams per day; at 12
months protein intake was on average 5.8 g/d less than at baseline. However, this did not reach
significance (p = 0.458). When expressed as a percentage of energy, protein intake increased from
19.8% at baseline to 23.8% at 12 months (p < 0.001) (Table 9a, Figure 19a). Finally, when expressed
as grams per day per kilogram of body mass, protein intake did not change in any of the groups
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throughout the programme (overall from 0.81 ± 0.29 g/d/kg at baseline to 0.80 ± 0.33 at 12 months, p =
0.865). These values are in agreement with the Reference Nutrient Intakes (Department of Health
1991).
The absolute fat content of the diet did not significantly change (overall -5.9 ± 28.5 g/d, p = 0.303).
When expressed as a percentage of energy, fat content increased overall by 8.4 % at 12 months (p <
0.001) (Table 9a, Figure 20a).
Participants on the GL diet showed trend for reporting slightly lower energy and carbohydrate intakes
and higher protein and fat intakes than participants on PSMF diet; however, these differences were not
significant.
Completers
There was no difference between completers (n = 14) and non-completers (n = 27) in energy or
macronutrient intakes at baseline (Figures 17b, 18b, 19b, 20b). The participants who completed the
study had a mean weight loss of 8.2 ± 6.2 kg at 6 months and 5.0 ± 7.1 kg at 12 months, which
corresponded to the mean reduction in daily energy intake of approximately 315 kcal/d at 6 months,
and 96 kcal/d at 12 months. However, weight loss and energy restriction were not correlated at any of
the time points in this group.
Completers tended to report slightly higher protein and lower carbohydrate intakes throughout the
study than non-completers (Table 9b). At 6 months, completers reported lower carbohydrate intake (78
± 64 vs. 140 ± 98 g/d, p = 0.038) and at 9 months higher protein intake than non-completers (98 ± 40
vs. 75 ± 30 g/d, p = 0.041). At 12 months protein intake was still 14 g/d higher in completers, but the
difference was no longer significant (p = 0.195). Completers’ fat consumption did not differ from non-
completers at any of the time-points.
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Table 9b. Macronutrient composition changes of the diet in both treatment groups (completers, n= 14).
P-value
Baseline 6 months 12 months Total Change
Time
effect †
Group
effect
‡
Energy (kcal/d) a
GL (n=6)
PSMF (n=8)
Total (n=14)
1890 ± 757
2041 ± 795
1976 ± 753
1395 ± 522
1263 ± 244*
1319 ± 376*
1291 ± 520*
1401 ± 542*
1354 ± 515*
-559 ± 309
-640 ± 711
-622 ± 556
0.004
0.007
0.002
0.897
Carbohydrate (g/d) c
GL
PSMF
Total
208 ± 75
209 ± 87
209 ± 79
77 ± 87*
80 ± 46*
78 ± 63*
98 ± 47*
102 ± 89*
100 ± 72*
-110 ± 84
-108 ± 104
-109 ± 93
0.016
0.011
<0.001
0.959
Carbohydrate
(% of energy) c
GL
PSMF
Total
43.0 ± 7.1
39.5 ± 8.6
41.0 ± 7.9
19.1 ± 15.0
23.7 ± 11.7*
21.7 ± 12.9*
25.3 ± 11.8
25.6 ± 15.9
25.5 ± 13.8*
-17.7 ± 14.8
-13.9 ± 17.4
-15.5 ± 15.8
0.144
0.060
0.007
0.672
Protein (g/d) b
GL
PSMF
Total
91.3 ± 35.5
83.5 ± 30.7
86.7 ± 32.6
78.1 ± 14.6
78.4 ± 27.9
78.3 ± 23.2
85.2 ± 34.9
77.0 ± 31.3
80.3 ± 32.6
-6.1 ± 34.6
-5.6 ± 23.7
-5.8 ± 28.3
0.700
0.253
0.458
0.763
Protein (% of energy) a
GL
PSMF
Total
17.4 ± 3.5
20.2 ± 7.6
19.0 ± 6.2
25.5 ± 8.8
28.3 ± 4.7*
27.1 ± 6.6*
26.6 ± 8.7*
25.0 ± 6.9
25.7 ± 7.4*
+9.2 ± 7.7
+4.9 ± 9.4
+6.7 ± 8.7
0.042
0.041
0.004
0.377
Fat (g/day) b
GL
PSMF
Total
84.8 ± 38.5
89.5 ± 40.7
87.5 ± 38.3
85.4 ± 21.0
65.7 ± 14.9
74.1 ± 19.8
89.3 ± 38.7
73.5 ± 32.3
80.3 ± 34.7
+4.5 ± 25.0
-16.0 ± 39.6
-7.2 ± 34.6
0.908
0.720
0.881
0.289
Fat (% of energy) a
GL
PSMF
Total
38.8 ± 8.5
38.1 ± 4.4
38.4 ± 6.2
56.9 ± 12.4
46.3 ± 18.4*
50.8 ± 11.3*
52.4 ± 11.9
47.6 ± 12.3*
49.7 ± 11.9*
+13.6 ± 18.2
+9.5 ± 11.0
+11.2 ± 14.0
0.009
0.170
0.001
0.606
Presented values are means ± standard deviation. Abbreviations: GL, Go Lower; PSMF, protein sparing modified fast. There
were no differences at baseline between the diet groups.
† Time effect – significance level of changes over 12 months, calculated using repeated measures ANOVA or Friedman
ANOVA
‡ Group effect – significance level of the difference in 12 months changes between the diet groups, calculated using
independent t-test
* significant difference from the baseline within the groups, p < 0.05, calculated using paired t-test
a normal distribution
b positive skew, log transformation
c non-normal distribution, untransformed, non-parametric tests used
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reported energy content of the diet. Presented values are means ± 1 SE.
); b, completers’ analysis (
p < 0.05)
1000
1200
1400
1600
1800
2000
2200
0 3 6 9
Time (months)
0
500
1000
1500
2000
2500
0 3 6 9
En
er
gy
(k
ca
l/
d)
Time (months)
The two
GL, n = 6;
12
GL
PSMF
12
GL
PSMF
a)
b)
Figure 18. Changes in
SE. The two graphs show
n = 6; PSMF, n = 8).
* marks significant difference from baseline (
0
5
10
15
20
25
30
35
40
45
50
Ca
rb
oh
yd
ra
te
(%
of
en
er
gy
)
0
5
10
15
20
25
30
35
40
45
50
Ca
rb
oh
yd
ra
te
(%
of
en
er
gy
)
89
the reported carbohydrate content of the diet. Presented values are
: a, LOCF analysis (GL, n = 16; PSMF, n = 25)
p < 0.05)
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PSMF, n = 8).
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the reported protein content of the diet. Presented values are means ± 1 SE.
; b, completers’ analysis (GL, n = 6;
p < 0.05)
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Figure 20. Changes in
graphs show: a, LOCF analysis (GL, n = 16; PSMF, n = 25)
PSMF, n = 8).
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the reported fat content of the diet. Presented values are means ± 1 SE.
; b, completers’ analysis (GL,
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4.5 Compliance
Compliance to the programme was measured not only by the direct weight loss and indirect reported
dietary data assessment but also by the evaluation of the effects of the macronutrient composition of
the diet; namely concentrations of ketone bodies in urine and in capillary blood to assess carbohydrate
intake, and fasting serum urea and albumin concentrations to assess protein intake.
LOCF
Both urine and capillary blood ketone concentrations did not differ between the GL and PSMF groups
at baseline. The presence of ketone bodies in the urine did not change throughout the study (p = 0.921),
remaining detectable in about 10% of the participants. Similarly, concentration of ketone bodies in
capillary blood was low at baseline (0.1 ± 0.1 mmol/l) and did not change during the programme (p =
0.405).
Serum urea levels were similar at baseline in both groups (GL, 6.5 ± 1.5 mmol/l; PSMF, 5.9 ± 1.9
mmol/l, p = 0.315) (Table 10a). Overall, urea concentration increased significantly at 3 months (p =
0.014) and remained elevated until the end of the programme (p < 0.001). Serum albumin
concentrations were also not different between the diet groups at baseline (P = 0.886) and increased
overall at 3 months (p < 0.001), to remain significantly higher until the end of the programme (p <
0.001) (Table 10a).
Table 10a. Changes in serum albumin and urea levels (LOCF, n = 41).
Baseline 6 months 12 months Total
Change
Time effect
†
Group
effect ‡
Albumin (g/l) a
GL
PSMF
Total
45 ± 2
45 ± 2
45 ± 2
47 ± 2*
45 ± 3*
46 ± 3*
47 ± 3*
45 ± 3
46 ± 3*
+2 ± 2
0 ± 1
+1 ± 2
0.001
0.001
< 0.001
0.017
Urea (mmol/l) a
GL
PSMF
Total
6.5 ± 1.5
5.9 ± 1.9
6.1 ± 1.8
7.3 ± 1.6*
6.5 ± 2.8
6.8 ± 2.4*
7.5 ± 1.8*
6.4 ± 2.3
6.8 ± 2.2*
+1.0 ± 1.1
+0.5 ± 1.4
+0.7 ± 1.3
0.025
0.036
< 0.001
0.247
Presented values are means ± standard deviation. Abbreviations: GL, Go Lower; PSMF, protein sparing modified fast. There
were no differences between the dietary groups at baseline.
† Time effect – significance level of changes over one year time, calculated using repeated measures ANOVA
‡ Group effect – significance level of the difference in 12 months changes between the diet groups, calculated using Mann-
Whitney test
* significant difference from baseline, p < 0.05, calculated using paired t-test
a normal distribution
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Completers
Completers’ analysis gave similar findings in compliance as the LOCF analysis (Table 10b).
Completers were not different from non-completers for the measures of compliance.
Table 10b. Changes in serum albumin and urea levels (completers, n = 14).
Baseline 6 months 12 months Total
Change
Time effect
†
Group
effect ‡
Albumin (g/l) a
GL (n=6)
PSMF (n=8)
Total (n=14)
44 ± 2
46 ± 2
45 ± 2
47 ± 2*
47 ± 2*
47 ± 2*
46 ± 2*
46 ± 3
46 ± 3*
+2 ± 1
0 ± 1
+1 ± 1
0.019
0.019
0.001
0.043
Urea (mmol/l) a §
GL
PSMF
Total
7.4 ± 0.9
5.3 ± 1.0
6.2 ± 1.4
7.7 ± 0.8
6.3 ± 1.6*
6.9 ± 1.5*
8.2 ± 1.5
6.2 ± 1.9
7.0 ± 2.0*
+0.8 ± 1.0
+0.9 ± 1.6
+0.8 ± 1.3
0.035
0.013
0.003
0.852
Presented values are means ± standard deviation. Abbreviations: GL, Go Lower; PSMF, protein sparing modified fast.
† Time effect – significance level of changes over one year time, calculated using repeated measures ANOVA
‡ Group effect – significance level of the difference in 12 months changes between the diet groups, calculated using Mann-
Whitney test
* significant difference from baseline, p < 0.05, calculated using paired t-test
§ significant difference between the two diets at baseline
a normal distribution
4.6 Resting metabolic rate
4.6.1 Changes during the programme
LOCF
At baseline, resting metabolic rate (RMR, kcal/d) was similar in both diet groups, however, it was
significantly higher in men (2165 ± 418 vs. 1860 ± 413 kcal/d, p = 0.026) who had more fat free mass
than women (65.3 ± 10.4 vs. 50.6 ± 7.0, p < 0.001). There was still a significant effect of gender on
RMR (kcal/d) after controlling for FFM (p = 0.015). There was no difference in RMR (kcal/d) changes
between the genders or dietary groups during the programme (Table 11a).
Due to the fact that RMR (kcal/d) when corrected for FFM was significantly higher in women
(p=0.015), the RMR was also expressed as kilocalories per kilogram of fat free mass per day (kcal/kg
FFM/d). Females had significantly higher RMR (kcal/kg FFM/d) than men at all time points (Table
11a). However, just like in the RMR expressed by kcal/d, RMR (kcal/kg FFM/d) decreased throughout
94
the study. It decreased on average from 35 ± 5 kcal/kg/d at baseline to 33 ± 6 kcal/kg/d at 6 months (p
< 0.001) and was still different from baseline at the end of the programme (p = 0.004). There was no
difference in RMR (kcal/kg FFM/d) changes between the genders, diet groups or completers/non-
completers during the programme (Table 11a).
Table 11a. Changes in resting metabolic rate (LOCF, n = 41).
Baseline 6 months 12 months Total Change Timeeffect †
Group
effect ‡
RMR (kcal/d) a
GL (n=16)
PSMF (n=25)
Total (n=41)
m (n=17)
f (n=24)
1975 ± 550
1994 ± 360
1986 ± 437
2165 ± 418
1860 ± 413
1767 ± 499*
1872 ± 342*
1831 ± 408*
2001 ± 364*
1712 ± 401*
1773 ± 487*
1899 ± 330
1850 ± 398*
1989 ± 372*
1751 ± 393
-202 ± 287
-95 ± 248
-137 ± 265
-176 ± 267
-109 ± 265
0.004
0.032
<0.001
0.007
0.019
0.212
0.436
RMR
(kcal/kg FFM/d) a
GL
PSMF
Total
m
f
36.7 ± 5.4
34.2 ± 4.5
35.2 ± 5.0
33.2 ± 3.5
36.6 ± 5.4
33.4 ± 5.7*
32.5 ± 5.3*
32.9 ± 5.4*
30.7 ± 2.6*
34.4 ± 6.3*
33.8 ± 6.3*
32.7 ± 5.1
33.1 ± 5.6*
30.6 ± 2.9*
35.0 ± 6.3
-2.9 ± 4.8
-1.4 ± 3.8
-2.0 ± 4.2
-2.6 ± 3.9
-1.6 ± 4.4
0.007
0.054
<0.001
0.036
0.006
0.283
0.446
Presented values are means ± standard deviation. Abbreviations: RMR, resting metabolic rate; GL, Go Lower; PSMF, protein
sparing modified fast; m, male; f, female; FFM, fat free mass. There were no differences between dietary groups at baseline.
† Time effect – significance level of changes over 12 months, calculated using repeated measures ANOVA
‡ Group effect – significance level of the difference in 12 months changes between the diet groups, Mann-Whitney test used
* significant difference from the baseline, p < 0.05, calculated using paired t-test
a normal distribution
There was no correlation between RMR and energy intake. There were positive correlations between
change in RMR (kcal/d) and changes in FM (r = 0.621, p < 0.001) and FFM (r = 0.386, p = 0.013).
Change in RMR (kcal/kg FFM/d) was strongly correlated to change in FM (r = 0.715, p < 0.001) but
not correlated to change in FFM.
Completers
Completers’ analysis confirmed most of the above results (Table 11b). However, in completers there
was no difference between men and women in RMR (kcal/kg FFM/d) at any of the time points. There
were positive correlations between change in RMR (kcal/d) and changes in FM (r = 0.562, p = 0.037)
but not fat free mass. Change in RMR (kcal/kg FFM/d) was also strongly correlated with change in FM
(r = 0.834, p < 0.001).
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Table 11b. Changes in resting metabolic rate (completers, n = 14).
Baseline 6 months 12 months Total Change Timeeffect †
Group
effect ‡
RMR (kcal/d) a
GL (n=6)
PSMF (n=8)
Total (n=14)
m (n=8)
f (n=6)
1848 ± 428
2097 ± 346
1990 ± 389
2156 ± 354
1769 ± 338
1638 ± 329*
1978 ± 399
1833 ± 397*
1995 ± 368*
1616 ± 349
1653 ± 273
2061 ± 328
1886 ± 361
1972 ± 385
1771 ± 323
-195 ± 380
-35 ± 149
-104 ± 273
-184 ± 331
+3 ± 125
0.198
0.0112
0.05
0.138
0.052
0.573
0.228
RMR
(kcal/kg FFM/d) a
GL
PSMF
Total
m
f
34.9 ± 4.5
33.7 ± 4.4
34.2 ± 4.3
33.2 ± 3.5
36.6 ± 5.4
31.6 ± 3.8*
31.9 ± 5.7
31.7 ± 4.8*
30.7 ± 2.6*
34.4 ± 6.3
32.5 ± 6.2
31.9 ± 5.5
32.2 ± 5.5
30.4 ± 3.9
34.5 ± 6.9
-2.3 ± 6.3
-1.8 ± 3.7
-2.0 ± 4.8
-3.1 ± 4.9
-0.6 ± 4.6
0.251
0.170
0.064
0.099
0.379
0.755
0.108
Presented values are means ± standard deviation. Abbreviations: RMR, resting metabolic rate; GL, Go Lower; PSMF, protein
sparing modified fast; m, male; f, female; FFM, fat free mass. There were no differences between dietary groups at baseline.
† Time effect – significance level of changes over 12 months, calculated using repeated measures ANOVA
‡ Group effect – significance level of the difference in 12 months changes between the diet groups, Mann-Whitney test used
* significant difference from the baseline, p < 0.05, calculated using paired t-test
a normal distribution
4.6.2 RMR prediction equations for patients with T2DM
Twenty nine equations that predict RMR were tested for their accuracy (Figure 21) and bias (Figure
22). The most accurate estimation of RMR for the obese class I, II and III subjects with T2DM, was
obtained using the Lazzer equation that used FFM (Lazzer et al. 2007a, Lazzer et al. 2007b) (prediction
accuracy: 64.3 %; bias: -3.3 %) (Figure 21). This equation was derived from a sample of 346
volunteers (164 males, 182 females). Men were between 20 and 65 years of age and with the mean
BMI of 45 kg/m2. Women were between 19 and 60 years of age and had mean BMI of 45 kg/m2.
Predicted RMR for subjects with BMI > 35 kg/m2 (n = 35) was most accurate using the DeLorenzo
(DeLorenzo et al. 2001) equation (prediction accuracy: 65.7 %; bias: -3.4 %). De Lorenzo equation
was based on a sample of 127 males and 193 females aged between 18 and 59 years, and with mean
BMI 27 kg/m2 (range 17 – 40 kg/m2). For the group of volunteers with BMI > 35 kg/m2, the least
biased equation was the Müller equation (Müller et al. 2004) calculated using BMI (prediction
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accuracy 60.0%; bias -2.3%). Müller equation was derived from a sample of 388 males and 658
females, aged 5 – 80 years, and with the mean BMI of 27 kg/m2.
For BMI ≤ 35 kg/m2 (n = 21) the Korth equation (Korth et al. 2007) with FFM, and Johnstone equation
(Johnstone et al. 2006) with FFM were most accurate (prediction accuracy: 71.4 %; and biases: -0.02
% and -1.9 % respectively). The least biased equation for this group was the Korth equation (2007)
calculated using FFM (Figure 22). Korth equation was derived from a sample of 50 males and 54
females, with the mean age of 37 years (21–68), and the mean BMI of 26 kg/m2 (18 – 41 kg/m2). The
equation by Johnstone et al (2006) was based on a sample of 43 males and 107 females, with the age
ranging 21 to 64 and BMI between 17 and 49 kg/m2 (54 % of the sample were overweight or obese).
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Figure 21. Accuracy of prediction of the 29 prediction equations (in order from the least accurate to the most accurate) for all participants (♦),
participants with BMI > 35 kg/m2 (■) (n = 35), and with BMI ≤ 35 kg/m2 (▲) (n = 21). The accuracy of the equations was assessed by the
calculating the percentage of subjects whose estimated RMR fell within ± 10% of the measured RMR (mRMR).
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Figure 22. Prediction Bias of the 29 prediction equations (in order of the highest to the lowest) for all participants (♦), participants with BMI > 35
kg/m2 (■) (n = 35), and with BMI ≤ 35 kg/m2 (▲) (n = 21). Bias was expressed as the mean percentage difference between the predicted and
measured RMR.
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Figure 23. Comparison of the prediction accuracy of weight-based and fat free mass based equations
to predict RMR. Equations are presented in the order of the increasing accuracy of the weight based
version of equation.
The equations that had both weight-based and FFM-based versions were compared (Figure
23). With the exception of the equations by Müller with BMI (Muller et al. 2004) and Lazzer
(Lazzer et al. 2007a, Lazzer et al. 2007b), FFM-based equations seemed to predict RMR less
accurately in this population.
4.6.3 RMR prediction equation
The baseline data from an additional 15 participants obtained during patient screening were
used (total n = 56) to propose a predictive equation for the estimation of RMR in an obese
population with T2DM. The 15 subjects were excluded before randomisation because they no
longer wanted to participate or they did not fulfil the inclusion criteria. However, all of those
15 subjects had T2DM and were obese, and therefore their data was used for this analysis.
The independent variables, used to predict RMR were age, gender, body mass, stature, BMI,
waist circumference, FM, FFM, fasting glucose (logged) and HbA1c (Table 12). RMR varied
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between the subjects with a range from 1128 to 3345 kcal/d and a standard deviation of 394
kcal/d. Table 12 presents three models to predict RMR in obese people with T2DM. In the
stepwise multiple regression analysis, FFM (kg) was the strongest determinant of RMR and
explained 58% of its variability (Figure 24). Other determinants of RMR were waist
circumference (cm), gender, and HbA1c (%):
(Model 1) RMR (kcal/d) = - 901 + 28.6 * FFM (kg) + 16.7 * waist (cm) – 270 *
gender (male = 0 and female = 1) – 41.7 * HbA1c (%)
The four variables included in the above equation explained 81% of the variability in RMR.
Model 2 that explained a total of 79.4 % of RMR variability did not include HbA1c (%):
(Model 2) RMR (kcal/d) = - 1072 + 29.6 * FFM (kg) + 14.6 * waist (cm) – 269 *
gender (male = 0 and female = 1)
Additionally, Model 3 was also constructed. It included FFM, waist circumference, BMI and
gender; and explained 79.5 % of variability in RMR.
(Model 3) RMR (kcal/d) = -1079 + 28.9 * FFM (kg) + 11.6 waist (cm) + 8.6 *
BMI (kg/m2) – 212 * gender (male = 0 and female = 1)
Two further predictive equations were developed separately for men and women. The equations
explaining the most variability in RMR in men (84.8%) included FFM, waist circumference and
glycosylated haemoglobin:
(Model 4) RMR (kcal/d) = -1072.2 + 24.9 * FFM (kg) + 20.6 * waist (cm)
– 86.1 * HbA1c (%)
The proposed equation for women included FFM and waist circumference only and explained 77.1 %
of variability in RMR:
(Model 5) RMR (kcal/d) = -1201.0 + 28.8 * FFM (kg) + 11.7 * waist (cm)
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Table 12. Multiple regression models to predict resting metabolic rate in obese persons with T2DM,
showing regression coefficients.
Independent
variables
Model 1
(R2 = 0.811)
Model 2
(R2 = 0.794)
Model 3
(R2 = 0.795)
regression
coefficient
± SE P
regression
coefficient
± SE P
regression
coefficient
± SE P
Constant -900.7 256.5 0.001 -1072.1 256.4 <0.001 -1079.1 255.6 <0.001
Age (years)
Gender -270.4 63.1 <0.001 -268.7 65.7 <0.001 -212.2 82.1 0.013
Weight (kg)
Height (cm)
BMI (kg/m2) 8.6 7.5 0.258
Waist (cm) 16.7 2.5 <0.001 14.6 2.4 <0.001 11.6 3.5 0.002
FM (kg)
FFM (kg) 28.6 3.4 <0.001 29.6 3.5 <0.001 28.9 3.5 <0.001
log FG
(mmol/l)
HbA1c (%) -41.7 17.9 0.024
Abbreviations: R2, coefficient of determination; SE, standard error; Gender, male = 0, female = 1; BMI, body mass index;
FM, fat mass; FFM, fat free mass; log FG, logarithm to the base of 10 of fasting plasma glucose; HbA1c, glycosylated
haemoglobin.
Figure 24. Scatter plot of RMR and fat free mass in 56 obese subjects. RMR was significantly related
to fat free mass (r = 0.763, R2 = 0.580, p < 0.001).
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4.7 Glycaemic control
LOCF
At baseline, there were no differences between the two diets in fasting plasma glucose, fasting plasma
insulin, and glycosylated haemoglobin concentrations, and in HOMA index. Proportions of subjects on
insulin and on metformin treatment were the same between GL and PSMF groups. At baseline there
were no differences in any of the glycaemic measures between participants on insulin or not, and those
on metformin or not.
There were no differences in changes in any of the glycaemic measures between the two groups (Table
13a). There was an overall significant decrease in HBA1c (-0.4 ± 1.1 %, p < 0.001), fasting plasma
insulin (-1.9 ± 9.0 μU/ml, p = 0.005) and HOMA-IR index (-1.2 ± 5.6, p = 0.018). Change in HbA1c
was correlated with the change in weight (r = 0.427, p = 0.005) (Figure 25).
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Table 13a. Changes in glycaemic control (LOCF, n = 41).
Baseline 6 months 12 months Total Change Timeeffect †
Group
effect ‡
Fasting plasma
glucose (mmol/l) a
GL (n=15)
PSMF (n=25)
Total (n=40)
10.4 ± 2.9
10.1 ± 3.8
10.2 ± 3.5
9.4 ± 3.0
9.4 ± 3.8
9.4 ± 3.5
10.4 ± 4.5
9.6 ± 3.3
9.9 ± 3.8
0.0 ± 4.0
-0.4 ± 3.0
-0.2 ± 3.4
0.335
0.253
0.164
0.805
HbA1c (%) b
GL (n=16)
PSMF (n=25)
Total (n=41)
8.9 ± 1.5
9.1 ± 1.5
9.0 ± 1.5
8.1 ± 1.4*
8.5 ± 1.9
8.3 ± 1.7*
8.5 ± 1.5*
8.7 ± 1.6
8.6 ± 1.6*
-0.4 ± 0.7
-0.5 ± 1.3
-0.4 ± 1.1
<0.001
0.001
<0.001
0.710
Fasting plasma
insulin (μU/ml) a
GL (n=16)
PSMF (n=24)
Total (n=40)
17.1 ± 12.5
12.1 ± 11.0
14.1 ± 11.7
15.3 ± 14.2
10.1 ± 9.3*
12.2 ± 11.6*
15.4 ± 14.1
10.1 ± 8.9*
12.2 ± 11.4*
-1.7 ± 12.8
-2.0 ± 5.4
-1.9 ± 9.0
0.241
0.018
0.005
0.994
HOMA-IR a
GL (n=15)
PSMF (n=24)
Total (n=39)
7.6 ± 6.7
5.3 ± 5.3
6.2 ± 5.9
6.0 ± 5.9
4.2 ± 4.7
4.9 ± 5.2
6.3 ± 5.8
4.0 ± 3.4
4.9 ± 4.5
-1.3 ± 7.3
-1.2 ± 4.5
-1.2 ± 5.6
0.438
0.013
0.018
0.594
Presented values are means ± standard deviation. Abbreviations: GL, Go Lower; PSMF, protein sparing modified fast; m,
male; f, female; HBA1c, glycosylated haemoglobin; HOMA-IR, homeostatic model assessment of insulin resistance. There
were no differences between the dietary groups at baseline.
† Time effect – significance level of changes over one year time, calculated using repeated measures ANOVA or Friedman
ANOVA
‡ Group effect – significance level of the difference in 12 months changes between the diet groups, calculated using Mann-
Whitney test
* significant difference from the baseline, p < 0.05, calculated using Wilcoxon signed ranks test
a positive skew, log transformation
b non-normal distribution, untransformed
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Figure 25. Scatter plot of change in glycosylated haemoglobin (HbA1c) and change in weight at 12
months (n = 41). Presented data are for each individual (overall, r = 0.427, p = 0.005). The Go Lower
group is shown as squares; the protein sparing modified fast (PSMF) group is shown as triangles. R2
Linear coefficient of determination.
Of the participants using insulin (n = 13), the dose was reduced from baseline to 12 months by 40 ± 58
U/d (p = 0.028). Change in insulin dose was positively correlated with the decrease in weight (r =
0.654, p = 0.015) and fat mass (r = 0.681, p = 0.010). There were no changes in metformin and other
hypoglycaemic medications throughout the programme.
Completers
At baseline, there were no differences between the two diets in fasting plasma glucose, fasting plasma
insulin, and glycosylated haemoglobin concentrations, and in HOMA index. Proportions of subjects on
insulin and on metformin treatment were the same between GL and PSMF groups. At baseline there
were also no differences in any of the glycaemic measures between participants on insulin or not.
Completers’ analysis showed similar results to LOCF analysis; however changes in glycaemic control
although more pronounced, were not always significant (Table 13b). Completers, in contrast to
dropouts, displayed a nonsignificant trend for a decrease in fasting insulin and HOMA during the
programme (Table 13b). Completers’ analysis showed that there was an overall significant decrease in
HBA1c (-0.65 ± 1.36 %, p < 0.001) and fasting insulin (-4.0 ± 9.0 μU/ml, p = 0.041) but not HOMA
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index or fasting glucose. Change in HOMA index for the completers was actually more pronounced
than in all participants (LOCF) (-2.1 ± 6.6 vs. -1.2 ± 5.6). The fact that this did not reach significance is
probably due to the small sample size (n = 14) and high standard deviation. Additionally, the change in
HbA1c was not correlated with changes in weight or fat mass but with the change in fasting glucose (r =
0.600, p = 0.023).
Table 13b. Changes in glycaemic control (completers, n = 14).
Baseline 6 months 12 months Total Change Timeeffect †
Group
effect ‡
Fasting plasma
glucose (mmol/l) a
GL (n=6)
PSMF (n=8)
Total (n=14)
11.2 ± 2.4
11.1 ± 4.3
11.2 ± 3.5
9.4 ± 2.3
9.4 ± 4.1
9.4 ± 3.3
12.3 ± 5.3
9.5 ± 3.0
10.7 ± 4.2
+1.0 ± 6.0
-1.6 ± 3.9
-0.5 ± 4.9
0.730
0.745
0.559
0.572
HbA1c (%) b
GL
PSMF
Total
8.7 ± 1.3
9.4 ± 1.8
9.1 ± 1.6
7.4 ± 0.6*
8.1 ± 2.2
7.8 ± 1.7*
8.4 ± 1.5
8.4 ± 1.6
8.4 ± 1.6*
-0.2 ± 0.4
-1.0 ± 1.7
-0.6 ± 1.4
<0.001
0.029
<0.001
0.298
Fasting plasma
insulin (μU/ml) a
GL
PSMF
Total
14.8 ± 14.3
10.6 ± 6.6
12.4 ± 10.4
7.1 ± 3.3
10.6 ± 10.3
9.1 ± 8.0
7.3 ± 2.4
9.1 ± 8.8
8.3 ± 6.7
-7.5 ± 12.5
-1.4 ± 4.6
-4.0 ± 9.0
0.553
0.022
0.041
0.662
HOMA-IR a
GL
PSMF
Total
8.1 ± 9.5
4.5 ± 2.0
6.0 ± 6.3
3.0 ± 1.8
5.1 ± 7.1
4.2 ± 5.5
3.8 ± 1.4
4.0 ± 4.2
3.9 ± 3.2
-4.2 ± 9.2
-0.5 ± 3.7
-2.1 ± 6.6
0.699
0.080
0.159
0.755
Presented values are means ± standard deviation. Abbreviations: GL, Go Lower; PSMF, protein sparing modified fast; m,
male; f, female; HBA1c, glycosylated haemoglobin; HOMA-IR, homeostatic model assessment of insulin resistance. There
were no differences between the dietary groups at baseline.
† Time effect – significance level of changes over one year time, calculated using repeated measures ANOVA or Friedman
ANOVA
‡ Group effect – significance level of the difference in 12 months changes between the diet groups, calculated using Mann-
Whitney test
* significant difference from the baseline, p < 0.05, calculated using Wilcoxon signed ranks test
a positive skew, log transformation
b non-normal distribution, untransformed
4.8 Cardiovascular disease risk
LOCF
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At baseline, GL and PSMF groups had different total cholesterol concentration (p = 0.025) and systolic
blood pressure (p = 0.012). There were no baseline differences between the groups in any other
variables presented in this sub-chapter. Lipid profile change at 12 months was similar in both diet
groups (Table 14a). Overall, triacylglycerol decreased (-0.6 ± 2.4 mmol/l, p = 0.006), total cholesterol
and LDL cholesterol did not change and HDL cholesterol increased (+0.07 ± 0.18 mmol/l, P < 0.001)
(Figure 26). In addition, TC/HDL ratio decreased at 12 months (-0.3 ± 0.8, p = 0.009). Systolic blood
pressure decreased (-6 ± 14 mmHg, p = 0.014) and diastolic blood pressure did not change during the
programme.
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Table 14a. Changes in lipid profile (LOCF, n = 41).
Baseline 6 months 12 months
Total
Change
Time effect
†
Group
effect ‡
Total cholesterol
(mmol/l) a
GL (n=16)
PSMF (n=25)
Total (n=41)
5.4 ± 1.6 §
4.3 ± 1.0 §
4.8 ± 1.4
5.7 ± 1.7
4.3 ± 0.9
4.8 ± 1.4
5.1 ± 1.3
4.3 ± 1.0
4.6 ± 1.2
-0.4 ± 1.2
-0.1 ± 0.5
-0.2 ± 0.9
0.165
0.621
0.222
0.331
Triacylglycerol
(mmol/l) b
GL
PSMF
Total
3.7 ± 4.1
2.0 ± 0.7
2.7 ± 2.7
2.6 ± 1.7
1.6 ± 0.7*
2.0 ± 1.2*
2.5 ± 1.6
1.7 ± 0.7
2.1 ± 1.2*
-1.2 ± 3.8
-0.2 ± 0.7
-0.6 ± 2.4
0.153
0.038
0.006
0.947
HDL cholesterol
(mmol/l) c
GL
PSMF
Total
1.24 ± 0.30
1.10 ± 0.19
1.16 ± 0.24
1.37 ± 0.37*
1.18 ± 0.23*
1.26 ± 0.30*
1.32 ± 0.38
1.17 ± 0.73
1.23 ± 0.30*
0.08 ± 0.18
0.07 ± 0.18
0.07 ± 0.18
0.023
0.006
<0.001
0.554
LDL cholesterol
(mmol/l) b
GL
PSMF
Total
2.9 ± 1.5
2.3 ± 0.8
2.5 ± 1.1
3.3 ± 1.6
2.4 ± 0.7
2.7 ± 1.2
2.6 ± 1.3
2.3 ± 0.8
2.4 ± 1.0
-0.3 ± 1.0
-0.0 ± 0.4
-0.1 ± 0.7
0.265
0.598
0.147
0.414
TC/HDL b
GL
PSMF
Total
4.6 ± 1.8
4.0 ± 1.0
4.2 ± 1.4
4.5 ± 1.7
3.7 ± 1.0*
4.0 ± 1.3*
4.2 ± 1.6
3.8 ± 1.0*
3.9 ± 1.3*
-0.5 ± 1.1
-0.2 ± 0.6
-0.3 ± 0.8
0.295
0.018
0.009
0.908
Systolic BP
(mmHg) a
GL
PSMF
Total
161 ± 19 §
145 ± 17 §
152 ± 19
153 ± 23*
144 ± 18
147 ± 21*
152 ± 23*
143 ± 18
147 ± 20*
-9 ± 16
-3 ± 13
-6 ± 14
0.031
0.384
0.014
0.385
Diastolic BP
(mmHg) a
GL
PSMF
Total
86 ± 9
85 ± 10
85 ± 10
82 ± 11
83 ± 9
83 ± 10
83 ± 12
83 ± 9
83 ± 10
-3 ± 12
-1 ± 8
-2 ± 10
0.323
0.723
0.234
0.414
Presented values are means ± standard deviation. Abbreviations: GL, Go Lower; PSMF, protein sparing modified fast; HDL,
high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; TC/HDL, ratio of total cholesterol and high-
density lipoprotein cholesterol; BP, blood pressure.
† Time effect – significance level of changes over 12 m, calculated using repeated measures ANOVA or Friedman ANOVA
‡ Group effect – significance level of the difference in 12 m changes between the diet groups, Mann-Whitney test used
* significant difference from baseline, p < 0.05, calculated using paired t-test or Wilcoxon signed ranks test
§ significant difference between the two diets at baseline
a normal distribution
b positive skew, log transformation
c non-normal distribution, untransformed, non-parametric tests used
Figure 26. Changes in the
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Table 14b. Changes in lipid profile (completers, n = 14).
Baseline 6 months 12 months
Total
Change
Time effect
†
Group
effect ‡
Total cholesterol
(mmol/l) a
GL (n=6)
PSMF (n=8)
Total (n=14)
5.3 ± 2.1
4.2 ± 0.6
4.7 ± 1.5
6.0 ± 2.2
4.0 ± 0.6
4.9 ± 1.7
4.4 ± 0.7
4.0 ± 0.8
4.2 ± 0.8
-0.9 ± 1.2
-0.1 ± 0.8
-0.5 ± 1.4
0.163
0.791
0.285
0.345
Triacylglycerol
(mmol/l) b
GL
PSMF
Total
2.6 ± 1.0
1.9 ± 0.7
2.2 ± 0.9
2.2 ± 1.4
1.2 ± 0.4*
1.6 ± 1.0*
2.2 ± 0.8
1.4 ± 0.5
1.7 ± 0.7
-0.4 ± 1.4
-0.5 ± 0.7
-0.4 ± 1.0
0.656
0.117
0.088
0.852
HDL cholesterol
(mmol/l) c
GL
PSMF
Total
1.38 ± 0.34
1.14 ± 0.19
1.24 ± 0.28
1.56 ± 0.41
1.31 ± 0.25*
1.42 ± 0.34*
1.47 ± 0.46
1.25 ± 0.30
1.34 ± 0.38
0.08 ± 0.24
0.11 ± 0.29
0.10 ± 0.26
0.122
0.099
0.009
0.980
LDL cholesterol
(mmol/l) b
GL
PSMF
Total
2.7 ± 1.6
2.2 ± 0.7
2.4 ± 1.2
3.4 ± 2.0
2.3 ± 0.5
2.7 ± 1.4
2.0 ± 0.5
2.2 ± 0.7
2.1 ± 0.6
-0.8 ± 1.3
-0.0 ± 0.7
-0.4 ± 1.0
0.557
0.625
0.351
0.468
TC/HDL b
GL
PSMF
Total
3.8 ± 1.3
3.7 ± 0.4
3.8 ± 0.9
4.0 ± 1.3
3.2 ± 0.6
3.5 ± 1.0
3.2 ± 0.8
3.4 ± 0.9
3.3 ± 0.8
-0.6 ± 1.3
-0.3 ± 1.0
-0.4 ± 1.1
0.448
0.148
0.161
0.968
Systolic BP
(mmHg) a
GL
PSMF
Total
161 ± 10
144 ± 19
152 ± 17
139 ± 15*
142 ± 16
141 ± 15*
137 ± 7*
141 ± 13
140 ± 11*
-24 ± 11
-3 ± 17
-12 ± 18
0.002
0.909
0.035
0.018
Diastolic BP
(mmHg) a
GL
PSMF
Total
89 ± 7
87 ± 13
88 ± 11
77 ± 15*
83 ± 10
81 ± 12*
83 ± 17
85 ± 10
84 ± 13
-6 ± 17
-2 ± 12
-3 ± 14
0.106
0.717
0.055
0.432
Presented values are means ± standard deviation. Abbreviations: GL, Go Lower; PSMF, protein sparing modified fast; HDL,
high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; TC/HDL, ratio of total cholesterol and high-
density lipoprotein cholesterol; BP, blood pressure. There were no differences between the dietary groups at baseline.
† Time effect – significance level of changes over 12 m, calculated using repeated measures ANOVA or Friedman ANOVA
‡ Group effect – significance level of the difference in 12 m changes between the diet groups, Mann-Whitney test used
* significant difference from baseline, p < 0.05, calculated using paired t-test or Wilcoxon signed ranks test
a normal distribution
b positive skew, log transformation
c non-normal distribution, untransformed, non-parametric tests used
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Lipid profile and blood pressure changes at 12 months were not significantly different in both diet
groups within the completers, and also between completers and dropouts (Figure 27).
Figure 27. Percentage change of cardiovascular risk factors (mean ± SE): comparison of completers
and dropouts. Tchol, total cholesterol; TG, triacylglycerols; HDL, high density lipoprotein cholesterol;
LDL, low density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure.
The changes from baseline for completers were very similar or even of greater magnitude than those
obtained in the LOCF analysis, however, perhaps due to the smaller participant numbers, some of the
changes were no longer significant. For example, decreases in TG and TC/HDL ratio were no longer
significant. Total cholesterol, LDL cholesterol did not change but HDL cholesterol increased (+0.10 ±
0.26 mmol/l, p = 0.009) and systolic blood pressure decreased (-12 ± 18 mmHg, p = 0.035). The
number of participants whose CVD risk was over 30% decreased from 5 at baseline to 3 at 12 months
and the number of participants whose heart age was estimated to be over 80 years, decreased from 11
at baseline to only 8 at 12 months but none of these changes were significant. The differences in
changes in CVD risk or heart age by Framingham score between completers and dropouts were not
significant.
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4.9 Liver, kidney and thyroid function
LOCF
Participants on both diets showed similar changes in liver, kidney and thyroid function (Table 15a).
Overall through 12 months of the intervention, kidney function remained unchanged (serum creatinine,
p = 0.081; glomerular filtration rate, p = 0.341). Concentration of thyroid stimulating hormone did not
change either (p = 0.535). Liver function improved, with significant decreases in alanine
aminotransferase (ALT) (-5 ± 14 U/l, p < 0.001) and gamma-glutamyl transferase (GGT) (-9 ± 37 U/l,
p < 0.001) levels. Furthermore, there were no changes in total bilirubin (p = 0.072) and alkaline
phosphatase (ALKP) (p = 0.183) concentrations.
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Table 15a. Changes in liver, kidney and thyroid function (LOCF, n = 41).
Baseline 6 months 12 months
Total
Change Time effect
† Group
effect ‡
Creatinine
(µmol/l) b
GL (n=16)
PSMF (n=25)
Total (n=25)
72 ± 20
75 ± 20
74 ± 20
76 ± 17
76 ± 19
76 ± 18
76 ± 18
76 ± 20
76 ± 19
+4 ± 10
+1 ± 6
+2 ± 8
0.165
0.414
0.081
0.741
Cr. clearance
(ml/min) b
GL (n=7)
PSMF (=14)
Total(n=21)
86 ± 64
79 ± 36
82 ± 46
81 ± 52
79 ± 42
80 ± 46
92 ± 46
68 ± 33
76 ± 40
+6 ± 34
-11 ± 21
-6 ± 8
0.538
0.195
0.571
0.145
eGFR
(ml/min/1.73m2) a
GL (n=16)
PSMF (n=25)
Total (n=41)
84 ± 20
91 ± 21
89 ± 20
81 ± 19
91 ± 21
87 ± 21
83 ± 20
89 ± 22
87 ± 21
-1 ± 9
-2 ± 8
-2 ± 8
0.626
0.399
0.341
0.307
TSH (µmol/l) d
GL
PSMF
Total
1.9 ± 1.0
1.7 ± 0.9
1.8 ± 1.0
2.0 ± 0.8
1.7 ± 1.1
1.8 ± 1.0
2.0 ± 0.9
1.8 ± 1.1
1.9 ± 1.0
+0.1 ± 0.6
+0.1 ± 0.7
+0.1 ± 0.7
0.164
0.749
0.535
0.170
ALT (U/l) c
GL
PSMF
Total
40 ± 21
34 ± 23
36 ± 22
31 ± 17*
28 ± 21*
29 ± 20*
33 ± 19
30 ± 24*
31 ± 22*
-7 ± 12
-4 ± 15
-5 ± 14
0.001
0.044
< 0.001
0.643
ALKP (U/l) b
GL
PSMF
Total
76 ± 28
73 ± 25
74 ± 26
71 ± 26
74 ± 29
71 ± 28
70 ± 27
74 ± 31
72 ± 30
-6 ± 15
+1 ± 12
-2 ± 13
0.175
0.810
0.183
0.183
GGT (U/l) b
GL
PSMF
Total
75 ± 60
53 ± 37
61 ± 1.4
57 ± 43
46 ± 42*
50 ± 42*
53 ± 38*
52 ± 53*
52 ± 47*
-22 ± 43
-1 ± 32
-9 ± 37
0.020
0.021
< 0.001
0.771
Total bilirubin
(µmol/l) c
GL
PSMF
Total
9.0 ± 4.6
9.4 ± 3.9
9.2 ± 4.1
9.2 ± 3.9
9.7 ± 4.4
9.5 ± 4.2
9.7 ± 4.1
9.4 ± 4.1
9.5 ± 4.1
+0.7 ± 2.4
-0.0 ± 2.4
+0.3 ± 1.9
0.138
0.291
0.072
0.151
Presented values are means ± standard deviation. GL, Go Lower; PSMF, protein sparing modified fast; eGFR, estimated
glomerular filtration rate, calculated from CKD-EPI equation; Cr. Clearance, creatinine clearance adjusted for body surface
area; ALT, alanine amino transferase; ALKP, alkaline phosphatase; GGT, gamma-glutamyl transferase; TSH, thyroid
stimulating hormone. There were no differences between the dietary groups at baseline for any of the variables in the table.
† Time effect – significance level of changes over 12 m, calculated using repeated measures ANOVA or Friedman ANOVA
‡ Group effect – significance level of the difference in 12 m changes between the diet groups, Mann-Whitney test used
* significant difference from baseline, p < 0.05, calculated using paired t-test or Wilcoxon signed ranks test
a normal distribution
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b positive skew, log transformation
c positive skew, reciprocal transformation
d non-normal distribution, untransformed, non-parametric tests used
Completers
Completers’ analysis showed similar results to LOCF analysis (Table 15b). Overall, kidney and thyroid
functions remained unchanged. Liver function improved, with significant decreases in ALT (-8 ± 21
U/l, p = 0.006) and GGT (-19 ± 51 U/l, p = 0.017) levels. Also, there were no changes in total bilirubin
and ALKP concentrations.
Table 15b. Changes in liver, kidney and thyroid function (completers, n = 14).
Baseline 6 months 12 months Total
Change Time effect
† Group
effect ‡
Creatinine
(µmol/l) b
GL (n=6)
PSMF (n=8)
Total (n=14)
75 ± 16
77 ± 21
76 ± 19
78 ± 16
80 ± 17
79 ± 16
76 ± 18
78 ± 20
77± 18
+1 ± 10
+1 ± 9
+1 ± 9
0.250
0.458
0.186
0.923
Cr. clearance
(ml/min) b
GL (n=2)
PSMF (n=5)
Total (n=7)
29 ± 14
83 ± 40
67 ± 43
59 ± 33
76 ± 34
67 ± 33
76 ± 21
61 ± 28
68 ± 25
+24 ± 7
-24 ± 31
-10 ± 34
0.706
0.480
0.752
0.190
eGFR
(ml/min/1.73m2) a
GL (n=6)
PSMF (n=8)
Total (n=14)
81 ± 18
88 ± 18
85 ± 17
79 ± 18
84 ± 22
82 ± 20
79 ± 18
87 ± 21
84 ± 19
-2 ± 8
-1 ± 8
-1 ± 7
0.718
0.446
0.480
0.774
TSH (µmol/l) d
GL
PSMF
Total
2.5 ± 1.1
1.8 ± 1.0
2.1 ± 1.1
2.3 ± 0.6
2.0 ± 1.3
2.2 ± 1.0
2.5 ± 0.8
2.3 ± 1.3
2.4 ± 1.0
0.0 ± 0.8
+0.4 ± 1.2
+0.3 ± 1.1
0.818
0.834
0.616
0.852
ALT (U/l) c
GL
PSMF
Total
41 ± 19
38 ± 18
40 ± 18
26 ± 9*
24 ± 6*
25 ± 7*
30 ± 8
33 ± 20
32 ± 15
-12 ± 16
-5 ± 25
-8 ± 21
0.008
0.184
0.006
0.662
ALKP (U/l) b
GL
PSMF
Total
70 ± 24
74 ± 23
72 ± 23
67 ± 33
70 ± 20
69 ± 25
65 ± 35
76 ± 31
71 ± 32
-5 ± 16
+2 ± 12
-1 ± 13
0.234
0.830
0.383
0.362
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GGT (U/l) b
GL
PSMF
Total
87 ± 82
67 ± 48
76 ± 63
59 ± 51
44 ± 28
51 ± 39*
48 ± 37
63 ± 64
56 ± 53*
-40 ± 53
-4 ± 46
-19 ± 51
0.097
0.155
0.017
0.662
Total bilirubin
(µmol/l) c
GL
PSMF
Total
10.8 ± 6.5
9.7 ± 3.0
10.2 ± 4.6
10.7 ± 4.5
10.7 ± 4.6
10.7 ± 4.4
11.7 ± 4.8
8.7 ± 3.8
10.0 ± 4.1
+0.8 ± 3.2
-1.0 ± 1.3
+0.2 ± 2.4
0.306
0.049
0.169
0.148
Presented values are means ± standard deviation. GL, Go Lower; PSMF, protein sparing modified fast; eGFR, estimated
glomerular filtration rate, calculated from CKD-EPI equation; Cr. Clearance, creatinine clearance adjusted for body surface
area; ALT, alanine amino transferase; ALKP, alkaline phosphatase; GGT, gamma-glutamyl transferase; TSH, thyroid
stimulating hormone.
† Time effect – significance level of changes over 12 m, calculated using repeated measures ANOVA or Friedman ANOVA
‡ Group effect – significance level of the difference in 12 m changes between the diet groups, Mann-Whitney test used
* significant difference from baseline, p < 0.05, calculated using paired t-test or Wilcoxon signed ranks test
§ significant difference between the two diets at baseline
a normal distribution
b positive skew, log transformation
c positive skew, reciprocal transformation
d non-normal distribution, untransformed, non-parametric tests used
4.10 Questionnaires
4.10.1 Physical activity
Physical activity was assessed by the General Practice Physical Activity Questionnaire (GPPAQ) that
categorizes subjects into one of the four categories: inactive, moderately inactive, moderately active
and active.
LOCF
There were no differences between the diet groups at baseline and at any of the recorded time points.
LOCF analysis showed that physical activity did not change during the study (p = 0.285). Most
participants were inactive and moderately inactive throughout the programme (Figure 28). There was
no association between physical activity and weight, FFM or BMI.
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Figure 28. Physical activity changes in all participants with last observations carried forward (n = 41)
(a) and in completers only (n = 14) (b).
Completers
Completers’ analysis seems to show slightly higher physical activity during the program than LOCF
analysis. There were no differences between the diet groups at baseline and at any of the recorded time
points. Also, at baseline there was no difference in physical activity between completers and dropouts.
Although it appears that more participants were moderately active at 12 months (Figure 28b), physical
activity did not significantly change during the study (p = 0.161). Most participants were inactive and
moderately inactive throughout the programme. There was no association between physical activity
and weight, FFM or BMI.
4.10.2 Attitude towards weight loss
LOCF
At baseline there were no significant differences in motivation to lose weight between GL and PSMF
groups. The attitudes towards weight loss did not change from baseline to 12 months (LOCF, p =
0.959) with the majority of participants being positive. Despite the fact that the general attitude
towards weight loss remained positive throughout the programme (Table 16a), the mean weight
decisional balance (WDB) scores decreased (LOCF, p = 0.007). Finally, there was a positive
association between the change in weight and change in the attitude towards weight loss (r = 0.340, p =
0.03).
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Table 16a. Weight decisional balance scale rating changes (LOCF, n = 41)
Time (months)
0 3 6 9 12
Attitude towards
weight loss
Positive n (%)
Negative n (%)
Undecided n (%)
40 (98)
1 (2)
0 (0)
39 (95)
2 (5)
0 (0)
39 (95)
2 (5)
0 (0)
37 (90)
2 (5)
2 (5)
36 (88)
3 (7)
2 (5)
WDB score (± SD) 1.42 ± 0.69 1.35 ± 0.76 1.18 ± 0.68 1.13 ± 0.74 1.11 ± 0.76
Abbreviation: WDB, weight decisional balance.
Completers
Completers’ analysis showed similar results to LOCF analysis (Tables 16a and 16b). At baseline there
were no significant differences in motivation to lose weight between GL and PSMF groups. There
were also no differences between completers and dropouts. The attitudes towards weight loss did not
change from baseline to 12 months (LOCF, p = 0.959; completers, p = 0.564) with the majority of
participants being positive. Despite the fact that the general attitude towards weight loss remained
positive throughout the programme (Table 16b), the mean weight decisional balance (WDB) scores
decreased (completers, p = 0.03). The association between the change in weight and change in the
attitude towards weight loss in the completers’ analysis was no longer significant.
Table 16b. Weight decisional balance scale rating changes (completers, n = 14)
Time (months)
0 3 6 9 12
Attitude towards
weight loss
Positive n (%)
Negative n (%)
Undecided n (%)
14 (100)
0 (0)
0 (0)
14 (100)
0 (0)
0 (0)
14 (100)
0 (0)
0 (0)
12 (86)
1 (7)
1 (7)
11 (79)
2 (14)
1 (7)
WDB score (± SD) 1.21 ± 0.54 1.11 ± 0.57 0.97 ± 0.53 0.81 ± 0.67 0.77 ± 0.71
Abbreviation: WDB, weight decisional balance.
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4.10.3 Obesity related wellbeing
LOCF
There were no differences in ORWELL-97 scores between diet groups at baseline and at any of the
recorded time points (Figure 29a). There was a significant decrease in the overall scores (p = 0.018)
indicating an improvement in quality of life. There was a positive association between the change in
weight and the change in obesity related quality of life (r = 0.392, p = 0.011).
Figure 29a. Obesity related wellbeing changes (LOCF; GL n = 16, PSMF n = 25).
* significant difference from baseline (p < 0.05)
Completers
There were no differences in ORWELL-97 scores between diet groups (Figure 29b) or between
completers and dropouts at baseline and at any of the recorded time points. Although it seems that
changes in LOCF and completers’ analyses are similar (Figures 29a and 29b), according to the
completers’ analysis, the overall scores of the questionnaire did not significantly change (p = 0.337).
The association between the change in weight and the change in obesity related quality of life was no
longer significant for the completers’ analysis.
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Figure 29b. Obesity related wellbeing changes (completers; GL n = 6, PSMF n = 8).
4.10.4 Diabetes related quality of life
LOCF
At baseline there was no difference in the average weighted impact (AWI) and the 18 items between
GL and PSMF. According to the LOCF analysis (n = 41), AWI of diabetes on quality of life
significantly decreased (from -1.6 ± 1.4 to -1.4 ± 1.3, p = 0.049). Overall, there were significant
decreases in the diabetes negative impact on holidays and leisure activities and worries about the
future. However, the enjoyment of food decreased (Figure 30a).
ADDQoL also has two items rating present quality of life (per se) and the potential quality of life
without diabetes (impact of diabetes on quality of life). Both LOCF and completers analyses showed
that the present quality of life significantly increased indicating a shift from ‘good’ towards ‘very
good’; and the potential quality of life without diabetes did not change.
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Figure 30a. Impact of diabetes on individual life domains: baseline and 12 month scores for LOCF
analysis (n = 41). * marks significant change from baseline to 12 months (p < 0.05). Error bars refer to
1 standard deviation.
Completers
At baseline there was no difference in the average weighted impact (AWI) and the 18 items between
GL and PSMF. At baseline, completers (n = 14) rated the impact of diabetes on their enjoyment of
food more negative than the dropouts (-2.5 ± 0.5 vs. -1.3 ± 0.4. p = 0.011) but the impact of diabetes on
their confidence to do things was smaller than for dropouts (-0.9 ± 0.6 vs. -2.1 vs. 0.4, p = 0.029).
For completers, the AWI of diabetes on quality of life showed a bigger change than in LOCF analysis,
but it was not significant (decrease from -1.6 ± 0.4 at baseline to -1.1 ± 0.3 at 12 months). There was a
significant change only in two life domains: holidays and leisure, and society’s reaction to the
participants (Figure 30b).
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Figure 30b. Impact of diabetes on individual life domains
completers (n = 14). * marks significant change from baseline to 12 months (p < 0.05).
to 1 standard deviation.
4.10.5 Depression
Depression was monitored with the Major Depression Inventory (MDI) scored as a depression rating
scale that ranged from 0 to 50.
LOCF
There were no differences between the dietary groups at baseline or during the programme. There was
a significant overall decrease in the score during the programme (from 13.0 ± 8.7 at baseline to 10.4 ±
9.7 at 12 months, p <
highest at baseline but even then they were still within the normal ranges
depression. There was a positive
GL group (r = 0.547, p = 0.028) but not in PSMF group (r =
Completers
The results of completers’ analysis were very similar to LOCF analysis.
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: baseline and 12 month scores
0.001) suggesting an improvement in any depressive states. MDI scores were
association between change in weight and change in the MDI score
-0.040, p = 0.849).
between completers and dropouts.
baseline 12 months
*
*
for
Error bars refer
and did not indicate
in
There were no baseline
There was a significant
121
overall decrease in the score during the programme (from 13.2 ± 8.2 at baseline to 8.9 ± 10.5 at 12
months, p = 0.007) suggesting an improvement in any depressive states. MDI scores were highest at
baseline but did not indicate depression. There was a positive association between change in weight
and change in the MDI score in GL group (r = 0.896, p = 0.016) but not in PSMF group (r = -0.098, p
= 0.817).
4.10.6 Energy and Fatigue
A visual analogue scales (VAS-F) were used to evaluate subjective fatigue and energy level changes
during the programme (Lee, Hicks et al. 1991).
LOCF
There were no baseline differences between dietary groups. No changes in the fatigue or energy levels
were reported (Table 17a), however, there was a trend towards an increase in energy levels towards the
end of the study. There was a negative correlation between change in weight and in energy ratings (r =
-0.309, p = 0.049).
Table 17a. Changes in the fatigue and energy rating (LOCF, n = 41).
Baseline 6 months 12 months Total change P
VAS-F
Fatigue b 22.0 ± 17.1 22.9 ± 21.4 22.6 ± 19.2 +0.6 ± 13.0 0.799
Energy a 51.8 ± 25.8 54.1 ± 20.5 56.9 ± 23.0 +5.1 ± 18.2 0.487
Values presented are in mm on 100mm scale (means±SD). VAS-F, Visual Analogue Scale to measure Fatigue Severity
a normal distribution
b positive skew, log transformation
Completers
Completers’ analysis showed very similar results to LOCF analysis. There were no baseline differences
between dietary groups or between the completers and dropouts. No changes in the fatigue or energy
levels were reported (Table 17b), however, there was a trend towards an increase in energy levels
towards the end of the study. There was no correlation between changes in weight and fatigue ratings.
The correlation between change in weight and energy ratings was no longer significant (r = -0.275, p =
0.341).
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Table 17b. Changes in the fatigue and energy rating (completers, n = 14).
Baseline 6 months 12 months Total change P
VAS-F
Fatigue b 21.5 ± 14.4 22.1 ± 18.8 21.2 ± 12.7 -0.3 ± 16.3 0.799
Energy a 55.7 ± 25.8 57.1 ± 19.6 63.7 ± 23.6 +8.0 ± 24.9 0.487
Values presented are in mm on 100mm scale (means±SD). VAS-F, Visual Analogue Scale to measure Fatigue Severity
a normal distribution
b positive skew, log transformation
4.10.7 Sleepiness
The Epworth Sleepiness Scale (ESS), which measures the general level of daytime sleepiness, had
possible scores between 0 and 24.
LOCF
Figure 31a shows changes in ESS rating throughout the programme. At all time points the scores were
not different between PSMF and GL (data not shown). There was an overall decrease in the score (p <
0.001).
Figure 31a. Change in Epworth Sleepiness Scale scores (LOCF, n = 41).
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Completers
At all time points the scores were not different between PSMF and GL, as well as between completers
and dropouts. There was an overall decreasing trend (Figure 31b). Despite more pronounced decrease
than with LOFC analysis (Figure 31a), the changes did not reach significance, most likely due to the
smaller sample size.
Figure 31b. Change in Epworth Sleepiness Scale scores (completers, n = 14).
4.10.8 Diabetes Treatment satisfaction
The Diabetes Treatment Satisfaction Questionnaire status (DTSQs) was rated on a scale from 0
(dissatisfaction with the treatment) to 36 (full satisfaction with the treatment).
LOCF
At baseline there was no difference between dietary groups in the DTSQs score. Overall, LOCF
analysis showed that the diabetes treatment satisfaction increased (28.6 ± 6.9 at baseline to 29.7 ± 6.4
at 12 months, p = 0.039). This change was not correlated with change in weight.
Completers
Completers’ analysis showed very similar results to LOCF analysis. At baseline there were no
differences between dietary groups or between completers and dropouts in the DTSQs score. Overall,
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completers’ analysis showed that the diabetes treatment satisfaction increased (28.6 ± 7.3 at baseline to
29.5 ± 6.0 at 12 months, p = 0.045).
4.11 Adverse events
Most of the complaints recorded were characteristic for the switch of the main body energy fuel from
glucose to fatty acids. During the first 2 weeks of the intervention participants reported headaches (n =
8, 20.0 %), hunger (n = 5, 12.5 %), sickness (n = 4, 10.0 %), diarrhoea (n = 4, 10.0 %), tiredness (n = 4,
10.0 %), nausea (n = 3, 7.5 %), irritated stomach (n = 1, 2.5 %), constipation (n = 1, 2.5 %), bloody
stools (n = 1, 2.5 %), and mood swings (n = 1, 2.5 %). Three persons reported hypoglycaemia (Table
18). A subject who experienced constipation, bloody stools and sickness during the first week decided
to discontinue the study. Another one, who had a bowel resection in the past, experienced both
recurrent diarrhoea and bowel irritation; this subject dropped out after 7 months of participation.
There were no differences between the GL and PSMF groups in the proportion of the subjects with an
adverse event (Table 18).
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Table 18. Adverse events recorded from 2 weeks to 12 months of the intervention. Presented data are
for as many volunteers as there were in the study at the reported times.
Event
Adverse events (n, %)
during the first 2 weeks at 3 months at 12 months
GL
(n=16)
PSMF
(n=25)
Total
(n=41)
GL
(n=13)
PSMF
(n=15)
Total
(n=28)
GL
(n=6)
PSMF
(n=8)
Total
(n=14)
Mood swings 1
(4.2)
1
(2.5)
Nausea 1
(6.3)
2
(8.3)
3
(7.5)
1
(6.7)
1
(3.6)
Sickness 1
(6.3)
3
(12.5)
4
(10.0)
2
(15.4)
2
(7.1)
Weakness 1
(6.7)
1
(3.6)
Tiredness 2
(12.5)
2
(8.3)
4
(10.0)
1
(7.7)
1
(6.7)
2
(7.1)
1
(16.7)
1
(12.5)
2
(14.3)
Light-
headedness
1
(6.7)
1
(3.6)
Lack of
appetite
Hunger 5
(20.8)
5
(12.5)
2
(15.2)
2
(7.1)
1
(16.7)
1
(7.1)
Irritated
stomach
1
(6.3)
1
(2.5)
1
(7.7)
1
(3.6)
1
(16.7)
1
(7.1)
Constipation 1
(4.2)
1
(2.5)
1
(16.7)
1
(7.1)
Bloody stools 1
(4.2)
1
(2.5)
Diarrhoea 2
(12.5)
2
(8.3)
4
(10.0)
3
(23.1)
3
(10.7)
Sound
stomach
1
(7.7)
1
(3.6)
Flatulence 1
(6.7)
1
(3.6)
Headache 5
(31.3)
3
(12.5)
8
(20.0)
1
(6.7)
1
(3.6)
Halitosis
(7.7)
1
(6.7)
1
(3.6)
Bad taste in
mouth
1
(6.7)
1
(3.6)
Hypoglycemia 2
(12.5)
1
(4.2)
3
(7.5)
2
(15.4)
1
(6.7)
3
(10.7)
1
(16.7)
1
(7.1)
GL, Go Lower; PSMF, protein sparing modified fast. Lack of appetite was recorded at 1 month in two participants (GL = 1
and PSMF = 1). Empty fields mean that no adverse events were recorded at a time.
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There were five individual serious adverse events recorded during the trial (Table 19). None of them
were likely to have been caused by the participation in the programme.
Table 19. Serious adverse events among 41 participants over 12 months (n = 5).
Recorded Dietary group Serious adverse event Related
2nd day Protein sparing
modified fast
Septicaemia; hospitalization No
first week Go Lower Suspected blockage in the
bile duct
Very unlikely
first week Protein sparing
modified fast
Kidney stones;
hospitalization
Possibly, but unlikely; occurred
very early in the trial
10th month Protein sparing
modified fast
Breast cancer; hospitalization No
11th month Protein sparing
modified fast
Death No; external post-mortem
showed that the cause of death
was the coexistence of
cardiovascular disease, diabetes,
hypertension and chronic
obstructive pulmonary disease
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5 Discussion
The results from this study showed that for obese individuals with poorly controlled T2DM, the two
approaches to high-protein LCKD, PSMF and GL, had similar effects on weight loss, diabetic control
and CVD risk after 12 months. The hypothesis that convenience of ready made meals would results in
better adherence and consequently greater weight loss at 12 months was not proved. The similar effects
of PSMF and GL could be the evidence of matching nutritional composition of the participants’ diet in
both groups. It could also be an indication that the outcomes of being randomly assigned to either of
the investigated approaches for 12 months would be very similar in this population. Overall, the
LCHOD improved glycaemia, HDL-cholesterol, TG concentrations, systolic blood pressure, and was
safe for obese people with T2DM when used for 12 months.
Due to problems with funding, only n = 41 (and not planned n = 120) volunteers started the
programme. Apart from the funding issue, there also was a problem with participant recruitment.
Initially, volunteers were identified from the Woolmanhill Diabetic Clinic. As most of the available
potential volunteers were approached, new way of recruiting had to be planned. We have applied for
and were grated ethical approval to recruit volunteers from GP surgeries in Aberdeen. This was
supported by both the MCN lead for Diabetes and the Diabetes lead for Aberdeen City. The study was
advertised by the means of posters in GP surgeries (Appendix 11). The participants were planend to be
recruited by the PhD student who was responsible for discussing the study with each volunteer
individually and for obtaining a signed consent. Unfortunately, the effectiveness of this new approach
was not evaluated as the funding for the study did not allow continuation of the recruitment (i.e. the
posters were taken down).
Simple randomization, used in this study, is not an ideal approach when recruitment target is not
reached. Smaller than planned sample size resulted in uneven group numbers (n = 16 in GL group and
n = 25 in PSMF group). Additionally, groups were not matched for gender, which in turn resulted in
different proportion of men and women between the groups at baseline (see Results).
The above problem could have been prevented by the appropriate choice of randomisation method. For
example, block randomization would help to ensure equal group numbers (Julious et al. 2010). In this
approach blocks of n participants have equal numbers. Blocked randomisation would minimise the
possibility of a long sequence of assignments to the same dietary group. Moreover, to ensure equal
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proportions of genders within the groups, stratification into genders should have been conducted
(Durham et al. 2008). Alternatively, equal proportions of genders could be assured by the matched-
group design – matching for gender between the diet groups of equal numbers (Polgar and Thomas
2008). Finally, a more sophisticated but also more accurate method of minisation could be used.
Minimization is an adaptive stratified sampling, recommended when there are a few stratification
factors. This method has been given a status of “a platinum standard” (Treasure and MacRae 1998).
The differences between GL and PSMF approaches may appeal to individuals with different lifestyles.
Randomisation of participants in our study did not match a given approach to a patient’s lifestyle. This
explained some of the dropouts we have seen (e.g. inability to adhere to the Go Lower diet when on
holiday/business trips; unwillingness to learn about PSMF). Additionally, the fact that Go Lower food
was provided for free and foods for the PSMF group were not may have affected decision to drop out
from the study, as protein is the most expensive source of energy in the diet (St. Jeor 2000). However,
no difference in dropout rates between the two diets was noted at any of the time points. Thus, each
diet had advantages and disadvantages which were counterpoised against one another. Personal cost
and preparation time may elicit greater engagement with the PSMF, balancing the convenience of GL.
The dropout rate in the study was quite high (66 %) compared to other studies. The anticipated dropout
(30%) based on the study by Samaha et al. (2003) unfortunately underestimated the real dropout.
Participants did not have to give reasons for discontinuing the present study, however some of them
did. Table 3 outlines the times when most of the participants dropped out and, where available, gives
reasons for dropout. The reason given most often was the mismatch between lifestyle and the
restrictions of the diet. In other words, those who dropped out were not willing to make the changes in
their lives that would allow success in the programme. This is an important finding, as it reflects the
participants’ dedication to the programme and their readiness for change. Lifestyle interventions,
unlike drugs, require substantial involvement and work both on the side of a patient as well as a health
professional. Perhaps some of the participants did not realize the challenge they took when they joined
this one-year-long lifestyle intervention programme. On the other hand, participants were recruited
from the secondary care and had poorly controlled diabetes. Most of them were struggling with
diabetes for years, had various complications and were recommended lifestyle interventions before.
The fact that diabetes and obesity treatments were not successful until the start of the present study was
perhaps a proof that this specific population was less likely to succeed in the programme. Among other
reasons for dropout were medical concerns. Those were mostly cases when a participant was
hospitalized and could not adhere to the diet for a longer time. Also, there was a case when a
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participant dropped out due to dissatisfaction with the new body image. Again, this shows lack of
readiness to change. In the GL group only, four participants said the reason they dropped out was the
fact that they did not enjoy the food. The ready-meals approach has got the disadvatange of restricted
choices. The lack of food enjoyment was never the reason for dropout in the PSMF group.
The times of dropout were different between the two approaches. Participans seemed to drop out from
the PSMF group at the beginning and at the end of the programme, while dropouts in the GL group
were distributed throughout the duration of the study (Table 3). It was clear however, that attrition was
high during the first month of the study in both groups (17.6 % dropped out from PSMF and 30 %
from the GL). This was in agreement with Larsen et al. (2010) who noticed that most people drop out
at the beginning of trials. Interestingly, during the second month none dropped out from the GL group
but over 41 % (n = 7) dropped out from the PSMF group. Out of these seven, one dropped out because
of the medical concern, one did not give any reason, and the rest blamed lifestyle issues. It can be
speculated that after one month of dieting, some of the participants realised that they need to make a
permanent change to their diet, food shopping, cooking and eating habits. Perhaps, ready made meals
approach of the GL diet made this phase easier by eliminating element of planning, shopping and
cooking. Additionally, participants of the GL group by receiving ready meals were being educated
about portion sizes and kinds of food that they should be having on this diet. Learning through
experience of food and its quantities could have made this stange of the programme easier.
Further investigation of the dropout reasons was planned and ethical approval was obtained. A simple
questionnaire was developed asking participants anonymously for the resons of dropping out or
completing the programme, and the study arm they were randomized into. The questionnaire was
prepared in a written form (Appendix 12). It was planned to be posted to participants after they
completed the study or dropped out. The posted materials would also include an addressed and
stamped return envelope. The written answers were supposed to undergo thematic analysis to identify
what factors affected dropping out from the study or completing the programme. This investigation,
however, did not take place because, in light of the lack of funding, the research team decided against
it.
The main analyses performed in this study were on 41 participants using the last observation carried
forward (LOCF) method to deal with the dropout cases. The completers’ analysis was performed as
well, however, the sample size in this case was small (n = 14). In the LOCF method, the last recorded
measurement was carried forward through the remaining time points to the finish. The approach
130
allowed keeping the sample size at baseline level and examining trends over time. LOCF is also more
widely used than the baseline observation carried forward method or other ways of addressing dropout
in clinical trials of dietary intervention. The arguments proposed against using this method include
biased estimate of the treatment effect and underestimation of the sample’s variability (Liu-Seifert et
al. 2010). Last observation carried forward can be a conservative approach (underestimating the effect
of a treatment) when considered from the point of view that participants no longer receive any
treatment and therefore cannot benefit from it (i.e. lose weight). However, it can overestimate the effect
in cases when the intervention is not effective and completers gain weight towards the end of the
programme. Based on the available literature it was concluded that the use of a high protein LCHOD is
an effective way of addressing excess weight in this population and therefore overestimating the effect
in dropouts when using LOCF should not be an issue. Finally, there were different approaches reported
to be used to classify dropouts. For example, Larsen et al (2011) did not treat a participant as a dropout
when they discontinued the programme and included those cases in the analysis (intention to treat).
Therefore, only those that were not available for measurements were treated as dropouts.
Contrastingly, in the current study when a patient declared inability to comply with the programme, he
or she was excluded. The latter approach provided evidence of the diet’s effect in participants who
declared adhering to the programme.
5.1 Participants at baseline
The baseline characteristics of the participants in the present study were similar to those reported by
the Diabetes Outcome Progression Trial (ADOPT) and The Anglo–Danish–Dutch study of intensive
treatment in people with screen-detected diabetes in primary care (ADDITION). ADOPT reported
baseline data for Caucasians with T2DM from Europe (n = 2037) and Caucasians from North America
(n = 1815) (Viberti et al. 2006). In the ADDITION study, 94.7% of about 3000 participants were
Caucasians (Sandbaek et al. 2008). Unlike our study, obesity was not an inclusion criterion in ADOPT
or ADDITION, therefore BMIs, waist circumferences and blood pressures were slightly lower (Table
20). The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study reported baseline
characteristics in ranges (e.g. 39.4 % of 9795 participants were overweight and 48.4 % were obese) so
it was not included in Table 20. The participants for the FIELD study were recruited from Australia,
New Zealand and Finland. Caucasians were 92.8 % of the whole sample, the percent of men was
62.7% of the whole sample, and only 56.6 % of the whole sample had hypertension (Scott et al. 2005).
The other two large multicentre trials (The Action to Control Cardiovascular Risk in Diabetes,
ACCORD and United Kingdom Prospective Diabetes Study, UKPDS) had slightly different
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populations to the one from which we have taken our sample. The ACCORD trial recruited only 64.5
% of Caucasians, the remainder being Black and Hispanic (Action to Control Cardiovascular Risk in
Diabetes Study Group 2008). The UKPDS included cases of only newly diagnosed diabetes and
recruitment age was up to 65 years (UKPDS Group 1991). The similarities between our sample’s,
ADOPT’s and ADDITION’s baseline characteristics, suggest that apart from the small number of
participants, our sample was comparable to the population of obese Caucasians with T2DM.
Table 20. Baseline characteristics of ADOPT and ADDITION cohorts compared to our sample.
ADOPT
North America
(n = 1815)
ADOPT
Europe
(n = 2037)
ADDITION
NL, UK, DK
(n 3000)
Current study
Scotland
(n = 41)
Age (years) 56 ± 10 58 ± 10 60 ± 7 56 ± 9
Men (%) 56.5 60.6 57.9 41.5
BMI (kg/m2) 33.4 ± 6.8 31.0 ± 5.5 31.6 ± 5.6 38.8 ± 5.8
Waist (cm) 108 ± 15 104 ± 14 107 ± 13 122 ± 12
SBP (mmHg) 130 ± 14 137 ± 16 151 ± 23 152 ± 19
DBP (mmHg) 79 ± 9 82 ± 9 87 ± 12 85 ± 10
Antihypertensive
therapy (%)
74.2 84.2 41.0 78.0
Values represent mean and 1 standard deviation.
Baseline characteristics of participants could influence the response to the diet (Noakes et al. 2005).
For example, Noakes and co-workers (2005) found no difference in the effects of high-protein and
high-carbohydrate diets in women with low TG concentrations at 3 months but reported greater fat
mass loss (6.4 ± 0.7 kg vs. 3.4 ± 0.7 kg) in high-protein compared to high-carbohydrate diet in women
with baseline TG concentrations >1.5mmol/L. They chose TG as a marker of insulin resistance
syndrome. The group proposed that an interaction of phenotype and diet can influence weight loss and
suggested a mechanism of higher weight loss in the high TG group. We have observed no such
relationship in our study. However, all of the participants in our study had T2DM, and hence insulin
resistance. The reason could be the fact that people with T2DM find it more difficult to lose weight
that those without diabetes (Pi-Sunnyer 2005). The mean fat mass loss in women was -8.1 ± 4.5 kg at 3
months (n = 15; those who completed 3 months) and -3.0 ± 7.3 kg at 12 months (n = 6; those who
completed 12 months). This fat mass loss was therefore similar to the one reported by Noakes et al
(2005) in women with TG > 1.5 mmol/l. If the high TG levels in the Noakes et al (2005) study
indicated insulin resistance, then what the current study have observed seems to confirm their
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suggestion that women who are insulin resistant lose more fat mass on a high-protein diet at 3 months.
It has to be noted that firstly, the present study had a smaller number of participants; and secondly the
nutritional composition of the diet in these two studies was slightly different; the diet in the Noakes
study had more protein (34% vs. 24%) and carbohydrate (46% vs. 31%) but less fat (20% vs. 47%).
5.2 Weight loss and body composition
Participants on both diets achieved mean weight loss of about 5.5 kg which was just over 5% of their
body mass. This significant decrease at 12 months was in agreement with findings from the six
previous trials investigating effects of LCHODs on weight loss in obese patients with T2DM or insulin
resistance (Robertson et al. 2002, McAuley et al. 2006, Dashti et al. 2007, Davis et al. 2009, Elhayany
et al. 2010, Larsen et al. 2011).
The body mass loss in the current study equated to the median response in the above studies. As
described before, the amount of carbohydrate in the diet throughout the study was higher than
recommended (126 ± 91 g/d vs. recommended 40g/d or less). Also, with carbohydrate restriction it was
expected for the energy intake to be about 1200 kcal/d, in the current study at 12 month 1467 ± 637
kcal/d were reported. However, the reported dietary intake had very similar gross composition to the
low-carbohydrate Mediterranean diet described by Elhayany et al (2010) (CHO, 35%; P, 20%; F, 45
%). In that study participants lost over 10 kg of body mass over the 12 months of the programme.
Apart from the similar reported macronutrient composition of the diet and the fact that participants
reported slightly higher energy intakes in that study, their weight loss was almost double the one
observed in the current study. Elhayany et al (2010) reported that the low carbohydrate Mediterranean
diet contained 23% of energy from monounsaturated fatty acids (MUFA) and only 7% from saturated
fatty acids (SFA). We did not investigate this aspect of the diet. It is not certain whether fatty acid
composition could account for a difference in weight loss. The population in both studies was similar
(overweight and obese with T2DM); however, Elhayany et al (2010) conducted their trial in Israel
where the Mediterranean diet is a more habitual way of eating than the LCKD is in Scotland. Greater
familiarity with the diet, along with more varied fresh products may have resulted in better adherence
and more accurate dietary reporting in their study. Elhayany and associates used 24-h food recall
questionnaire and a food frequency questionnaire to collect dietary data, while we have used 3-day
food diaries (2 week days and one weekend day). The method chosen in the current study was shown
to be representative of seven day habitual intake in free living subjects (Fyfe, Stewart et al. 2010).
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Finally, in the Elhayany et al study, participants attended 24 scheduled meetings as opposed to our 14
meetings. Interestingly, in a study by Larsen and colleagues (2011), where weight loss on a high-
protein diet was only -2.2 kg, there was only 9 individual and 4 group visits conducted. This suggests
that the main difference observed was due to more intensive support in the Elhayany study.
Due to the small numbers, the current study did not have the statistical power to ascertain any
difference in weight loss between the two approaches. As a result, it cannot be assumed the weight loss
would be similar in both diets in a much larger sample.
Fat mass accounted for the most of the weight lost (-5.1 ± 6.7 kg, p < 0.001) while reduction in fat free
mass was not significant (-0.3 ± 3.7, p = 0.350). This confirms our hypothesis that high protein
component of the diet would result in losing fat mass and not fat free mass regardless of the approach
(ready-made meals vs. self-prepared meals). Preservation of fat free mass during weight loss is
beneficial as it increases chances of successful weight loss maintenance and, in those with T2DM,
improves glucose control.
Out of the five randomised trials mentioned earlier, only one reported changes in body composition.
McAuley and associates (2006) used bioelectrical impedance and showed that on high-fat LCHOD
(CHO, 33 %; P, 21 %; F, 41 %) women lost 3.4 kg of fat mass and 2.0 kg of fat free mass. Fat mass
loss could have been underestimated due to the choice of measurement method. The bioelectrical
impedance method assumes that hydration of FFM is constant and not different between normal weight
and obese individuals (Deurenberg 1996). However, body water distribution changes with the
fluctuating weight and glycogen depletion (that may occur during restriction of dietary carbohydrate
intake). As prediction formulas are developed in normal-weight subjects, fat mass in obese individuals
may be underestimated (Deurenberg 1996). This seemed to be confirmed in the present study, because
at all time points FM (%) measurements were about 5% lower than the ones delivered by the air
displacement plethysmography (p < 0.001). In the current study most of the body mass lost was fat and
there was no difference in body composition changes between men and women. The fact that most of
the weight lost was FM was perhaps a result of a higher reported protein content of the diet. Another
factor that may preserve fat free mass during weight loss is exercise, but it was not a part of the current
study.
There were also four other 12 month long trials of LCHOD that reported body composition changes;
however participants in those studies did not have T2DM or insulin resistance. All of the four studies
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used dual-energy X-ray absorptiometry (DXA). Gardner et al (2007), Clifton et al (2008), and Due et al
(2004) reported CHO intakes being 35 % of total energy intake or higher and weight loss about 5 kg
with FM constituting about three quarters of it. The reported macronutrient proportions in the study by
Brinkworth and colleagues (2009) were different (CHO, 8.9%; P, 32.3 %; F, 54.9 %) and weight loss
was greater (-14.5 ± 1.7 kg). Out of 14.5 kg of body mass lost, 11.3 kg was fat mass. Based on those
results, it seems that weight loss was more pronounced and FFM loss was smaller with very low
carbohydrate intake suggesting that protein sparing enhances weight loss. It has to be noted, however,
that DXA interprets glycogen as FFM and water as about 8 % fat. Some of the apparent FFM loss will
be due to these.
5.3 Dietary intake and adherence
The total energy intake and macronutrient composition of the diet (carbohydrate, fat and protein
content) were analysed. Alcohol, if consumed, was included into the total calorie count. Alcohol was
consumed in very small quantities by only some participants; therefore it was not distinguished along
carbohydrate, fat and protein as a source of energy.
The baseline dietary macronutrient composition of the participants in the current study was not
different between the ready-made meals and self-prepared meals, and had slightly higher fat and lower
carbohydrate contents (CHO, 41 %; P, 20 % (less than 1g/kg body mass); F, 39 %) than the levels
recommended by Diabetes UK (CHO, 45-60%, P not more than 1g/kg body mass; F less than 35 %)
(Connor et al. 2003). Ma and associates (2006) have found the similar trend in the population of obese
patients with poorly controlled T2DM (HbA1c > 7%) in the United States (CHO, 35%; P, 20%; F,
45%). The authors expressed concern for cardiovascular implications of this macronutrient
composition in the vulnerable group of type 2 diabetics.
It is known that a standard energy restricted, low-fat diet may be difficult to adhere to (Hession et al.
2009) and the high-protein LCHOD is an alternative method for weight loss. The only restriction put
on patients on a high-protein LCHOD is in the amount of carbohydrate they ingest. The recommended
carbohydrate intake in the current intervention was 40g/d. At this, or a lower intake, it is likely that
participants develop ketosis.
Efficiency of detection of ketone bodies by electrochemical sensor was shown to be better than the
measurement in the urine by using a reagent strip (Guerci et al. 2003). In the present study, ketone
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body concentrations both in urine (acetoacetic acid) and capillary blood (β-hydroxybutyrate) did not
change through the study in neither of the dietary groups, remaining at their baseline levels. This could
be an indication of poor adherence or diluted urine if a lot of liquids were consumed. The analysis of
food diaries confirmed that the intake of carbohydrate at 6 months and at 12 months was about 120 g/d
(Table 8), which was 80 g/d higher than recommended and too high to induce ketosis. Diets with more
than 60 g/d of CHO are unlikely to have a ketotic effect. The LCKD was advised as it was shown to be
a more successful way of reducing body mass than a low-fat diet at 6 months and as successful at 12
months (Hession et al. 2009). In the present study participants did not achieve ketosis. Therefore, the
expected physiological effects (hormonal changes that trigger lipolysis) could not have taken place.
The participants lost on average 5.5 ± 7.3 kg of body mass at 12 months, however, this was rather
modest compared to the weight loss reported by Dashti et al (2007) in which obese patients with
T2DM on LCKD for a year decreased their body mass from 108.1 ± 21.21 to 83.5 ± 18.0 kg. It can be
only speculated that if the ketosis was achieved, weight loss would have been much higher.
Poor adherence was not unique to the present study. McAuley and associates (2006) investigated
effects of high carbohydrate, high-protein and high-fat (low-carbohydrate) diets on weight loss in
overweight, insulin resistant women (n = 93) and at 12 months concluded that dietary compliance was
poor in all groups. The high-fat diet was based on Atkins’ idea and carbohydrate intake at 12 months
was supposed to be between 20 and 100 g/d; carbohydrate intake was reported to be about 160g/d
(33% of total energy intake). This was even higher than what we have seen in our study (less than
31%). Similarly, in another twelve month long study by Davis and associates (2009) where the LCKD
was based on the Atkins diet, at 12 months reported carbohydrate intake was 33% of total energy
intake. Davis et al (2009) suggested that a high percentage of Hispanics in their study may have been
the reason, as diets of Hispanics traditionally had higher carbohydrate amounts than the general U.S.
population’s diet, and therefore switching to a low-carbohydrate regime could have been more difficult
for the participants. In the current study, participant’s reported baseline carbohydrate intake was
actually lower than recommended by the Diabetes UK (41.4 ± 9.4 % of energy intake; the
recommended range is 45-60 % of energy intake). This could have been caused by underreporting as
participants at the time of filling in food diaries were aware of the low-carbohydrate nature of the
intervention. The reason for the decrease in compliance with time could have been limited food choice.
Carbohydrate foods are a principal part of many diets, and removing them may be difficult in a long
term.
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Serum urea increased significantly from baseline to 12 months (6.1 ± 1.8 to 6.8 ± 2.2 mmol/L, p <
0.001), as did albumin (45 ± 2 to 46 ± 3 g/l, p < 0.001). This effect cannot be associated with the fact
that the diet was high in protein because the reported amount of dietary protein did not change when
expressed as grams per day (p = 0.458) (it increased when expressed as percentage of total energy
intake). It was discovered previously by Keys (1950) that albumin concentration did not change during
24 weeks of semi starvation (Energy, 1570 kcal/d; P, 12.7 %; CHO, 70 %; F, 17.2 %) during which
mean weight loss was 16.9 kg (24 % of baseline body weight). Albumin concentration was also found
to increase after a 3-day total starvation (Broom et al. 1986). This was related to albumin diffusion
coefficient change rather than to the albumin production rates. Urea concentrations increased most
likely because more protein was metabolized (Broom 1986) rather than as the effect of high-protein
diet.
Most of the compliance measures (ketone bodies and plasma urea concentrations) in completers were
no different to dropouts, and there were no differences in the reported energy or fat (g/d) intakes
between these two groups. However, completers reported lower intakes of carbohydrate (g/d). This was
only significant at 6 months (141 vs. 78 g/d, p = 0.038). Completers also reported higher protein
intakes but this was only significant at 9 months (98 vs. 75 g/d, p = 0.041). Only one measure of
compliance, serum albumin concentration, was higher in completers at 6 months (46.9 vs. 45.4 g/l, p =
0.036) which is in agreement with slightly higher reported intake of protein in this group (g/d) (Mutlu
et al. 2006). It is not entirely clear why the completers were better at adhering to the programme. There
were no differences in any of the measures that were taken at baseline between completers and those
who dropped out. It could be that other than the weight loss effects of the diet (perhaps glycaemic
control or improved wellbeing) encouraged completers to continue. The difference could have also
been in factors not measured in the present study, such as participant’s family or friends’ support or
participant’s own goals.
5.4 Resting metabolic rate
In the present study RMR (kcal/d) significantly decreased (-137 ± 265 kcal/d, p < 0.001) at 12 months
and there was no difference in changes between the genders or dietary groups. However, the range of
individual changes was rather wide from -1040 kcal/d to +184 kcal/d. Therefore, following the idea of
Senechal and colleagues (2010) the whole sample (n = 41) was divided into participants whose RMR at
12 months increased 5 % from baseline and into those whose RMR did not increase more than 5 %
from baseline value. We have found that over 12 months, RMR increased in the “increasers” group (n
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= 4) from 1597 ± 421 to 1713 ± 461 kcal/d (p = 0.065) and decreased in the “decreasers” group (n =
37) from 2029 ± 423 to 1864 ± 394 (p < 0.001). As a result, the difference in RMR between these two
groups changed, from approaching significance (p = 0.054) at baseline to non significant (p = 0.653) at
12 months. Unlike Senechal et al (2010), there were no observed differences in baseline fat mass
between these two groups. There could have been several possible reasons for this. Participants in
Senechal et al (2010) study were only non-diabetic women who on average lost 9.5 kg of body mass
(about 12% of baseline value) on a calorie restricted diet (CHO, 55%; P, 15%; F, 30%) with no
information about body composition changes. Therefore, their intervention was shorter and much more
intensive. It is possible that if participants in the current study lost 12% of their initial body mass,
changes in RMR would classify them differently to the groups with increased or decreased RMR.
None of the 6- and 12-month-long trials of LCHOD in obese with T2DM, insulin resistance or obese
but otherwise healthy participants reported RMR measurements. Trials investigating other dietary
interventions however, showed results similar to ours. Those studies used mostly energy restriction
with the general aim to keep macronutrient composition close to the standard recommendations (CHO,
55%; P, 15%; F, 30%). For example, in a 12 month long programme of 121 overweight sedentary men
who achieved significant body and fat mass loss, RMR (both kcal/d and kcal/FFM/d) significantly
decreased (Frey-Hewitt et al. 1990). Interestingly, in a parallel group that received the same dietary
intervention but also undertook exercise (jogging), RMR did not change (Frey-Hewitt et al 1990). In
the Minnesota experiment (Keys et al. 1950), change in basal metabolic rate was expressed as
percentage of baseline oxygen volume uptake. It was reported that after 6 months of semi-starvation,
oxygen consumption declined with weight loss, achieving about 60 % of the baseline value per average
person but about 80 % of baseline value when expressed in kg of body mass and about 85 % when
expressed in kg of active tissue (Keys et al. 1950). It should be noted that participants in this
experiment were not overweight and they lost about 24% of body mass during the 6 months of semi-
starvation.
LOCF analysis showed that females had significantly higher RMR (kcal/kg FFM/d) than men at all
time points (Table 11). This was not the case in completers. In contrast, a study of 114 males and 121
females without diabetes found that RMR was 5-10 % lower in females than in males after adjusting
for differences in body composition, age and activity (Ferraro et al. 1992). This theoretically should be
applicable to the present study because there was no association found between insulin resistance and
RMR (De Luis et al. 2006). The higher RMR (adjusted for FFM) in women in the current study was
found probably due to the small sample.
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Severely obese patients with T2DM have higher measured RMR than obese non-diabetic people
(Huang et al. 2004, Bitz et al. 2004, Pi-Sunyer 2005). Therefore, Bitz et al. (2004) suggested that a new
predictive equation for people with T2DM should be developed. Huang and associates (2004) proposed
an equation that included age, gender, body mass, stature and information about the presence of
diabetes. The equation proposed by Huang et al. (2004) explained 75% of the variation in RMR in their
participants.
All twenty nine equations that were tested, underestimated RMR in obese people with poorly
controlled T2DM. The equation by Lazzer et al. (2007) was the most accurate in estimating RMR;
however its accuracy was only 62.5 %. There was no accurate equation available to predict RMR in
obese patients with poorly controlled T2DM. Additionally, weight based and fat free mass based
equations were compared. Fat free mass based equations did not seem to be more accurate than weight
based ones. Therefore, RMR prediction accuracy in this population may not be improved by body
composition data.
Based on the data from the current study, an RMR prediction equation was developed for obese people
with T2DM. The equation included FFM, waist circumference, gender and glycosylated haemoglobin
(section 1.6.2, Model 1), and explained 81% of the variability in RMR. Due to the fact that
glycosylated haemoglobin explained only about 1% of the variability in RMR, another model was
suggested that included only FFM, waist circumference and gender (section 1.6.2, Model 2). The
second model explained 79.4 % of the variability in RMR, and it therefore could also be used when
glycosylated haemoglobin data are not available. Moreover, two equations were developed separately
for men (Model 4) and women (Model 5). Model 4 explaned as much as 84.8 % of variability in RMR
and apart from FFM and waist circumference included glycosylated haemoglobin. Model 5 explained
77.1 % of variability in RMR and included only FFM and waist circumference. Based on this sample,
glycosylated haemoglobin did not explain variability in RMR in women. Gougeon and colleagues
(2002) reported that prediction of RMR in people with T2DM was improved by including glycaemic
control into the equation. This therefore, was confirmed only in men in the current study. Prediction of
RMR based on the larger sample of both men and women would be needed to confirm these results.
The equation from Model 1 did not explain 19 % of the variability in the RMR. Weyer and colleagues
(1999) proposed that considerable variability in RMR that remains after adjusting for the variables
described previously, is partly genetically determined. Moreover, it has been suggested that
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sulphonylurea therapy was associated with reduction in RMR (Nair et al. 1984, Bogardus et al. 1986).
It was not the case in the current study, as participants were instructed to discontinue sulphonylureas
when included in the programme because some of the side effects (weight gain, diarrhoea, constipation
or loss of appetite) could influence weight loss. However, insulin therapy could have been one of the
factors explaining some of the remaining 19 % of variability in RMR. Welle and associates (1988)
reported that insulin therapy was associated with the reduction in RMR. While Gougeon and
colleagues (2002) reported that prediction of RMR in people with T2DM was improved by including
glycaemic control into the equation, their equation had only 60.7 % accuracy when used for the current
study’s participants (see Figure 21). The equation proposed by these authors included weight, hip
circumference and fasting plasma glucose and explained 81% of the variability in RMR (Gougeon et
al. 2002). Both the current and the Gougeon et al (2002) studies had similar participant characteristics,
sample sizes, and variables measured. The difference in the factors resulted perhaps from the body
composition measurement method. In the study by Gougeon et al (2002) body composition was
determined by the bioelectrical impedance analysis as opposed to the air displacement
plethysmography method (BodPod) which was used in the present study. Air displacement
plethysmography is currently one of the most accurate available methods of body composition
assessment and often used as a standard (Marcias et al. 2007).
5.5 Glycaemic control
Significant improvement in insulin resistance and glycaemic control in the current study suggests a
positive effect of the high-protein LCKD in the investigated population. The changes in hypoglycaemic
medication were not likely to be influential in the improvements because only three of the fourteen
participants that completed the study had their hypoglycaemic medication reduced or withdrawn and
one had the dose of metformin increased.
The fasting plasma glucose concentration was 10.2 ± 3.5 mmol/l at baseline, which was comparable to
the baseline values reported by Dashti et al. (2007) which was 10.5 ± 3mmol/l and Elhayany et al.
(2010) which were 10.3 ± 1.7, 10.1 ± 1.8 and 10.5 ± 2.0 mmol/l for three randomised groups. Both
Dashti et al (2007) and Elhayany et al (2010) reported significant decreases in fasting glucose
concentrations. In the current study, there was a decreasing trend but it did not reach significance
possibly due to the small sample size. Other 12 month long trials involving type 2 diabetics did not
report fasting glucose but the HbA1c changes. The HbA1c is considered to be a better representative of
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diabetic control as it identifies the average plasma glucose concentration over 2 to 3 months (American
Diabetes Association 2008).
Glycosylated haemoglobin significantly decreased at 12 months (-0.4 ± 1.1 %, p < 0.001). This was in
agreement with most of the other studies that reported this measure (Robertson et al. 2002, Elhayany et
al. 2010, and Larsen et al. 2011) apart from the study by Davis et al. (2009). The fact that weight loss
of 5 to 10% of body mass improves diabetic control (Turner et al. 2002) may explain why Davis et al.
(2009) did not see HbA1c decrease at 12 months; the average weight loss in that study was 3.3% of the
initial body mass. Moreover, the duration of T2DM could have been a factor. Daly et al (2006)
proposed that with an increasing duration of T2DM, the capacity for an improvement in glycaemic
control diminishes. The positive relationship between the changes in HbA1c and weight (Figure 25) in
the current study confirms the importance of weight management in patients with T2DM.
There was a decrease in overall fasting plasma insulin concentration in the current study (-1.9 ± 9.0, p
= 0.005). Both the participants with baseline insulin therapy and those without showed the decrease.
McAuley et al (2006) who recruited insulin-resistant, but not diabetic, women reported a similar
decrease. Elhayany et al (2010), however, saw a significant increase in fasting insulin concentrations.
The patients who were on insulin treatment were not included in their trial. There were no striking
baseline differences between participants in the present study and two others. Also insulin resistance
measured by HOMA improved in the present study as well as in the Elhayany et al (2010) study.
Reported dietary compositions were also similar, therefore it is unclear why the difference occurred.
Homeostatic model assessment (HOMA) assesses β-cell function and insulin resistance from fasting
glucose and insulin concentrations (Matthews et al. 1985). It is a suitable method to assess the effects
of a treatment (Wallace et al. 2004). Although change in fasting glucose in the current study was not
significant, there was an overall significant decrease in the insulin resistance measurement by HOMA
(-1.2 ± 5.6, p = 0.018). Improvement in HOMA index was also seen at 12 months by Elhayany and
colleagues (2010). Other 12 month long trials did not report this measure probably due to the lack of
both fasting glucose and insulin concentration data.
The fatty acid composition of the diet may play a role in improving glycaemic control in patients who
are insulin resistant or have T2DM. Elhayany proposed that a low carbohydrate Mediterranean diet
rich in MUFA (reported CHO, 35%; P, 20%; F, 45 %), was better at improving glycaemic control than
traditional Mediterranean diet or diet recommended by the ADA (2003). In contrast, Larsen and
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colleagues suggested that glycaemic control was improved by the reduction in energy content of the
diet rather than by the nutritional composition (reported values at 12 months for high-protein diet were
CHO, 42 %, P, 26 %; F, 30.7 % and for high-carbohydrate diet was CHO, 48 %; P, 19 %; F, 32 %).
The main difference between the two above studies seems to be in the contents of fat. However, Davis
and colleagues (2009) stated that the Atkins diet (reported at 12 months CHO, 33%; P, 23%; F, 44%)
had effects on glycaemia similar to that of a low-fat diet (CHO, 50 %; P, 19 %; F, 31 %). Those
seemingly contradictory results may be explained when fatty acid composition of dietary fat is taken
into account. McAuley stressed that when recommending high-protein diet, an appropriate composition
of dietary fat must be ensured. As expected, the diet in McAuley et al. (2006) and Larsen et al. (2011)
studies had about twice as much SFA and half the amount of MUFA and PUFA by comparison.
Unsurprisingly, consumption of MUFA was suggested to improve insulin sensitivity (Elhayany et al.
2010, Brunerova et al. 2007). It is possible that for successful longer term dietary intervention for
obese patients with T2DM the recommended macronutrient proportion is not as important as the type
of carbohydrate (low glycaemic index) and fat (proportion of SFA, MUFA and PUFA).
5.6 Cardiovascular disease risk
One of the major arguments against the use of high-protein diets, according to the AHA, was that the
high intakes of saturated fat, cholesterol, and other associated dietary factors, may cause increased risk
for coronary heart disease (St. Jeor et al. 2001). Lipid profile outcomes of LCHODs usually include
decreases in serum TG levels and increases in HDL cholesterol (Yancy et al. 2004, Nordmann et al.
2006). These favourable changes are contrasted by elevated LDL-cholesterol levels and total
cholesterol levels. In their review, Nordmann and colleagues (2006) noted that every 10% decrease in
CHO intake decreased TG by 7.6 ± 0.6 % but highlighted that it was not known whether favourable
effects of LCHODs on lipid profiles outweighed adverse effects. However, it has been observed that
LCHOD was associated with an increase in LDL-cholesterol particle size, from small and dense to
large and buoyant (Volek et al. 2005b, Westman et al. 2006, Morgan et al. 2009). This change is
considered beneficial, as high levels of small, dense LDL cholesterol are associated with an increased
CVD risk (Lamarche et al. 1997). Additionally, accumulation of large LDL-cholesterol sub fraction
was not associated with an increased CVD risk (St-Pierre et al. 2005, Volek et al. 2005a). Moreover,
since 2006 when Nordmann and associates published their review, several new reviews have been
published. Accurso et al (2008) reviewed the use of LCHODs in T2DM and metabolic syndrome and
stated that carbohydrate restriction, even without weight loss, improves markers of cardiovascular
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health. Similar conclusions were presented by Volek et al (2008) and Acheson (2010). Boling and
associates (2009) reviewed the use of LCHOD for obesity and related diseases and concluded that
LCHODs improved dyslipidaemia associated with the metabolic syndrome better than diets higher in
carbohydrate or lower in fat. The effect on LCHOD on LDL-cholesterol was found to be mostly neutral
or beneficial but due to the wide range of LDL-cholesterol responses, Boling et al (2009) suggested
monitoring lipid profiles of patients on LCHODs.
Confirming the beneficial effect of LCHOD in obese patients with T2DM, the lipid profile in the
current study improved. HDL-cholesterol increased and TG decreased. LDL-cholesterol and total
cholesterol did not change (Table 14), possibly because they were in the normal ranges at baseline.
Systolic BP decreased while diastolic BP did not change (Table 14). The completers’ analysis showed
very similar outcomes.
It has been demonstrated that LCHODs are safe and beneficial for obese individuals with T2DM.
McLaughlin and associates (2006) reported that although there was no difference in weight loss
between the patients on the high protein diet (CHO, 15 %; P, 40%) compared to the standard diet
(CHO, 60 %; P, 15%) after 4 months, obese hyperinsulinaemic patients had greater reduction in fasting
TG, higher increase in HDL-cholesterol and an increase in LDL cholesterol particle size. It was
concluded that high-protein, high-fat diets for the short term can be efficient in reducing markers for
cardiovascular disease risk in obese hyperinsulinaemic people (McLaughlin et al. 2006). Similarly,
replacement of dietary carbohydrate with protein, showed to have beneficial effects at 6 months by
Stern and co-workers (2004). They reported that although weight loss was similar between LCKD (less
than 30g CHO/day) and conventional diet with an energy deficit of 500kcal (less than 30% F), the
effects on atherogenic dyslipidaemia and glycaemic control were more favourable with LCKD. It was
suggested that in obese people, who may have high carbohydrate intake at baseline, the restriction of
carbohydrates for 6 months may have beneficial metabolic effects (Stern et al. 2004, Volek et al.
2004). Brinkworth and co-workers (2004) proposed that high-protein diets in people with T2DM may,
in the long term (over 1 year), decrease cardiovascular risk more than low-protein diets with similar
weight loss. The group showed that high-protein diet (planned CHO, 40%; P, 30%; F, 30% but
reported CHO, 46%; P, 20%; F, 32%) attenuated blood pressure increase with weight regain after
weight loss. The finding supported reports from larger studies (Liu et al 2002, Appel 2003) that dietary
protein intake may be negatively related to blood pressure. Finally, Dashti and colleagues (2007)
reported that LCKD had beneficial effects in obese people with T2DM after 1 year. They compared the
effect of LCKDs in obese subjects with either high or normal blood glucose levels. After 56 weeks of
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the diet, body weight, BMI, blood glucose, total cholesterol, LDL and HDL cholesterol, and TG
improved in both groups. However, this effect was more pronounced in subjects with high baseline
glucose levels. The group concluded that LCKDs are safe and beneficial for long-term use by obese
diabetic individuals.
The observed decrease in blood pressure in the current study (systolic: -6 ± 14 mmHg, p = 0.014;
diastolic: -2 ± 10 mmHg, p = 0.234) could have been related to weight loss. The new SIGN guideline
on obesity (2010) stated that a 5kg weight loss at 12 months is associated with systolic blood pressure
decrease from 3.8 to 4.4 mmHg and diastolic blood pressure reduction from 3.0 to 3.6 mmHg.
However, due to large individual variation and possible confounding variables, a specific effect cannot
be implied. Changes in blood pressure in the current study were very similar to those reported at 12
months in people with T2DM by Davis et al (2009) and Larsen et al (2011).The decrease in blood
pressure can also be facilitated by an increase in the dietary protein content. It has been previously
shown that blood pressure may be inversely related to dietary protein intake (Appel 2003, Liu et al.
2002).
The Framingham CVD risk score (%) showed a decreasing trend but did not significantly change
during the study remaining quite high. At 12 months, fourteen participants (3 in completers’ analysis)
had CVD risk over 30%. Similarly, at 12 months almost 70% participants had their heart age estimated
to be over 80 years old (mean age was 55.6 ± 9.9 years). It is important to note that the population
investigated came from secondary care, and therefore most of the participants in the study had diabetes
and its complications long before joining the programme. The Framingham risk score (D'Agostino et
al, 2008) seems to be better suited to estimate CVD risk in the general population or in newly
diagnosed diabetics (D'Agostino RB et al. 2008).
Changes in CVD risk can also be estimated from the changes in concentration of plasma C-reactive
protein (CRP) as elevated CRP levels are associated with an increased risk for cardiovascular disease.
As described in the introduction, CRP is a marker of inflammation. CRP was initially planned to be
analyzed, however, CRP assay provided by the Clinical Biochemistry reported specific values only if
they were over 10 mg/l as those levels are considered alarming (Shine et al. 1981, Seshadri et al. 2004).
Only highly sensitive assay of CRP (hsCRP) could detect differences that would be caused by the
intervention like ours as changes would probably be in the range between 1 and 4 mg/l (Kip et al.
2004). The analysis of plasma samples in Robert Gordon University has been considered, however it
was not delivered due to the funding issues.
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5.7 Liver and kidney function
The data from the UK Prospective Diabetes Study stressed the role of blood pressure and glycaemic
control in prevention of diabetic nephropathy (Bilous 2008). It has been agreed that the most effective
strategies for preventing diabetic nephropathy is to achieve appropriate glycaemic control (HbA1c <
7%), blood pressure (<130/80 mmHg) and normalize LDL-cholesterol level (<2.6 mmol/l). The
strategies also include the use of the drugs that block the rennin-angiotensin-aldosterone system (Gross
et al. 2005). Although the science, medicine and pharmacology are advancing, the prevalence of
diabetes as a cause of chronic kidney disease is increasing (Eknoyan 2005). There are different reasons
for renal lesions in T2DM and some of the kidney damage cannot be reversed, especially that related to
ageing. However, pancreas transplant studies have shown that normo-glycaemia sustained for ten years
can reverse kidney damage (Firetto et al. 2006). It has not been shown whether the improvement in
blood pressure and other factors would induce the regeneration of the damaged kidneys in T2DM.
Impaired liver or kidney functions were exclusion criteria in the current study. After 12 months of the
LCHOD kidney function was not altered and some of the markers of liver function tests improved
(ALT, -5 ± 15 U/L, P < 0.001; GGT, -9 ± 37 U/l, p < 0.0014). There were no differences between the
GL and PSMF in any kidney or liver function tests. Completers’ results were not significantly
different.
Creatinine concentration was in the low end of the normal range at baseline and showed an increasing
trend but it did not significantly change (Table 15). Creatinine clearance adjusted for body surface area
was in the low end of the normal range at baseline as well and did not change during the study (Table
15). Estimated glomerular filtration rate (eGFR) calculated from the CKD-EPI equation, which was
shown to be more accurate than the Modification of Diet in Renal Disease Study equation (MDRD)
(Levey et al. 2009), showed a decreasing trend but again the change was not significant (Table 15).
Similarly, a recent randomised controlled trial demonstrated that renal function was not adversely
affected by weight loss on a LCKD (planned CHO less than 4% energy) in obese but otherwise healthy
individuals (Brinkworth et al. 2010). These results were not different from the outcomes of weight loss
on a high-carbohydrate diet in the study by Brinkworth et al (2010).
The burden of liver disease in patients with T2DM is significant and the prevalence of elevated liver
enzymes in T2DM is quite high. Kotronen et al. (Kotronen et al. 2008) have reported that people with
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T2DM have 80% more fat in the liver than healthy people matched for age, weight and sex. Elevated
levels of ALT (found in 16% of people with T2DM) and GGT (found in 23% of people with T2DM)
were found to be related to BMI, metabolic control and the presence of metabolic syndrome (Forlani et
al. 2008). The aetiologies of elevated liver enzymes vary, but a common one is non-alcoholic fatty liver
disease (NAFLD). The presence of NAFLD was associated with abdominal obesity, elevated levels of
TG and elevated but still normal ALT levels (Leite et al. 2008).
The significant decreases in two liver enzyme levels: alanine transaminase (ALT) and gamma-glutamyl
transpeptidase (GGT) observed in this study would suggest an improvement in liver function when
using LCHOD in poorly controlled T2DM (Table 15). Both the mean ALT and ALKP concentrations
were above the normal ranges at baseline but at 12 months they decreased to be in the upper limits of
the normal ranges. There were no changes in alkaline phosphatase (ALKP) and total bilirubin
concentrations. These findings are in agreement with other trials. The 12 month long study involving
reduced carbohydrate Mediterranean diet (Elhayany et al. 2010) showed that ALT levels dramatically
improved (Fraser et al. 2008). Interestingly, this improvement was more pronounced on this diet than
on a standard Mediterranean diet or on a diet recommended by the ADA (2003) (Fraser et al. 2008).
Similar outcomes were reported in 2007 by Ryan and colleagues who wrote that for obese insulin
resistant patients, diet moderately lower in carbohydrate improved ALT levels better than high
carbohydrate diet, apart from equal weight loss. The authors suggested this to be an effect of overall
decreased insulin levels (Ryan et al. 2007).
Albumin is a marker of nutritional status and is useful for monitoring liver function. Low albumin
levels may be a sign of altered liver function and / or altered kidney function. In the current study
albumin levels were quite high at baseline and a small but significant increase was seen (Table 9). It is
therefore a further confirmation that liver and kidney functions were not negatively affected by the
treatment. The change in albumin level, as mentioned before in this chapter, was probably related to
the decreased energy content of the diet.
Such changes in liver function tests suggest a marked improvement. Hepatic steatosis, that is
associated with the increased visceral fat, is now thought to be a part of the metabolic syndrome
(Forlani et al. 2008). A large proportion of people with T2DM also present different characteristics of
MS. Alexander and colleagues (2003) analysed NHANES III data and reported that 87% of US citizens
(n = 3510) over 50 years old who had T2DM met criteria for metabolic syndrome (National
Cholesterol Education Program ATP III). A similar observation was reported by an Italian group
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(Bianchi et al. 2008), who found that 70% of people with T2DM (n = 1610) met the NCEP ATP III
criteria for MS.
5.8 Quality of life and wellbeing
The questionnaires were secondary measures in the current study. The study was not powered to detect
differences in quality of life (QoL), physical activity, depression, fatigue, sleepiness or treatment
satisfaction.
The quality of life of people with T2DM is associated with even mild diabetes complications (Lloyd et
al. 2001) and may be affected by hypoglycaemic episodes during insulin therapy (SIGN, 2010).
Obesity has a negative impact on QoL as well (Gough et al. 2009). In the current study, the quality of
life in diabetes was assessed with the Audit of Diabetes Dependent Quality of Life (ADDQoL). This
tool consisted of two general items (to assess quality of life and impact of diabetes) and of 18 items
focusing on varied aspects of life. The present quality of life (one item directly asking about the QoL)
shifted from ‘good’ towards ‘very good’ over the duration of the study. It has been previously reported
that people with obesity and people with T2DM suffer from reductions in health related QoL (Gough et
al 2009). The effects of obesity and T2DM were found to be additive (i.e. individuals who are both
obese and have T2DM, experience reduction in health related QoL equal to the sum of the two
independent effects) (Gough et al. 2009). As participants of the current study experienced both weight
loss and improvements in glycaemic control, improvement in QoL were expected.
The impact of diabetes on some of the eighteen life domains was different between completers and
dropouts at baseline in the current study. Firstly, completers rated the impact of diabetes on their
enjoyment of food higher than dropouts, possibly suggesting greater awareness of foods which are not
recommended, or the lack of eating pleasure associated with recommended foods. Secondly, the
completers reported significantly lower impact of diabetes on their confidence to do things. It is an
interesting finding, as completers had no different attitude towards weight loss than dropouts. If the
confidence to do things helped completers in finishing the programme, the question arises as to what
would help dropouts gain more confidence to do things. Phrased differently, if confidence is just a
character trait of completers, then it can be suggested that confident people respond better to this kind
of intervention. And again a question follows as to, what kind of intervention would be suitable for less
confident people.
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The obesity related quality of life questionnaire (ORWELL-97) (Appendix 4) is a subjective measure
of physical and psychological distress generated by overweight (Mannucci, Petroni et al. 2010). A
score of 70 or more in the ORWELL 97 questionnaire was considered indicative of a clinically
significant burden of obesity on health related QoL (Mannucci et al. 2010). In the present study, at
baseline, the mean score was 32.3 ± 27, suggesting that the impact of obesity on QoL was not
dramatic. ORWELL-97 scores in the completers’ analysis showed a nonsignififcant decreasing trend
over the duration of the study; however, LOCF analysis showed a significant decrease (Figure 29a)
indicating improvement in QoL. The reasons for not reaching the statistical significance in completers’
analysis could have been the fact that rating of wellbeing was quite positive already at baseline, or due
to the smaller than in LOCF sample size. When interpreted in the perspective of the improvements in
body mass and composition, cardiovascular risk factors and glycaemic control, increased quality of life
and a trend towards an improved wellbeing could confirm a successful intervention.
5.9 Physical activity
According to the results from the General Practice Physical Activity Questionnaire (GPPAQ)
(Appendix 6), physical activity did not change during the programme. Physical activity was not a part
of the intervention, and information about its stable levels throughout the study eliminates the
possibility of weight and body composition changes due to exercise and not diet. However, it is
possible that the choice of GPPAQ for the assessment of physical activity, which has only 4 possible
outcomes (inactive, moderately inactive, moderately active and active), was not the ideal choice. A
measure that is more precise would perhaps be more sensitive (such as Scottish Physical Activity
Questionnaire) and suit the present study better.
5.10 Depression
Prevalence of depression in patients with T2DM is more common in people with diabetes than in the
general population (SIGN, 2010). Raval et al (2010) reported that 23% of patients in the tertiary care in
India had major depression and 18% had moderate depression (diagnosed with Patient Health
Questionnaire 9). The research group from the Netherlands (Pouwer et al. 2010) reported that about
40% of patients from an out-patient clinic had a depressive affect (assessed by the World Health
Organization-5 Well Being Index). Pouwer and associates (2010) also reported, based on the results
from the Composite International Diagnostic Interview, which 2% of men and 21% of women with
T2DM suffered from a depressive disorder. The reported risk factors for depression in patients with
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diabetes included obesity, central obesity, age, various diabetic complications, and increased pill
burden (Raval et al. 2010; Pouwer et al. 2010).
In the present study, the Major Depression Inventory (MDI) scores at baseline were within the normal
ranges and did not indicate depression. Although the numbers were not recorded, a substantial part of
patients that otherwise fulfilled the inclusion criteria, could not be included in the study due to the
antidepressant therapy (i.e. diagnosed with and treated for depression). Those patients were not
included into the intervention because of the possible effects of antidepressants on body mass. In the
current study, there was a significant overall decrease in MDI score during the programme, suggesting
improvement in any depressive states. Although the participants in the current study did not have
depression, this result seems to be in agreement with the evidence used in SIGN (2010) guideline, that
an improvement in depression was associated with the improvement in glycaemic control.
5.11 Fatigue, energy and sleepiness
Fatigue, assessed with VAS-F, was at about 20 mm level on a visual analogue scale (see Table 17)
during the whole programme; where the 0 mm end of the scale meant no fatigue at all and the 100 mm
end meant absolute exhaustion. This was a rather low rating as compared to the rating of healthy
controls (41.3 ± 23.2 mm) from Lachapelle’s and Finalyson’s study (1998). The study tested three
tools to measure fatigue and compared results of healthy controls and patients with brain injury
(LaChapelle, Finlayson 1998). Lachapelle and Finalyson (1998) found no significant rating on the
VAS-F fatigue scale between the groups, which they explained by the scale’s failure to distinguish
between sleepiness and fatigue, as pointed out by Chambers and Docktor (1993). In the current study,
the change in sleepiness assessed by the Epworth Sleepiness Scale was also not significant.
Baseline energy levels were 55.7 ± 25.8 mm (see Table 17) where 0% was ‘no energy at all’ and 100%
was ‘feeling extremely energetic’. Energy rating showed an increasing trend by the twelfth month
(+8.0 ± 24.9 mm) but this was not significant (Table 17). Perhaps, the change would be more
pronounced with the greater weight loss or larger number of participants.
The sleepiness levels evaluated by the Epworth Sleepiness Scale (ESS) (Appendix 9) did not change.
There was a decrease from 8.1 to 5.9 on a 24-point scale but this was not significant. The ESS was
originally developed to distinguish between normal patients and patients with a range of sleep
disorders (Johns 1991). The control group of normal patients in Johns’ study (1991) had a mean rating
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of 5.9 ± 2.2 while the mean score for 104 medical students was 7.6 ± 3.9 (Johns 1992). Participants by
the end of the current study rated their sleepiness 5.9 ± 3.8. These results suggest that participants in
the investigated sample, on average, did not have sleep disorders at baseline and their sleepiness levels
did not change during the study.
5.12 Attitude towards weight loss
The weight decisional balance (WDB) was constructed to assess baseline attitudes to weight loss and
then, during weight loss, to alert about shifts in the attitudes that could undermine chances for success
(O'Connell et al. 1988). It was expected that in the current study, there would be a baseline difference
between completers and dropouts in the attitude toward weight loss that would at least partly explain
reasons for dropout. No such difference was detected and all the participants were positive about
weight loss at baseline. Although it was not expected that all dropouts would be positive about weight
loss at baseline, it could be explained by a finding from the study by Green and associates (2007) who
reported that people with T2DM and those with cardiometabolic risk had good awareness of healthy
lifestyle (diet, exercise, benefits of weight loss) but did not translate it into healthy behaviour.
Although the majority of participants remained positive about losing weight throughout the
programme, the mean WDB score decreased (p = 0.03). The fact that there was a positive association
between the change in weight and change in the mean WDB score (r = 0.340, p = 0.03) in the LOCF
analysis but not in the completers’ analysis was probably due to the small sample size. Such an
association would mean a diminishing motivation to lose weight with the progress of the program (or
with weight loss). It would seem logical for the motivation to pursue something to decline when the
goal is closer.
5.13 Diabetes treatment satisfaction
The diabetes treatment satisfaction status version (measured by DTSQs, Appendix 5) score was quite
high at the beginning (28.6 ± 7.3 out of 36.0) and despite showing an increasing trend, it did not
change in completers during the study. Although it was recommended to also administer DTSQ-change
at the completion of the study or at the time of dropout, these data were collected only from a subset of
participants were therefore not presented. DTSQc was designed to overcome possible ceiling effect of
DTSQs.
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5.14 Adverse events
The adverse events reported in the first two weeks of the intervention were characteristic for going into
ketosis (e.g. headaches, sickness, tiredness and nausea) (Rolland et al. 2009). However, the numbers of
participants that reported these events were small and apart from the trend for less adverse events as the
study progressed, the frequency did not significantly change. Considering the fact that the majority of
participants were not in ketosis during the study, these effects were more likely associated with the
change in type of food consumed or calorie restriction.
A recent study from Aberdeen, Scotland suggested that LCHODs are high in protein and low in fibre
may increase risk of colon cancer (Russell et al. 2011). The researchers reported that after 4 weeks on
high protein and reduced in carbohydrate, weight maintaining diets, obese participants displayed
decrease in fecal cancer-protective metabolites and increase in carcinogenic compounds. As fibre and
resistant carbohydrate can counteract negative metabolic outcomes of high protein LCHODs, it was
recommended to include sufficient amounts of them in the weight loss diets (Russell et al. 2011).
5.15 Limitations
We are aware of certain limitations to this study. First limitation was the small sample size as the
recruitment for this study was stopped due to the cuts in funding. The chosen randomisation method
did not allow for this event. This resulted in uneven numbers of participants in the two study arms and
different gender proportions between the groups. Secondly, 66% of patients dropped out by 12 months
which further reduced the sample. However, both last observation carried forward and completers
analyses were performed and the outcomes of them were very similar. Thirdly, most of the participants
were on diabetic, lipid-lowering and/or antihypertensive medications which could have affected the
study outcome measures. It was reported that, at baseline, there were no differences between the two
groups in use of these medications. The changes in medication doses were not significant but due to the
small sample size, the effect of medication cannot be ruled out. Fourthly, some of the measures we
have taken, like quality of life, depression rating, physical activity or motivation to lose weight, could
have been influenced by factors other than the diet. Due to the nature of the trial, we were unable to
control for those possible confounding factors. Fifthly, in real life, unlike in this trial, individuals need
to pay for the Go Lower products which may either put them off choosing this option or make them
responsible for their choice and motivate them to follow the programme more closely. Sixthly, the
current study did not measure readiness to change before an intervention. It was found that a
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substantial number of participants dropped out due to the lifestyle issues. Perhaps the use of readiness
to change assessment before an intervention could help to differentiate between people who are ready
to make a life style change and those who are not. Finally, patients in this study were randomised to
their treatment, which did not reflect their preferences matched to life style. This could possibly
influence the study outcomes, i.e. dropout rates.
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6 Conclusions
The results presented in this work should be viewed with caution as the recruitment target was not
reached and the study was not sufficiently powered to demonstrate differences in the outcomes.
The outcomes of the present study suggest that protein sparing modified fast and commercially
available Go Lower diet, two different approaches to administering a high-protein LCKD, had similar
effects on weight loss and related metabolic changes. This is a novel research, as different approaches
to administration of low-carbohydrate diet have not been compared before. The hypothesis that
convenience of ready made meals provided by Go Lower would produce greater weight loss at 12
months was not confirmed. Therefore, it seems that the two approaches could be used according to a
patient’s preferences or perhaps interchangeably. Secondly, the present study supports previous
findings that a high-protein LCKD administered for 12 months is a safe and effective means for weight
loss in obese people with T2DM. Thirdly, weight loss in the present study was similar to those reported
in studies with similar dietary macronutrient composition. Studies in which adherence to the low
carbohydrate requirement was good, achieved much better weight loss than the present study and other
studies with lower adherence. Moreover, observed changes in body composition were anticipated –
most of the body mass lost was fat mass. Fourthly, both completers and the last observation carried
forward analyses gave very similar results, confirming that the last observation carried forward
approach did not cause over- or underestimation of the diet effect. It was also clear that completers’
analysis, apart from showing the same or even more pronounced changes, did not always give
statistically significant results due to the smaller sample size. Fifthly, comparison of dietary
intervention trials is difficult as often there is no consistency in reporting macronutrient composition
(grams per day versus percentage of energy intake), dietary data (method used), frequency of support
(number and frequency of visits and contact with the participant), or the extent of adherence to the
programmes. Sixthly, it is possible that for a successful longer term dietary intervention for obese
patients with T2DM the recommended macronutrient composition is not as important as the type of
dietary carbohydrate (low glycaemic index) and fat (proportions of SFA, MUFA and PUFA). Finally,
questionnaires together with the hard data outcomes from the present study show that the intervention
was beneficial on many levels (such as physiology, quality of life and wellbeing).
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7 Suggested future work
There are six suggestions for the future work in relation to the present study. Firstly, the target
recruitment numbers were not reached; therefore the relationships in the defined population cannot be
fully identified. The present study could act as a pilot for a bigger intervention which would be able to
clarify conclusions about the effects of these approaches in a poorly controlled type 2 diabetic
population. Secondly, a follow-up of the participants from the current study could provide an insight
into the longer term effects of the two compared approaches. Thirdly, some of the trials that
investigated diets with comparable nutritional composition on similar populations had very different
weight loss outcomes. One apparent difference seemed to be the type and frequency of participant
support. Perhaps an investigation into how the frequency and kind of professional support influences
the adherence to the lifestyle interventions in different populations would provide useful suggestions
for practice. Fourthly, the present study had a high dropout rate. Many participants who dropped out
declared lifestyle issues as the reason for discontinuation. Perhaps a trial, in which participants would
not be randomised into the dietary groups but would be able to choose the type of intervention
themselves according to their preferences, would reduce those dropouts. Moreover, the participants’
freedom to choose the type of diet or lifestyle modification would reflect a real-life situation where
everyone is in charge of making these choices for themselves. The experiment designed in this way
could deliver results that would be a better reflection of an intervention’s effect in the non-
experimental setting. Fifthly, a study investigating differences between approaches to a diet would be
supplemented by an element of qualitative data exploring participant’s experiences and views on the
diets. Exploration of subjective experience of the diet could be taken further to investigate reasons for
dropout and completion of the programme. These aspects would be very useful, acting as directions for
new lifestyle interventions. Finally, the equation developed in the current study for predicting RMR
explained 81% of the variability in RMR. It was hypothesized that some of the remaining 19 % could
be explained by the type and doses of medications used. Future design of RMR prediction equations
for this particular population should perhaps include medication. Additionally, to develop more
accurate predictive equations in the future, bigger databases should be used.
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9.4 Appendix 4 – ORWELL 97 Questionnaire
ORWELL 97 Questionnaire
Date: _______________________
PIN: _______________________
This questionnaire consists of 18 pairs of questions. After reading each question carefully, underline only
one of the four answers which best describes your current situation.
1. R
O
How important is it for you to exercise regularly?
not at all just a little not so much much
Is your weight an obstacle for your physical activity?
not at all just a little not so much much
2. R
O
How important is it for you to have regular sexual activity?
not at all just a little not so much much
Does your weight represent a physical obstacle for your sexual activity?
not at all just a little not so much much
3. O
R
Do you suffer from shortness of breath?
not at all just a little not so much much
Does shortness of breath represent an obstacle for your daily activities?
not at all just a little not so much much
4. O
R
Do you feel sleepy?
never occasionally sometimes often
Does sleepiness interfere with your daily activities?
not at all just a little not so much much
5. O
R
Do you suffer from excessive sweating?
not at all just a little not so much much
Does sweating interfere with your daily activities?
not at all just a little not so much much
6. O
R
Mass media (TV, newspapers, etc.) often report that obesity is a major risk for health. Do you
pay attention to this subject?
not at all just a little not so much much
Does this information increase your preoccupation with your health?
not at all just a little not so much much
7. R
O
Is it important for you to live in a serene family environment?
not at all just a little not so much much
Does being overweight prompt discussions in your family?
not at all just a little not so much much
8. R
O
Is it important for you to be successful in your job?
not at all just a little not so much much
Does your weight represent an obstacle in your job?
not at all just a little not so much much
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9. R
O
Is it important for you to spend your free time with friends?
not at all just a little not so much much
Does your weight interfere with your social activities?
not at all just a little not so much much
10. O
R
Do you feel uneasy in showing your body?
not at all just a little not so much much
Does this uneasiness interfere with your social activities?
not at all just a little not so much much
11. O
R
Is it important for you to be sexually attractive?
not at all just a little not so much much
Does being overweight make you less sexually attractive?
not at all just a little not so much much
12. O
R
Do others ever tease you about your weight?
never occasionally sometimes often
If this happens, does it worsen your mood?
not at all just a little not so much much
13. R
O
Do you feel excessively worried about unimportant matters?
not at all just a little not so much much
Do you think that being overweight makes you more apprehensive?
not at all just a little not so much much
14. R
O
Do you ever feel sad?
not at all just a little not so much much
Do you ever feel sad because of being overweight?
not at all just a little not so much much
15. R
O
Do you ever feel very nervous?
not at all just a little not so much much
Does being overweight make you more nervous?
not at all just a little not so much much
16. R
O
Do you have a negative opinion of yourself?
not at all just a little not so much much
Does being overweight interfere with your opinion of yourself?
not at all just a little not so much much
17. R
O
Do you ever experience a feeling of immediate danger with no apparent reason?
not at all just a little not so much much
Do you feel more exposed to risks because of being overweight?
not at all just a little not so much much
18. O
R
The world of fashion and entertainment pursues a model of lean persons. How far do you feel
from this model?
not at all just a little not so much much
Would it be important for you to reach this model of thinness?
not at all just a little not so much much
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9.5 Appendix 5 – Diabetes Treatment Satisfaction Questionnaire s
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9.6 Appendix 6 – General Practice Physical Activity Questionnaire
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9.7 Appendix 7 – Weight Decisional Balance
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9.8 Appendix 8 – Major Depression Inventory
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9.9 Appendix 9 – Epworth Sleepiness Scale
PIN: ________________________ Date: ____________________
Epworth Sleepiness Scale
How likely are you to doze off or fall asleep in the following situations, in contrast to feeling just
tired?
This refers to your usual way of life in recent times. Even if you have not done some of these things
recently try to work out how they would have affected you.
Use the following scale to choose the most appropriate number for each situation:
 0 = no chance of dozing
 1 = slight chance of dozing
 2 = moderate chance of dozing
 3 = high chance of dozing
Situation Chance Of Dozing
Sitting and reading
Watching TV
Sitting inactive in a public place (e.g. a theatre or a meeting)
As a passenger in a car for an hour without a break
Lying down to rest in the afternoon when circumstances permit
Sitting and talking to someone
Sitting quietly after a lunch without alcohol
In a car, while stopped for a few minutes in traffic
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9.10Appendix 10 – Fatigue Visual Analogue Scales
PIN: …………………………….. Date: …………………....
Time: ……………………
Lee Fatigue Scale
This questionnaire will check your level of energy at the moment. There are 18 items. Completing
should take only about 1 minute.
Directions: Place an ‘X’ through these lines to indicate how you are feeling right now.
Please complete the following items:
Not at all
tired
Extremely
tired
Not at all
sleepy
Extremely
sleepy
Not at all
drowsy
Extremely
drowsy
Not at all
fatigued
Extremely
fatigued
Not at all
worn out
Extremely
worn out
Not at all
energetic
Extremely
energetic
Not at all
active
Extremely
active
Not at all
vigorous
Extremely
vigorous
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Not at all
efficient
Extremely
efficient
Not at all
lively
Extremely
lively
Not at all
bushed
Totally
bushed
Not at all
exhausted
Totally
exhausted
Keeping my
eyes open is
no effort at all
Keeping my
eyes open is a
tremendous
chore
Moving my
body is no
effort at all
Moving my
body is a
tremendous
chore
Concentrating
is no effort at
all
Concentrating
is a
tremendous
chore
Carrying on a
conversation
is no effort at
all
Carrying on a
conversation
is a
tremendous
chore
I have
absolutely no
desire to
close my eyes
I have a
tremendous
desire to close
my eyes
I have
absolutely no
desire to lie
down
I have a
tremendous
desire to lie
down
Now check that you have answered ALL the questions and that you have only give one answer to
each.
Thank you!
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9.11Appendix 11 – Poster for GP surgeries
Do you have type 2 diabetes
and want to lose weight?
Take part in a weight loss study!
We need people who:
 Have poorly controlled type 2 diabetes (HbA1c ≥ 7.5%)
 Are overweight with a BMI ≥ 30kg/m²
 Are 18 years of age or over
 Have no history of kidney, liver or cardiovascular disease
Benefits for you:
 Dietary advice and guidance for 12 months
 Possible weight loss and improvements in blood sugar levels
To find out more about the randomized clinical trial
of low carbohydrate diets,
please contact Miss Ania Gryka
at 01224 553739
or by email: a.a.gryka@rgu.ac.uk
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9.12Appendix 12 – Investigating reasons for dropout
Date
Dear volunteer,
We would like to thank you for taking part in our weight loss study and visiting Westburn
House. We truly appreciate your time and commitment. We would be grateful if you could
help us once more and answer one question. It does not matter whether you have completed
the study or not. Your reply is anonymous. Please return your answer in the enclosed
envelope. Thank you very much.
Kind regards,
Prof Iain Broom
Dr Catherine Rolland
Miss Anna Gryka
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Diet:
a) Go Lower (ready meals) □
b) Protein Sparing Modified Fast (own cooking) □
Completion of one-year diet programme:
a) Yes □
b) No □
Could you describe in a few sentences what made you complete the one-year diet
programme? If you have not completed, could you describe the obstacles that made it
difficult?
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
………………………………………………………………………………………………….
